Pathology In Depth

Library › Clinical chemistry foundations: methods, quality control, proteins, enzymes and organ function tests

Clinical chemistry foundations: methods, quality control, proteins, enzymes and organ function tests

Last reviewed 2026-11-17 by a board-certified pathologist. 264 references.

Analytical Methods and Immunoassays in Clinical Chemistry

Definition. Clinical chemistry analyzers convert the concentration or activity of an analyte into a measurable signal. The main signal types are light absorbance or emission (photometry, fluorometry and chemiluminescence), electrical potential or current (potentiometry and amperometry), antibody binding (immunoassay), migration in an electric field (electrophoresis) and mass-to-charge ratio (mass spectrometry). Each principle has characteristic interferences. Immunoassays are vulnerable to endogenous antibodies, biotin and the high-dose hook effect (Ghazal 2022). Liquid chromatography–tandem mass spectrometry (LC-MS/MS) adds chromatographic separation and mass selection that improve specificity (Thomas 2022).

Related page: Automated Blood Counts, Reticulocyte Count and Peripheral Smear Review (impedance and optical cell counting in hematology analyzers) Related page: Hemoglobin Variant Analysis and Laboratory Diagnosis of Thalassemia (hemoglobin HPLC, capillary electrophoresis and mass spectrometry for hemoglobin variants) Related page: Plasma Proteins, Protein Electrophoresis, Free Light Chains and CSF Oligoclonal Bands (serum protein electrophoresis, immunofixation and free light chain interpretation) Related page: Diagnostic Enzymes and Serum Tumor Markers (enzyme activity measurement and tumor-marker interference) Related page: Preanalytic Variables, Specimen Integrity and Point-of-Care Testing in Clinical Chemistry (hemolysis, icterus and lipemia indices and glucose meters) Related page: Method Validation, Statistical Quality Control and Proficiency Testing in Clinical Chemistry (calibration, detection limits, interference studies and quality control)

Units, conversion factors and centrifugation

Conventional-to-SI conversion factors. The conventional result is multiplied by the factor to give the SI result.

Analyte Conventional unit SI unit Factor Source
Glucose mg/dL mmol/L 0.0555 Münte 2025
Creatinine mg/dL µmol/L 88.4 Münte 2025
Total bilirubin mg/dL µmol/L 17.104 Münte 2025
Uric acid mg/dL mmol/L 0.0595 Sun 2025
Total cholesterol, HDL and LDL cholesterol mg/dL mmol/L 0.0259 Münte 2025
Triglycerides mg/dL mmol/L 0.0113 Münte 2025
Albumin and total protein g/dL g/L 10 Münte 2025
C-reactive protein mg/dL mg/L 10 Münte 2025
ALT, AST, ALP and GGT U/L µkat/L 0.0167 Münte 2025
Insulin µIU/mL pmol/L 6.945 Münte 2025
Sodium, potassium, chloride and bicarbonate mEq/L mmol/L 1.0 Münte 2025

Relative centrifugal force (RCF). Rotor speed is converted to force with RCF = 1.118 × 10⁻⁵ × r × (rpm)², where r is the rotor radius in centimeters (Klionsky 2026).

Reagent water. CLSI GP40 (5th edition, 2024) specifies the types of purified water used in the medical laboratory, including clinical laboratory reagent water (CLRW), special reagent water and instrument feed water (CLSI 2024).

Photometry and the Beer-Lambert law

  • Beer-Lambert law. Absorbance (A) equals log(I₀/I), where I₀ is incident and I is transmitted light intensity. Absorbance is proportional to molar absorptivity (ε), path length (l) and concentration (c), so A = εlc (Oshina 2021).
  • Linearity limits. Absorbance is linear with concentration at low concentrations. Deviations appear at high concentrations (Oshina 2021).
  • Stray light. Light of wavelengths outside the selected band that reaches the detector reduces peak absorbance. Observed absorbance is lower than true absorbance, and the error increases with concentration (Oshina 2021).
  • Spectral interference by lipemia. Lipoprotein particles absorb light inversely with wavelength from 300 to 700 nm. Methods read at 340 nm are therefore most affected. The direction and size of the error depend on the wavelength, the direction of the indicator reaction and the blanking of the method (Nikolac 2014).
  • Rate measurements. Michaelis and Menten measured the initial velocity of the reaction to avoid product inhibition. Their equation, in modern form v = Vmax[S] ÷ (Km + [S]), relates velocity to substrate concentration (Michaelis 2011). Vmax is the product of a constant and the total enzyme concentration, so velocity approaches a value set by enzyme concentration when substrate concentration greatly exceeds Km (Michaelis 2011). Enzyme activity assays are covered in Diagnostic Enzymes and Serum Tumor Markers.
  • Reflectance photometry. Dry-slide (multilayer film) analyzers place about 2 µL of serum on a slide. The colored spot formed in the film is read by reflectance photometry and expressed as percentage reflectance (Neeley 1988). Dry-slide results can differ from other methods: lithium by dry slide agreed with atomic absorption spectrometry and differed significantly from ISE (Serdarević 2006).

Beer-Lambert concentration and Michaelis-Menten velocity.

Quantity Formula Terms Source
Absorbance A = log₁₀(I₀ ÷ I) I₀ incident intensity; I transmitted intensity Oshina 2021
Concentration c = A ÷ (ε × l) ε molar absorptivity; l path length in cm Oshina 2021
Initial velocity v = Vmax[S] ÷ (Km + [S]) Vmax maximal velocity; Km substrate concentration at half-maximal velocity Michaelis 2011

Luminescence, fluorescence, light scattering and elemental analysis

  • Chemiluminescence. Direct chemiluminescent methods use luminophore labels such as acridinium and ruthenium esters. Indirect methods use enzyme labels: alkaline phosphatase with an adamantyl dioxetane phosphate substrate, or horseradish peroxidase with luminol and its derivatives. Either type can be competitive or noncompetitive (Cinquanta 2017). The advantages of chemiluminescence are a wide dynamic range, high signal intensity, absence of interfering emissions and full automation (Cinquanta 2017).
  • Fluorescence polarization immunoassay (FPIA). A fluorescent label is excited with polarized light. The degree of polarization of the emitted light depends on how much labeled ligand is bound to the antibody (Qriouet 2019).
  • Turbidimetry and antigen excess. Turbidimetric immunoassays on general chemistry analyzers measure the change in absorbance caused by light scattered from antigen–antibody complexes. When antigen exceeds the maximum precipitating point, absorbance declines rapidly (antigen excess). Particle-enhanced turbidimetric immunoassays (PETIA) use antibodies conjugated to particles and retained a strong scatter signal at high antigen concentrations (Larsson 2022). Detection of antigen excess differs between reagents and platforms (Messiaen 2017). Free light chain antigen excess is covered in Plasma Proteins, Protein Electrophoresis, Free Light Chains and CSF Oligoclonal Bands.
  • Atomic absorption and inductively coupled plasma mass spectrometry (ICP-MS). Atomic absorption and flame emission spectrophotometry are partially obsolete for trace elements. ICP-MS measures many elements in serum and whole blood. Hemolysis raises elements with high intracellular concentration, such as manganese, iron and potassium (Laur 2020).

Electrochemistry and osmometry

Potentiometry and ion-selective electrodes

  • Nernst equation. Electrode potential is E = E⁰ + (59.2 mV ÷ z) × log a, where a is the ion's activity (approximated by concentration) and z is ionic charge. The theoretical slope for a monovalent cation is 59.2 mV per tenfold change in concentration at 25 °C (Hajdin 2026).
  • Analytes. Ion-selective electrodes (ISEs) measure sodium, potassium, chloride, ionized calcium, magnesium and lithium on laboratory and point-of-care analyzers. Their selectivity is high, and interferences still occur (Dimeski 2010).
  • Direct and indirect ISE and the electrolyte exclusion effect. Normal plasma is about 92% water. In lipemic samples the lipid phase can reach 25%. Indirect ISE and flame photometry dilute the whole plasma volume before measurement and give falsely low electrolytes in proportion to the excess lipid. Direct ISE measures concentration in the water phase without dilution and is unaffected (Nikolac 2014).
  • Selectivity. Chloride electrodes with quaternary ammonium salt membranes respond to bicarbonate. They overestimate chloride at high bicarbonate and underestimate it at low bicarbonate. Selectivity decreased over the life of one manufacturer's electrode. Adjusting the calibrator bicarbonate from 30 to 20–24 mmol/L reduced samples with unacceptable bias from 77.3% to 12.6% (Monteyne 2022).

Amperometry and enzyme electrodes

  • Clark electrodes. Clark first developed an oxygen electrode for intravascular use. Clark and Lyons proposed the amperometric glucose electrode with glucose oxidase in 1962 (Pullano 2022).
  • Sensor generations. First-generation glucose sensors measure oxygen consumption or hydrogen peroxide production and depend on background oxygen. Second-generation sensors replace oxygen with synthetic mediators. Third-generation sensors transfer electrons directly from enzyme to electrode (Pullano 2022).
  • Electroactive interferents. The applied potential also oxidizes other electroactive species, such as ascorbic acid and uric acid, which reduces selectivity (Pullano 2022). Meter interferences are covered in Preanalytic Variables, Specimen Integrity and Point-of-Care Testing in Clinical Chemistry.

Osmometry

  • Methods. Serum osmolality is measured by freezing point depression or vapor pressure (Lin 2018). The reference range is about 275–295 mOsm/kg H₂O, and an osmolal gap above 10 mOsm/kg suggests ethanol, methanol or acetone (Lin 2018).
  • Volatile solutes. Vapor pressure osmometry does not detect volatile solutes. A patient with methanol poisoning had no osmolal gap because osmolality was measured by vapor pressure. In vitro testing confirmed insensitivity to toxic methanol and ethanol concentrations (Walker 1986). The difference between freezing point and vapor pressure osmolality multiplied by 4.2 estimates serum ethanol in mg/dL (Draviam 1984).
  • Calculated osmolality and the osmolal gap. Calculated osmolality = 2 × Na (mmol/L) + glucose (mg/dL) ÷ 18 + urea nitrogen (mg/dL) ÷ 2.8. The osmolal gap is measured minus calculated osmolality (Lin 2018). Ethanol contributes about ethanol (mg/dL) ÷ 3.7 mOsm/kg to the gap, or 1.25 × ethanol in mmol/L in SI units. A residual gap after this correction indicates another unmeasured osmole (Purssell 2001).

Immunoassay principles

History. Berson and Yalow described the first insulin immunoassay, which received the 1977 Nobel Prize. Monoclonal antibodies (Köhler and Milstein, 1975) made two-site sandwich immunoassays possible (Ghazal 2022).

Feature Competitive (limited-reagent) immunoassay Noncompetitive (sandwich, immunometric) immunoassay Source
Principle Sample analyte competes with labeled analyte (tracer) for limited antibody Analyte is bound between a capture antibody and a labeled antibody Ghazal 2022
Signal Inversely related to concentration Directly related to concentration Ghazal 2022
Typical analytes Small molecules (steroids, thyroxine, 25-hydroxyvitamin D, drugs) Larger proteins with two epitopes (TSH, hCG, thyroglobulin) Ghazal 2022
Reagent amount Limited antibody Excess antibody Ghazal 2022
Main weaknesses Cross-reaction with precursors, metabolites and drugs; endogenous antibodies; biotin Endogenous antibodies; biotin; high-dose hook effect Ghazal 2022
Effect of high biotin with streptavidin capture Falsely high Falsely low Ghazal 2022; Li 2020
  • Simultaneous and sequential formats. Most competitive assays add sample and labeled antigen at the same time. Sequential assays add the labeled antigen after the antibody-antigen reaction reaches equilibrium (Ghazal 2022).
  • Labels. The label can be an enzyme, a fluorescent or luminescent compound, or an isotope. A capture antibody separates the immune complexes on a solid phase (Ghazal 2022).
  • Homogeneous enzyme immunoassays. Homogeneous assays need no separation step. In the cloned enzyme donor immunoassay (CEDIA), two inactive fragments of β-galactosidase reassociate into active enzyme. Drug in the sample binds the antibody and leaves the drug-labeled fragment free to reassociate, so enzyme activity rises with drug concentration (Qriouet 2019). In the enzyme-multiplied immunoassay technique (EMIT), the analyte is conjugated to glucose-6-phosphate dehydrogenase (G6PDH), and antibody binding to the conjugate inhibits the enzyme. Free analyte in the sample competes for the antibody and prevents this inhibition, so measured enzyme activity rises with analyte concentration (Chiu 2011; Kimura 2001). Kinetic interaction of microparticles in solution (KIMS) is another homogeneous format used in drug screening (Bodor 2012).
  • Multiplex bead assays. In xMAP technology, microsphere sets are dyed internally with two fluorophores in different ratios, giving 100 spectrally distinct sets (500 with a third dye). A red classification laser (635 nm) identifies the bead set and a green reporter laser (525–532 nm) measures the bound analyte (Reslova 2017).

Immunoassay interference

Interference Mechanism Usual direction Detection or remedy Source
Heterophile antibodies and human anti-animal antibodies (mostly HAMA) Bridging of capture and labeled antibodies; rarely blocking of one antibody Mostly falsely high in sandwich assays Alternative immunoassay, nonlinear dilution, heterophile blocking tubes, protein A pretreatment Ghazal 2022
Rheumatoid factor Binding to assay antibodies Falsely high Removal of rheumatoid factor and repeat testing Ghazal 2022
Biotin Free biotin blocks streptavidin capture of biotinylated reagents Competitive: high; sandwich: low Drug history, repeat after withdrawal, alternative method, adsorption if validated Ghazal 2022; Li 2020
Anti-streptavidin and signal-specific antibodies (anti-ruthenium, anti-ALP) Antibodies against assay components Competitive: high; sandwich: low Alternative method Ghazal 2022
Macro-analytes (macroprolactin, macro-TSH) Analyte bound to IgG with long half-life Falsely high (biologically inactive analyte) Polyethylene glycol (PEG) precipitation Ghazal 2022
Anti-thyroglobulin autoantibodies Tg bound to autoantibody escapes sandwich formation Falsely low thyroglobulin Anti-Tg antibody testing with every Tg; recovery studies; LC-MS/MS or RIA (both imperfect); TgAb trend Ghazal 2022; Hoofnagle 2009; Petrovic 2024
Thyroid hormone autoantibodies Binding of labeled analyte in one-step free hormone assays Falsely high free T4 or T3 Alternative method Ghazal 2022
Cross-reactivity Structurally similar compounds bind the antibody Usually falsely high in competitive assays Knowledge of assay specificity; LC-MS/MS for steroids Ghazal 2022
High-dose hook effect Antigen saturates both antibodies Falsely low in sandwich assays Serial dilution Ghazal 2022
EDTA and azide EDTA chelates metal labels such as europium and the zinc cofactor of ALP; azide destroys peroxidase labels Variable Correct specimen type and preservative Ghazal 2022

Heterophile antibodies and HAMA

Heterophile antibodies are endogenous, weakly polyspecific human antibodies that react with immunoglobulins of several species. Human anti-animal antibodies arise after exposure to animals or to murine monoclonal antibodies used in therapy. The reported prevalence of interference is 0.4%–0.5% (Ghazal 2022). No blocking reagent prevents all heterophile interference. Manufacturers add nonimmune animal immunoglobulin, use chimeric or humanized antibodies or use F(ab) fragments (Ghazal 2022). Interference is detected with an alternate assay, by measurement before and after added blocking reagent, or by dilution in nonimmune serum. On serial dilution, recovery outside 80%–120% is a nonlinear response that suggests interfering antibodies. Loss of the result after antibody depletion also indicates interference (Oyatogun 2021). Laboratory-physician communication about discordant results is part of the investigation (Tate 2004; Ward 2017).

Biotin

  • Mechanism. Tests that use streptavidin-biotin binding are affected by high circulating biotin. Interference is positive in competitive assays and negative in sandwich assays (Li 2020).
  • Doses and kinetics. Over-the-counter supplements contain 1–30 mg/day, and doses of 300 mg were used in trials in progressive multiple sclerosis. Peak biotin concentration occurs about 1.5 hours after intake, and the mean half-life is 15 hours (Ghazal 2022). The relatively fast elimination of biotin allows rapid follow-up testing (Li 2020).
  • Thyroid pattern. Biotin can produce falsely high free T4, free T3 and TSH-receptor antibody with falsely low TSH, a pattern that mimics hyperthyroidism (Ghazal 2022).
  • Regulatory warnings. Since February 2019, the European Medicines Agency has required a warning on supplements with more than 150 µg of biotin (Ghazal 2022). The FDA issued a safety communication in 2017 and later updated it. FDA continued to receive reports of falsely low troponin results and lists troponin assays that have not addressed biotin interference (FDA 2022).

Macro-analytes and anti-analyte antibodies

  • Macroprolactin. Monomeric prolactin bound to IgG forms macroprolactin, which has a longer half-life and is biologically inactive. It causes unnecessary investigation in about 4%–10% of women. PEG precipitation identifies it, although IgA complexes precipitate only partially (Ghazal 2022).
  • Macro-TSH. Macro-TSH was found in 0.17% of infertile women screened with PEG and causes false hyperthyrotropinemia (Ghazal 2022).
  • Anti-thyroglobulin antibodies. Up to 10% of healthy people and up to 25% of patients with differentiated thyroid cancer have anti-Tg antibodies (Hoofnagle 2009). Anti-Tg interference is the main limitation of Tg immunoassays, and guidelines require anti-Tg testing with every Tg measurement (Ghazal 2022).

Cross-reactivity in competitive immunoassays

Competitive assays are susceptible to cross-reaction with precursors, metabolites and drugs, such as fulvestrant in estradiol assays and pegvisomant in growth hormone assays (Ghazal 2022). Opiate screening immunoassays detect hydrocodone and hydromorphone at about 600 ng/mL, twice the 300 ng/mL morphine cutoff, and do not reliably detect oxycodone at therapeutic concentrations (Bodor 2012).

High-dose hook effect

Mechanism. In sandwich immunoassays, very high antigen concentrations saturate both the capture and the labeled antibodies. Few complete sandwiches form, and the result is falsely low. The hook effect affects only sandwich assays. It is most typical of two-site assays in which the sample and the signal antibody are added together: excess antigen occupies both antibodies, few sandwiches remain on the solid phase after the liquid is discarded, and the signal indicates a low or mildly raised concentration (Haddad 2019). Serial dilution reveals it, and dilution continues until two successive dilutions give consistent results (Ghazal 2022). Manufacturers reduce its frequency with excess antibody or smaller sample volumes (Ghazal 2022).

Reported hook effects.

Analyte Result before dilution Result after dilution Clinical setting Source
Prolactin 164.5 ng/mL 26,000 ng/mL Pituitary macroadenoma Ghazal 2022
Calcitonin 182 ng/L 450,000 ng/L Thyroid carcinoma Ghazal 2022
Thyroglobulin 3.8 ng/mL 207,855 ng/mL Thyroid carcinoma Ghazal 2022
hCG Low or normal 5,899,478 mIU/mL Gestational trophoblastic disease Ghazal 2022
Total PSA and total hCG Falsely low Corrected by dilution Metastatic prostate cancer; molar pregnancy Benamour 2024
Urine hCG (qualitative) Repeatedly negative Not applicable Molar pregnancy with choriocarcinoma Hunter 2011
Ferritin Falsely low; hook seen at concentrations as low as 86,028 µg/L on one analyzer Corrected by upfront dilution Routine ferritin testing Wu 2018
Ferritin More than 1000-fold lower at a reference laboratory Corrected by dilution Hemophagocytic lymphohistiocytosis-like syndrome after CAR T-cell therapy Harb 2024
  • Clinical consequence. An unrecognized hook effect can lead to the diagnosis of a nonfunctioning pituitary tumor and unnecessary surgery in a patient with a macroprolactinoma (Ghazal 2022).
  • Analyzer differences. Susceptibility to the hook effect differed among immunoassay analyzers. Automatic dilution is recommended when clinical suspicion of very high tumor or hormone markers exists (Benamour 2024).

Electrophoresis methods: agarose gel and capillary zone electrophoresis

  • Gel electrophoresis. Cellulose acetate and agarose gel electrophoresis became the standard for serum protein electrophoresis. Gels immobilize the separated bands for staining and densitometric quantification (Opallage 2022).
  • Capillary zone electrophoresis (CZE). CZE uses buffers of high pH and ionic strength that give proteins a negative charge and reduce adsorption to the capillary wall. Negatively charged proteins migrate toward the anode but are carried toward the cathode by electro-osmotic flow. Migration time reflects the difference between the two movements (Opallage 2022).
  • Performance. CZE has better separation efficiency and repeatability than agarose gel electrophoresis and resolves C3 and transferrin in the beta region better. Gamma and beta proteins migrate first in CZE (Opallage 2022).
  • Applications. Serum protein electrophoresis and immunofixation are covered in Plasma Proteins, Protein Electrophoresis, Free Light Chains and CSF Oligoclonal Bands. Hemoglobin electrophoresis is covered in Hemoglobin Variant Analysis and Laboratory Diagnosis of Thalassemia.

Liquid chromatography and mass spectrometry

Liquid and gas chromatography

In liquid chromatography, molecules separate according to their equilibrium between a mobile and a stationary phase. Under tightly controlled conditions, each analyte elutes at a constant retention time. A routine clinical LC-MS/MS run takes 2–5 minutes. Chromatographic separation is essential for isobaric compounds, which have the same mass and can mimic each other's transitions (Thomas 2022). Gas chromatography–mass spectrometry (GC-MS) uses electron ionization, a hard ionization that fragments molecules into many product ions. GC-MS often needs a derivatization step to make analytes volatile and thermostable, a step that LC-MS/MS does not need (Chong 2018).

Ionization and mass analyzers

Component Types Clinical use Source
Atmospheric pressure ion source Electrospray ionization (ESI); atmospheric pressure chemical ionization (APCI); atmospheric pressure photoionization (APPI) ESI is most common and suits polar compounds that ionize in solution; APCI suits less polar compounds such as steroids and cannabinoids; APPI is rarely used Thomas 2022
Other ion sources Electron ionization; chemical ionization; inductively coupled plasma; matrix-assisted laser desorption ionization (MALDI) MALDI is used for microbial identification Thomas 2022; Clark 2013
Mass analyzers Quadrupole, magnetic sector, ion trap, time of flight (TOF), orbitrap, ion cyclotron resonance Hybrids include Q-TOF and Q-Trap instruments Thomas 2022
Tandem MS (triple quadrupole) First quadrupole selects the precursor ion; collision cell fragments it; third quadrupole selects a product ion Selected reaction monitoring of a precursor/product pair (transition), for example 289.1/97.1 and 289.1/109.1 for testosterone Thomas 2022

Quantification and quality in LC-MS/MS

  • Multiple reaction monitoring. Monitoring many transitions during one chromatographic run is multiple reaction monitoring and allows multiplexed quantification (Hoofnagle 2009).
  • Quantifier and qualifier transitions. Validated methods monitor one quantifier transition and at least one qualifier transition. The ion ratio between them confirms specificity (Thomas 2022).
  • Isotope-dilution internal standards. A stable isotope-labeled internal standard, usually labeled with deuterium or carbon-13, is added to all calibrators, controls and samples at the start of preparation. It has the same retention time as the analyte and differs only in mass. A mass difference of at least 3 atomic mass units is recommended for analytes up to 1,000 amu (Thomas 2022).
  • Ion suppression and carryover. Ion suppression varies from specimen to specimen, and normalization to the isotope-labeled internal standard corrects for it. Carryover ranges from 0.01% to 1% depending on the autosampler and analyte (Hoofnagle 2009).

Clinical applications of LC-MS/MS

  • Immunosuppressants. About 50% of tacrolimus and cyclosporine and more than 70% of sirolimus and everolimus measurements worldwide use LC-MS/MS (Thomas 2022).
  • Vitamin D. A fully automated LC-MS/MS analyzer is commercially available for 25-hydroxyvitamin D (Thomas 2022).
  • Steroids. LC-MS/MS allows steroid profiling of several hormones in one sample (Thomas 2022).
  • Newborn screening. LC-MS/MS is a leading technology in newborn screening, which covers about 3.8 million newborns each year in the United States (Thomas 2022).
  • Thyroglobulin. Immunoaffinity peptide enrichment with tryptic digestion and isotope dilution reached a limit of detection of 2.6 ng/mL. Trypsin digestion removes interfering immunoglobulins, and the mass spectrometric detector is not saturated, which eliminates the hook effect (Hoofnagle 2009).
  • Limitations for proteins. Protein assays by LC-MS/MS require multiple preparation steps, which limits their use (Thomas 2022).

MALDI-TOF mass spectrometry in microbiology

Matrix-assisted laser desorption ionization–time of flight (MALDI-TOF) mass spectrometry identifies microorganisms rapidly from cultured and some direct specimens. It is displacing automated phenotypic identification and, in some settings, sequence-based identification (Clark 2013).

Method Validation, Statistical Quality Control and Proficiency Testing in Clinical Chemistry

Definition. Analytical quality in clinical chemistry depends on three linked activities. Method verification or establishment documents the performance of a test system before patient results are reported (42 CFR 493.1253). Statistical quality control (SQC) monitors the accuracy and precision of the complete analytic process during routine testing (42 CFR 493.1256). Proficiency testing (PT) compares a laboratory's results on external samples with a target value under the Clinical Laboratory Improvement Amendments (CLIA) (42 CFR 493.801). The PT acceptance limits for chemistry changed on July 11, 2024 (87 FR 41194).

Related page: Analytical Methods and Immunoassays in Clinical Chemistry (measurement principles and immunoassay interference) Related page: Preanalytic Variables, Specimen Integrity and Point-of-Care Testing in Clinical Chemistry (hemolysis, icterus and lipemia indices, specimen stability and IQCP for point-of-care testing) Related page: Automated Blood Counts, Reticulocyte Count and Peripheral Smear Review (ICSH evaluation of hematology analyzers and delta checks for blood counts) Related page: CLIA '88 Cytology Regulations: Workload Limits, Workload Assessment, Personnel and Accreditation (the CLIA framework as it applies to cytology and gynecologic cytology PT)

Descriptive statistics used in quality control

The mean of repeated control measurements describes central tendency. The standard deviation (SD) and the coefficient of variation (CV) estimate random error, and bias, the difference between the laboratory mean and the true value, estimates systematic error (Gruber 2024).

Quantity Formula Error it estimates Source
Mean (x̄) Σxᵢ ÷ n Central value of the control Gruber 2024
Standard deviation (SD) √[Σ(xᵢ − x̄)² ÷ (n − 1)] Random error (imprecision) Gruber 2024
Coefficient of variation (CV) SD ÷ x̄ × 100 (%) Random error, scaled to concentration Gruber 2024
Bias Laboratory mean − true (target) value Systematic error Gruber 2024
Total analytical error (TAE) |bias%| + 1.65 × CV% Combined error at a one-sided 95% level Kim 2024
Sigma metric (TEa% − |bias%|) ÷ CV% Process capability relative to the allowable total error Westgard S 2018; Ricós 2022

Total error and measurement uncertainty. The EFLM Task and Finish Group on total error (2017) predicted that measurement uncertainty would become the dominant model and acknowledged that laboratories would continue to apply allowable total error in the near term (Westgard S 2018).

CLIA requirements for method verification and establishment

Situation Performance characteristics required before patient testing Source
Unmodified FDA-cleared or approved test system Accuracy, precision and reportable range comparable to the manufacturer's specifications; verification that the manufacturer's reference intervals fit the patient population 42 CFR 493.1253(b)(1)
Modified FDA-cleared test, test not subject to FDA clearance (in-house or textbook methods), or no manufacturer specifications Accuracy, precision, analytical sensitivity, analytical specificity including interfering substances, reportable range, reference intervals and any other required characteristic 42 CFR 493.1253(b)(2)
Test systems in use before April 24, 2003 No verification or establishment required 42 CFR 493.1253(a)
  • Reportable range. CLIA defines the reportable range as the span of test results over which the laboratory can establish or verify the accuracy of the measurement response (42 CFR 493.2).
  • Calibration verification. Calibration verification uses at least a minimal (or zero), a mid-point and a maximum value near the upper limit of the reportable range. It is performed at least every 6 months and after a complete reagent change, major preventive maintenance, or a QC shift or trend that other measures fail to correct (42 CFR 493.1255).
  • Analytical measurement range (AMR) and clinically reportable range (CRR). CAP divides the CLIA reportable range into two concepts. The AMR is the range of analyte values that a method measures directly on the specimen without dilution, concentration or other pretreatment outside the usual assay process. It is set by the manufacturer and does not exceed the linearity range. It is verified with matrix-appropriate calibrators or linearity standards at low, middle and high concentrations, each assayed at least in duplicate. The CRR includes results obtained after dilution or concentration of the specimen and applies to samples with concentrations above the AMR. Each laboratory verifies the maximum dilution that preserves accuracy, and a sample that remains inaccurate at that dilution is reported as exceeding the upper CRR limit (Abdel 2021).
  • Laboratory-developed tests (LDTs). An FDA final rule of May 6, 2024 that included LDTs among in vitro diagnostic products (89 FR 37286) was vacated by a federal district court on March 31, 2025, and FDA restored the earlier regulation text on September 19, 2025 (90 FR 45134). LDTs therefore remain subject to the CLIA establishment requirements in the table above.

CLSI study designs for method verification and validation

Characteristic CLSI document cited Design reported in a published evaluation Source
Repeatability and within-laboratory precision (user verification) EP15-A3 5 replicates per day for 5 days (25 measurements per sample) Ruffing 2024
Total precision (establishment) EP05-A3 Duplicate measurements per day for 20 days with several reagent lots and instruments Yanagihara 2023
Method comparison EP09-A3 At least 40 patient samples spanning the analytical measuring range, analyzed by Passing-Bablok regression Ruffing 2024
Linearity EP06 (2nd edition) Seven levels mixed from high and low pools (H, 5/6H + 1/6L … L), each measured twice Zhang 2025
Limit of blank and limit of quantitation EP17-A2 LoB as the 95th percentile of at least 60 replicates of zero-analyte samples; LoQ as the lowest concentration with a CV of 20% or less Yanagihara 2023
Interference EP07-A2 Each interferent tested in 12 replicates at two analyte concentrations Yanagihara 2023
Reference interval establishment and transference C28-A3 (now EP28-A3c) At least 120 reference subjects for nonparametric limits with confidence intervals; 20 subjects for transference Ozarda 2016

Method comparison and regression analysis

  • Correlation. Correlation measures the strength of a relationship between two methods. It does not measure agreement and is unsuitable for method comparison (Bland 1986; Giavarina 2015).
  • Bland-Altman analysis. Differences between methods are plotted against their mean. About 95% of differences lie within the mean difference ± 1.96 SD of the differences when the differences are normally distributed. The plot defines limits of agreement. Clinical acceptability of those limits is defined before the study (Giavarina 2015).
  • Passing-Bablok regression. This nonparametric regression is insensitive to outliers and to the distribution of errors. The intercept represents constant error and the slope represents proportional error. A 95% confidence interval for the intercept that includes 0 and one for the slope that includes 1 indicate agreement (Bilić-Zulle 2011).
  • Deming regression. Passing-Bablok regression is preferred to Deming regression when the measurement error is not normally distributed (Giavarina 2015).

Detection capability and carryover

Limit of blank, limit of detection and limit of quantitation (parametric formulas).

Term Definition Formula Source
Limit of blank (LoB) Highest apparent concentration expected in replicates of a blank sample Mean(blank) + 1.645 × SD(blank) Armbruster 2008
Limit of detection (LoD) Lowest concentration reliably distinguished from the LoB LoB + 1.645 × SD(low-concentration sample) Armbruster 2008
Limit of quantitation (LoQ) Lowest concentration that meets predefined goals for bias and imprecision; equal to or higher than the LoD Set by the laboratory's goal, for example CV ≤20% Armbruster 2008; Yanagihara 2023

Functional sensitivity. Functional sensitivity is the lowest concentration at which the interassay CV is 20% or less (Spencer 1995). It is measured on human serum pools analyzed 10 or more times over a clinically realistic period, about 6–8 weeks for TSH (Spencer 1996). TSH assays of "third-generation" functional sensitivity reach 0.01–0.02 mIU/L, and "second-generation" assays reach 0.1–0.2 mIU/L. Manufacturers' stated functional sensitivity is rarely reproduced in clinical laboratories, so each laboratory establishes its own (Spencer 1995).

Carryover. Sample carryover is measured by analyzing two high specimens (a₁, a₂) followed by two low specimens (b₁, b₂). Carryover (k) equals (b₁ − b₂) ÷ (a₂ − b₂) × 100%. Most automated analyzers show less than 1%–2%. A carryover of 1% from a specimen of 500 into one of 10 produces an error of nearly 50% in the low result (Broughton 1984). Random-access analyzers can also show reagent carryover between different tests (Broughton 1984).

Reference intervals and clinical decision limits

  • Definition. A reference interval is the central 95% of the distribution of results in a healthy reference population. Its limits are the 2.5th and 97.5th percentiles (Ozarda 2016).
  • Selection of reference individuals. In a priori selection, exclusion criteria are applied before sampling. In a posteriori selection, they are applied after sampling. Both are direct methods, which are the primary IFCC recommendation (Ozarda 2016).
  • Calculation. C28-A3 recommends the nonparametric method and at least 120 subjects to calculate confidence intervals for each limit (Ozarda 2016).
  • Transference. When a new method has similar imprecision, comparable calibration and known interferences, an existing interval can be transferred by method comparison with linear regression (Ozarda 2016).
  • Verification with 20 subjects. An interval is adopted when no more than 2 of 20 local reference values fall outside it. When 3 or more fall outside, a second set of 20 is tested. If 3 or more again fall outside, the analytical procedure and the population are re-examined (Ozarda 2016).
  • Indirect methods. Indirect methods derive intervals from routine patient results after statistical removal of diseased subpopulations, whose effect is their main limitation (Jones 2018). The 20-sample binomial verification cannot reliably detect intervals that are too wide, and Hoffmann and colleagues propose indirect verification with open-source tools (reflimR and refineR) (Hoffmann 2026).
  • Index of individuality. When the within-subject CV (CVI) divided by the between-subject CV (CVG) is below 0.6, a population interval is insensitive to change within one individual. When the ratio exceeds 1.4, an individual's values cover much of the interval (Ozarda 2016).
  • Clinical decision limits. Clinical decision limits are thresholds associated with a significantly higher risk of an adverse outcome or with a specific diagnosis, as for lipids, glucose, HbA1c and tumor markers (Ozarda 2018). They are derived from receiver operating characteristic curves and predictive values in clinical studies (Ozarda 2016).

Biological variation, reference change value and delta checks

Reference change value (RCV). The RCV is the smallest difference between two serial results that exceeds combined analytical and within-subject variation. The symmetric formula of Harris and Yasaka is RCV = 2^½ × Z × (CVA² + CVI²)^½, where Z is 1.96 for a two-sided 95% probability (Paal 2021). An asymmetric (log-normal) form is used for analytes that are not normally distributed (Paal 2021).

Biological variation database. The EFLM biological variation database publishes global within-subject and between-subject estimates derived from meta-analysis of quality-assured studies. It calculates analytical performance specifications automatically (Sandberg 2024).

Delta checks. A delta check compares a current result with the patient's previous result to detect changes that indicate errors such as specimen misidentification. Limits are analyte specific, and arbitrary limits increase unnecessary checks (Shin 2025).

Analytical performance specifications

  • Milan models (2015). The first EFLM Strategic Conference defined three models for analytical performance specifications: clinical outcome, biological variation and state of the art (Sandberg 2015; Westgard S 2018). The Milan consensus replaced the five-level 1999 Stockholm hierarchy (Westgard S 2018).
  • Sources of allowable total error (TEa). TEa goals differ among CLIA, the Royal College of Pathologists of Australasia, the German RiliBÄK guidelines and biological variation databases. Under the Milan consensus, regulatory and external quality assessment goals belong to the state-of-the-art model (Westgard S 2018).
  • CLIA PT limits as TEa. CMS states that the CLIA criteria for acceptable performance are meant for PT scoring only. They are not intended to set acceptability criteria for a laboratory's verification or establishment of performance specifications (87 FR 41194).

Control materials and Levey-Jennings charts

  • CLIA default control frequency. For each quantitative procedure, two control materials of different concentrations are run at least once each day patient specimens are tested. An electrophoretic procedure includes at least one control containing the substances measured (42 CFR 493.1256(d)).
  • Other CLIA control rules. Controls are run after a complete change of reagents, major preventive maintenance or replacement of a critical part. They are rotated among operators and tested in the same manner as patient specimens. A calibrator used as a control comes from a lot different from the one used to calibrate (42 CFR 493.1256(d)).
  • Statistical parameters. A mean and SD are defined for each lot of quantitative control. An assayed control's stated value is used only when it applies to the laboratory's method and is verified (42 CFR 493.1256(d)(10)).
  • Initial mean and SD. When no previous data exist, at least 20 control values on different days provide the initial estimates (Gruber 2024).
  • New lots and shifts. A new reagent or control lot can shift the control mean while the SD remains similar. Ten measurements on different days usually give a provisional mean (Gruber 2024).
  • Commutability. A control material is commutable when it behaves like patient samples. Matrix changes by the manufacturer can make a control noncommutable, and the control can then indicate a bias that is absent in patient samples (Gruber 2024).

Westgard multirule quality control

Westgard and colleagues described the multirule Shewhart procedure in 1981 (Westgard 1981). Individual rules were chosen to keep the probability of false rejection low. Their combination raises the probability of error detection (Ricós 2022). A multirule rejects a run when any one of its rules is violated (Gruber 2024).

Rule Violation Error usually indicated Source
1-2s One control exceeds the mean ± 2 SD Warning rule Gruber 2024; Cristelli 2025
1-3s One control exceeds the mean ± 3 SD Random error or the start of systematic error; rejection rule Gruber 2024; Cristelli 2025
2-2s Two consecutive controls exceed the same 2 SD limit (both above +2 SD or both below −2 SD) Systematic error Gruber 2024; Cristelli 2025
R-4s Difference between the high and low control results within a run exceeds 4 SD Random error Gruber 2024; Cristelli 2025
3-1s Three consecutive controls exceed the same 1 SD limit Systematic error Gruber 2024; Cristelli 2025
4-1s Four consecutive controls exceed the same 1 SD limit Systematic error Gruber 2024; Cristelli 2025
10x Ten consecutive controls fall on one side of the mean Systematic error Gruber 2024; Cristelli 2025
7T Seven consecutive controls trend in one direction Trend Gruber 2024
  • False rejection with 1-2s. As a rejection rule, 1-2s has a false rejection probability of 4.6% with one control level, 8.9% with two and 13.0% with three (Gruber 2024).
  • Stricter rules. Tighter limits detect smaller errors without improving the method. They also raise the rate of rule violations, troubleshooting and repeat testing (Gruber 2024).

Sigma metrics and risk-based statistical quality control

  • Sigma metric. Sigma equals (TEa% − |bias%|) ÷ CV%. Bias always reduces the allowable error (Westgard S 2018). A Six Sigma process produces about 3.4 defects per million on the short-term scale, which assumes a 1.5 SD long-term shift (Westgard S 2018).
  • Method decision chart. Bias is plotted against CV with zones for world class (6 sigma), excellent (5), good (4), marginal (3), poor (2) and unacceptable (below 2) performance (Westgard S 2018).
  • QC design by sigma. Operating specifications (OPSpecs) charts show which rules and how many controls give adequate error detection. A method near 6 sigma can use 3 SD limits and few controls. Methods with low sigma need the full multirule, more controls and more frequent QC (Westgard S 2018).
  • QC frequency and run size. Parvin's patient risk model, made practical by nomograms, links sigma to the number of patient samples between QC events (run size). Six Sigma methods can run 500 or more patient samples between QC events. Three Sigma methods need QC about every 50–100 samples (Westgard S 2018). A Sigma-metric run size matrix and Westgard Sigma Rules with run sizes summarize these choices (Westgard 2019).
  • CLSI C24 (4th edition). CLSI C24-Ed4 recommends risk-based SQC strategies. Run size can be adjusted for the patient risk of a test (Westgard 2021).
  • Limitations. A sigma value depends on the TEa source chosen (Westgard S 2018). The value of sigma metrics and of the TAE model is disputed (Bayat 2024).

Patient-based real-time quality control (PBRTQC). Moving averages of patient results were first described in the 1960s as the average of normals (Ricós 2022). They work best for analytes under tight biological control, such as electrolytes and calcium (Ricós 2022). PBRTQC avoids the matrix effects of synthetic controls and lowers QC cost (Gruber 2024).

Default quality control, IQCP and the end of Equivalent Quality Control

Current rule: Individualized Quality Control Plan (IQCP), effective January 1, 2016. IQCP is a voluntary alternative to the default control frequency in 42 CFR 493.1256(d). It applies to all nonwaived testing, and all CLIA specialties and subspecialties except pathology are eligible (CMS IQCP workbook).

IQCP part Content Source
Risk assessment Identification and evaluation of potential failures in the whole testing process; at minimum five components: specimen, test system, reagent, environment and testing personnel CMS IQCP workbook
Quality control plan The laboratory's procedure that describes the practices, resources and frequency of controls for the test CMS IQCP workbook
Quality assessment Ongoing monitoring of the effectiveness of the plan, with corrective action CMS IQCP workbook

Previous rule: Equivalent Quality Control (EQC). EQC let laboratories reduce external QC for test systems with internal electronic, internal or procedural controls if CMS approved the procedure (Anderson 2015). The transition period ran from January 1, 2014 to December 31, 2015. From January 1, 2016, EQC is no longer acceptable, and a laboratory that runs QC less often than the CLIA default needs an IQCP with supporting data (Anderson 2015). CMS describes the official IQCP procedure in Appendix C of the State Operations Manual (CMS 2026).

Proficiency testing under CLIA

Enrollment, handling of PT samples and referral

  • Enrollment. Each laboratory enrolls in an HHS-approved PT program for every specialty, subspecialty and analyte for which it is certified. A laboratory stays with a program for one year before changing (42 CFR 493.801(a)).
  • Same manner as patients. PT samples are tested with the regular workload, by personnel who routinely perform the test, with routine methods and the same number of replicate tests used for patients. The analyst and the laboratory director sign an attestation (42 CFR 493.801(b)).
  • Communication. Laboratories do not discuss PT results with other laboratories, or among their own sites, until after the reporting deadline (42 CFR 493.801(b)(4)).
  • Referral. A laboratory does not send PT samples to another laboratory for any test it is certified to perform. Intentional referral can lead to revocation of the certificate for at least 1 year. A laboratory that receives another laboratory's PT sample notifies CMS (42 CFR 493.801(b)(5)).
  • Records. PT records, including the attestation, are kept for at least 2 years (42 CFR 493.801(b)(6)).
  • Primary method. PT is required only for the test system used as the primary method for patient testing during the event (42 CFR 493.801(b)(7)).

CLIA PT program design, scoring and sanctions

Element Requirement Source
Challenges At least 5 samples per testing event 42 CFR 493.931(a)
Events At least 3 testing events per year at about equal intervals 42 CFR 493.931(a)
Target value Mean of all participants after removal of results beyond 3 SD; a definitive or reference-method value; or, if neither is available, the peer-group mean (peer groups of 10 or more) 42 CFR 493.2
Grading consensus Agreement of 80% or more of 10 or more referee laboratories, or of 80% or more of all participants 42 CFR 493.931(c)(1)
Satisfactory analyte score At least 80% acceptable responses for each analyte in each event 42 CFR 493.841(a)
Satisfactory event score Overall testing event score of at least 80% 42 CFR 493.841(b)
Failure to participate or late return Unsatisfactory performance with a score of 0 42 CFR 493.841(c)–(d)
Unsatisfactory performance Failure to reach the minimum score for an analyte, test, subspecialty or specialty in one event 42 CFR 493.2
Unsuccessful performance Unsatisfactory performance for the same analyte in 2 consecutive events or 2 of 3 consecutive events 42 CFR 493.2; 493.841(f)
Response to unsatisfactory performance Training and technical assistance, with remedial action documented and kept for 2 years 42 CFR 493.841(e)
First unsuccessful performance CMS may direct training or technical assistance as an alternative to sanctions, unless there is immediate jeopardy, inadequate correction or a poor compliance history 42 CFR 493.803(c)
Reinstatement Two consecutive satisfactory events after a suspension or limitation of at least 6 months 42 CFR 493.807

Analytes without PT. For tests not listed in subpart I, and for listed tests with no compatible PT, the laboratory verifies accuracy at least twice a year (42 CFR 493.1236(c)). Verification is also required when a PT program cannot score a sample (42 CFR 493.1236(b)).

CLIA PT acceptance limits for chemistry analytes, current and before July 11, 2024

Current rule. The final rule of July 11, 2022 (87 FR 41194) amended 42 CFR 493.2 and 493.801–493.959, effective July 11, 2024. It added 29 analytes and deleted 5: LDH isoenzymes, ethosuximide, quinidine, primidone and procainamide with N-acetylprocainamide. CMS tightened the limits because peer-group targets and improved precision had made the 1992 limits more tolerant than intended (87 FR 41194). A correction changed the CEA unit from ng/dL to ng/mL (87 FR 68912).

Previous rule. The criteria of 57 FR 7151 (1992, amended 2003) applied until July 10, 2024 (eCFR 42 CFR 493.931 and 493.933 as of January 1, 2024).

Routine chemistry (42 CFR 493.931).

Analyte From July 11, 2024 Before July 11, 2024
ALT and AST ±15% or ±6 U/L (greater) ±20%
Albumin ±8% ±10%
Alkaline phosphatase ±20% ±30%
Bilirubin, total ±20% or ±0.4 mg/dL (greater) ±0.4 mg/dL or ±20% (greater) (unchanged)
Blood gas pO₂ ±15% or ±15 mm Hg (greater) ±3 SD
Calcium, total ±1.0 mg/dL ±1.0 mg/dL (unchanged)
Chloride ±5% ±5% (unchanged)
Cholesterol, total ±10% ±10% (unchanged)
Creatinine ±10% or ±0.2 mg/dL (greater) ±0.3 mg/dL or ±15% (greater)
Glucose (excluding FDA-cleared home-use devices) ±8% or ±6 mg/dL (greater) ±6 mg/dL or ±10% (greater)
Hemoglobin A1c ±8% Not regulated
Potassium ±0.3 mmol/L ±0.5 mmol/L
Sodium ±4 mmol/L ±4 mmol/L (unchanged)
Troponin I ±30% or ±0.9 ng/mL (greater) Not regulated
Troponin T ±30% or ±0.2 ng/mL (greater) Not regulated
Urea nitrogen ±9% or ±2 mg/dL (greater) ±2 mg/dL or ±9% (greater) (unchanged)
Uric acid ±10% ±17%

The complete analyte lists are in 42 CFR 493.931 and 493.933. Sources: 42 CFR 493.931 (eCFR, current); 42 CFR 493.931 (eCFR, January 1, 2024); 87 FR 41194.

Endocrinology analytes used in chemistry (42 CFR 493.933; selected analytes).

Endocrine analyte From July 11, 2024 Before July 11, 2024
Carcinoembryonic antigen (CEA) ±15% or ±1 ng/mL (greater) Not regulated
Cortisol ±20% ±25%
Free thyroxine ±15% or ±0.3 ng/dL (greater) ±3 SD
Human chorionic gonadotropin (hCG; excluding waived visual urine tests) ±18% or ±3 mIU/mL (greater), or positive or negative ±3 SD, or positive or negative
Prolactin ±20% Not regulated
Thyroid-stimulating hormone (TSH) ±20% or ±0.2 mIU/L (greater) ±3 SD

Sources: 42 CFR 493.933 (eCFR, current); 42 CFR 493.933 (eCFR, January 1, 2024); 87 FR 41194; 87 FR 68912.

CLIA proficiency testing acceptance limit lookup (routine chemistry)

Preanalytic Variables, Specimen Integrity and Point-of-Care Testing in Clinical Chemistry

Definition. The preanalytic phase covers every step from test ordering and patient preparation to specimen collection, transport, processing and storage before analysis. It is the phase in which most laboratory errors arise (Plebani 1997; Carraro 2007). Hemolysis is the most common preanalytical error and accounts for more than 60% of specimen rejections (Simundic 2020). In point-of-care testing (POCT), hemolysis detection is limited because whole blood is analyzed without separation (Pighi 2025).

Related page: Coagulation Specimen Collection, Screening Tests and Mixing Studies (order of draw, citrate tube filling, and hemolysis, icterus and lipemia in optical clot detection) Related page: Automated Blood Counts, Reticulocyte Count and Peripheral Smear Review (EDTA specimens, underfilled EDTA tubes and spurious blood count results) Related page: Hemolytic Anemias: Red Cell Membrane and Enzyme Defects and Paroxysmal Nocturnal Hemoglobinuria (in vivo hemolysis markers and red cell membrane disorders) Related page: Liver, Kidney and Gastrointestinal Function Tests (ammonia stability and ex vivo uricolysis in rasburicase-treated patients) Related page: Anticoagulant Monitoring, DOAC Measurement and Heparin-Induced Thrombocytopenia Testing (point-of-care activated clotting time and INR) Related page: Analytical Methods and Immunoassays in Clinical Chemistry (biotin interference and the high-dose hook effect) Related page: Method Validation, Statistical Quality Control and Proficiency Testing in Clinical Chemistry (reference change value, delta checks and IQCP)

Distribution of laboratory errors by testing phase

Study Analyses monitored Errors Preanalytical Analytical Postanalytical Source
Padova stat laboratory, 1996 40,490 189 (0.47%) 68.2% 13.3% 18.5% Plebani 1997
Same design, 2006 51,746 160 (3,092 ppm) 61.9% 15.0% 23.1% Carraro 2007
  • Consequences. In the 1996 study, 74% of mistakes did not affect patient outcome. Mistakes led to further inappropriate investigations in 19% of affected patients and to inappropriate care in 6.4% (Plebani 1997).
  • Quality indicators. The IFCC Working Group on Laboratory Errors and Patient Safety recommends six essential quality indicators. Three are preanalytical: misidentified requests and samples, sample rejections, and hemolyzed samples (De Guire 2026).
  • Fasting. Postprandial lipemia interferes with laboratory measurements. Required fasting times differ by country, from at least 8 hours in Italian recommendations to 10–16 hours in Australian recommendations for lipid testing (Nikolac 2014). In 30 volunteers, results 4 and 6 hours after a controlled meal stayed within the reference change value of results after a 10-hour fast for all tested parameters, although some exceeded total allowable error criteria (Solé-Enrech 2025).
  • Coffee. One cup of coffee 1 hour before phlebotomy produced statistically significant changes in several analytes, none of which exceeded the reference change value (Benozzi 2023).
  • Posture. Changing position between sitting and lying shifts plasma volume. Sitting compared with lying raised albumin by 2.0% and total protein by 2.9% (Ialongo 2016).
  • Time of collection. Cortisol and testosterone concentrations are higher in the morning. Estradiol depends on the day of the menstrual cycle (Ghazal 2022).
  • Supplements and drugs. High-dose biotin interferes with streptavidin-biotin immunoassays. The mechanism and its management are covered in Analytical Methods and Immunoassays in Clinical Chemistry.

Venipuncture technique and collection errors

Current guideline. The joint EFLM-COLABIOCLI recommendation (2018) applies to closed blood collection systems. It grades each step by quality of evidence and strength of recommendation and was endorsed by 33 of 40 EFLM and all 21 COLABIOCLI member societies (Simundic 2018). Ialongo 2016 cites CLSI H3-A6 as the US venipuncture standard. CLSI GP41, Collection of Diagnostic Venous Blood Specimens, now provides the US procedure for venous collection, including the order of draw (CLSI 2019).

  • Tourniquet and venous stasis. Prolonged or excessive tourniquet pressure raises hydrostatic pressure in the vein and forces water into the tissue. The specimen then shows hemoconcentration and activation of coagulation (Ialongo 2016).
  • Fist clenching. Strenuous or prolonged fist clenching depolarizes skeletal muscle cells and raises extracellular potassium (Ialongo 2016). Don and colleagues described this pseudohyperkalemia in 1990 (Don 1990).
  • Mechanical hemolysis. Shear stress on red cells in a small-bore needle and needle probing of the tissue cause hemolysis and potassium release (Ialongo 2016).
  • Intravenous fluid contamination. Contamination with intravenous fluid is a common cause of rejection or erroneous results in hospitalized patients. Failed delta checks are neither sensitive nor specific for it. An algorithm based on two or more result criteria had a positive predictive value of 92% and a negative predictive value of 91% (Newbigging 2024). In one case, blood drawn from the arm receiving an infusion showed low sodium, potassium and chloride, extreme hypermagnesemia and glucose of 55.4 mmol/L. Repeat sampling gave results within reference ranges (Rolić 2026).
  • Documentation. Deviations from the standard procedure are reported to the laboratory, including failure to fast, a position other than sitting and a venous line in the same vascular region (Ialongo 2016).

Venous stasis and posture effects on chemistry analytes.

Factor Analyte bias reported Source
Tourniquet for 1 minute Albumin +1.6%; calcium +1.6%; potassium −2.8%; ALT +15.7% Ialongo 2016
Tourniquet for 3 minutes Albumin +8.6%; calcium +3.6%; cholesterol +9.1%; iron +8.8%; glucose −3.7%; potassium −4.8% Ialongo 2016
Sitting compared with lying Albumin +2.0%; total protein +2.9% Ialongo 2016

Collection tubes, additives and order of draw

Order of draw. The CLSI order of draw is blood culture, sodium citrate, serum tubes (with or without clot activator or gel), heparin (with or without gel), EDTA, and sodium fluoride/potassium oxalate. Only blood culture tubes, glass nonadditive serum tubes or plastic serum tubes without clot activator may be drawn before the coagulation tube (CLSI 2019). Collection of coagulation tubes is covered in Coagulation Specimen Collection, Screening Tests and Mixing Studies.

  • EDTA contamination. Contamination with K2- or K3-EDTA causes spurious hyperkalemia, hypocalcemia, hypomagnesemia, hypozincemia and hypophosphatemia. It also alters alkaline phosphatase and other enzyme activities and prolongs clotting times (Bazzano 2021).
  • Evidence on carryover. A systematic review found that cross-contamination from incorrect order of draw is limited to open collection systems. Its effect is negligible with closed systems (Bazzano 2021). In 388 outpatients, a serum tube drawn after a K-EDTA tube showed no EDTA contamination. Potassium nevertheless differed by more than 0.3 mmol/L in 24% of consecutive serum tube pairs, regardless of the tube between them (Ercan 2021).
  • Serum and lithium heparin plasma. Platelets release potassium during in vitro clotting, so serum potassium correlates with the platelet count (Delgado 2022). When centrifugation was delayed, lithium heparin tubes released more potassium than serum tubes (1.21 compared with 0.94 mmol/L). After 8 hours, pseudohyperkalemia developed in 164 of 201 lithium heparin specimens and 76 of 201 serum specimens (Reuter 2024).
  • Gel separators. Drugs adsorb to separator gel. In plasma separator tubes, about 50% of 53 drugs and metabolites were significantly lower after 1 day and about 75% after 3 months, with losses of up to 69%. Fentanyl, ketamine and several antidepressants were most affected (Shepard 2023).
  • Glucose and glycolysis inhibitors. Sodium fluoride tubes do not inhibit glycolysis immediately and lose glucose in the first 1–4 hours (Dibbasey 2024). A citrate-sodium fluoride-EDTA tube showed virtually no glucose loss over 48 hours (Nounou 2026). Serum separator tubes centrifuged within 2 hours and refrigerated gave glucose results stable for 3 days (Dibbasey 2024).
  • Underfilled tubes. Underfilling raises the ratio of additive to blood. In K2EDTA tubes filled with 1.5 or 3.0 mL of a nominal 6.0 mL, RNA yield and the GAPDH cycle threshold shifted significantly (Benati 2024). Underfilled citrate tubes are covered in Coagulation Specimen Collection, Screening Tests and Mixing Studies.

Specimen processing, temperature and stability

  • Delayed centrifugation. Most analytes remained stable for up to 24 hours before centrifugation. Potassium, inorganic phosphorus, magnesium, LDH, glucose and lactate were affected by delay, tube type or temperature (Oddoze 2012). Lactate is therefore analyzed promptly after collection.
  • Temperature and potassium. Cold inhibits the red cell Na⁺/K⁺-ATPase, and potassium leaks out of the cells. Low temperature causes pseudohyperkalemia and high temperature causes pseudohypokalemia (Umińska 2026).
  • Blood gas specimens. In arterial blood gas specimens, no variable exceeded the threshold for clinical relevance within 30 minutes. Partial pressure of oxygen exceeded it first, after 45 minutes (Kristinsdottir 2025).
  • Removal of lipids. Ultracentrifugation removes lipids effectively. A high-speed centrifuge at 10,000 × g is almost as effective, and lower-force centrifugation clears the sample only when chylomicrons cause the turbidity (Nikolac 2014). The relative centrifugal force formula is given in Analytical Methods and Immunoassays in Clinical Chemistry.
  • Ammonia. Ammonia specimen collection and stability are covered in Liver, Kidney and Gastrointestinal Function Tests.
  • Bilirubin and light. Bilirubin undergoes photodegradation. In CSF from patients with subarachnoid hemorrhage, bilirubin fell in 96% of samples stored in room light and degraded significantly faster than in samples stored in the dark. The authors note that serum bilirubin shows the same photodegradation and recommend immediate centrifugation and protection from light (Foroughi 2010).
  • Freeze–thaw cycles. After up to four freeze–thaw cycles at −80 °C, most of 42 analytes in plasma or serum pools were stable. HDL cholesterol, chloride and sodium were not (Mikkelsen 2025). Among 17 endocrine analytes, serum free thyroxine was unstable after four cycles (Tjernvoll 2025).

Stability of common chemistry analytes in published studies.

Condition Stable Unstable (time to instability where reported) Source
Lithium heparin plasma on cells, primary tube, 2–8 °C 24 of 29 analytes for 48 hours Glucose (2.7 h), LDH (2.9 h), potassium (4.7 h), inorganic phosphate (6.2 h), AST (7.9 h) Illana 2024
Separated plasma aliquots, 2–8 °C All analytes for 96 hours except LDH LDH (63 h) Illana 2024
Uncentrifuged clotted blood, 30 °C, up to 72 hours Albumin, ALP, total bilirubin, cholesterol, HDL, total protein, triglycerides, uric acid, hsCRP Remaining analytes of the 20 tested Iacovetti 2026
Separated serum, 30 °C, 72 hours Most analytes ALT, total bilirubin, carbon dioxide, creatinine, sodium Iacovetti 2026
Separated serum, 0 °C, 72 hours All 20 analytes None Iacovetti 2026
Unseparated whole blood, refrigerated Not applicable Potassium rose 5% at 4 hours and 20% at 8 hours Umińska 2026
Serum, −20 °C, 1–10 freeze–thaw cycles AST, ALT, CK, GGT, direct bilirubin, glucose, creatinine, cholesterol, triglycerides, HDL Urea nitrogen, uric acid, total protein, albumin, total bilirubin, calcium, LDH Cuhadar 2013

Hemolysis, icterus and lipemia

Hemolysis. Hemolysis is the release of intracellular components from red cells and other blood cells into serum or plasma. In vivo hemolysis reflects a pathological condition. In vitro hemolysis is preventable and can occur during collection, transport, handling or storage (Simundic 2020).

Mechanism of hemolysis interference Example effect Source
Spectrophotometric interference Absorbance of cell-free hemoglobin Simundic 2020
Release of intracellular components Potassium, LDH and AST rise Simundic 2020; Uçar 2022
Sample dilution Dilution of plasma analytes by cell contents Simundic 2020
Chemical interference Reaction of hemoglobin or cell contents with assay reagents Simundic 2020

Hemoglobin concentrations at which hemolysis exceeded the reference change value (Beckman Coulter AU680).

Analyte Reference change value Cell-free hemoglobin above which the result was rejected Source
LDH 19.2% 0.5 g/L Uçar 2022
AST 27.9% 0.8 g/L Uçar 2022
Potassium 12.1% 1.6 g/L Uçar 2022
Total bilirubin 61.2% 2.2 g/L Uçar 2022
ALT 29.6% 5.9 g/L Uçar 2022

EFLM reporting algorithm for hemolyzed samples (Lippi 2018).

Hemolysis index finding Action Source
Bias below analytical significance Result released Lippi 2018
Bias between analytical significance and the reference change value Result released with a comment on the direction of the bias and a request for recollection Lippi 2018
Bias above the reference change value Result suppressed with a comment that the sample is compromised Lippi 2018
Cell-free hemoglobin ≥10 g/L All results suppressed as grossly hemolyzed Lippi 2018
Correction formulas Discouraged because of inaccuracy and imprecision Lippi 2018
  • Automated indices. Automatic measurement of the hemolysis index is highly advisable (Lippi 2018).
  • Comparability of serum indices. On three chemistry analyzers, precision was best for the hemolysis index. The icterus index was inaccurate on all three and was not comparable between any pair of analyzers. Each laboratory verifies its serum indices (Nikolac Gabaj 2018).

Lipemia. Lipemia is turbidity caused by lipoproteins, and chylomicrons (70–1000 nm) cause the most turbidity. After centrifugation, water-soluble analytes are depleted in the upper lipid layer and lipophilic drugs accumulate in it (Nikolac 2014). Spectral interference and volume displacement by lipid are covered in Analytical Methods and Immunoassays in Clinical Chemistry.

Causes of spurious hyperkalemia

Cause Distinguishing features Source
In vitro hemolysis Raised hemolysis index; LDH and AST also raised Simundic 2020; Uçar 2022
Fist clenching Collection history; no hemolysis Ialongo 2016
EDTA contamination Low calcium, magnesium and ALP with high potassium Bazzano 2021
Thrombocytosis Serum potassium correlates with the platelet count; interference above 598 × 10³/µL Delgado 2022
Severe leukocytosis Markedly raised white cell count with normal hemolysis index Umińska 2026
Cold storage of whole blood Rise with time at 4 °C Umińska 2026
Familial pseudohyperkalemia Temperature-dependent red cell potassium leak; heterozygous ABCB6 variant in a reported case Xiong 2022; Flatt 2018
Dehydrated hereditary stomatocytosis Autosomal dominant PIEZO1 variants, with or without pseudohyperkalemia; KCNN4 (Gardos channel) variants also cause dehydrated stomatocytosis Martin-Almedina 2018; Flatt 2018

Capillary collection in infants and children

  • Site. The medial or lateral plantar surface of the heel is the preferred site in infants up to one year old. Venipuncture is preferred in term neonates because heel puncture is more painful and needs more resampling (Krleza 2015).
  • Technique. The first drop is wiped away unless a POCT device requires it. Squeezing or milking causes hemolysis and dilution with interstitial fluid (Krleza 2015).
  • Order of capillary collection. Blood gas samples are collected first, then EDTA samples, then other additives and serum last. This order limits platelet clumping (Krleza 2015).
  • Limits of capillary samples. Capillary potassium and calcium differ from venous values and are confirmed on venous blood when accuracy matters. Povidone-iodine contamination raises potassium, phosphorus and uric acid (Krleza 2015).
  • Dried blood spots. Spot homogeneity affects accuracy, precision and analyte recovery (Krleza 2015).

Completeness and preservation of urine collections

Completeness of a 24-hour urine collection is assessed by creatinine excretion. Criteria used include sex-specific creatinine excretion of 15–25 mg/kg/24 h in men and 10–20 mg/kg/24 h in women, a creatinine index of 0.7 or more, and recovery of para-aminobenzoic acid (Naser 2020). The EFLM European Urinalysis Guideline 2023 supports patient preparation and urine collection with two quality indicators: the contamination rate of cultures and urine density for chemistry and particle testing (Kouri 2024). For stone-related metabolites, single-voided urine without acidification stayed within 20% of baseline for 2 days for most analytes. Acidification before storage caused stability failures for oxalate and uric acid (Šálek 2025).

Point-of-care testing under CLIA

Test complexity and certificates. CLIA test complexity categories and certificate types are covered in CLIA '88 Cytology Regulations: Workload Limits, Workload Assessment, Personnel and Accreditation. Moderate-complexity testing, including provider-performed microscopy (PPM), and high-complexity testing meet the nonwaived quality standards and require PT for regulated analytes (42 CFR 493.5; 493.803).

  • Waived criteria. A waived test is cleared by FDA for home use, uses a method so simple and accurate that erroneous results are negligible, or poses no reasonable risk of harm if performed incorrectly (42 CFR 493.15(b)).
  • Examples in regulation. The waived list includes nonautomated dipstick urinalysis, nonautomated fecal occult blood, visual urine pregnancy tests and blood glucose by devices cleared by FDA for home use (42 CFR 493.15(c)).
  • Program management. A physician or doctoral scientist trained in laboratory medicine supervises the POCT program. A POCT coordinator handles training, audits and troubleshooting. The program defines written procedures, training and competency assessment, error mitigation, documentation and device connectivity (Khan 2021). AACC published guidance on POCT management in 2020 (Nichols 2020).
  • Quality control. POCT devices with internal monitoring can use an individualized quality control plan (Khan 2021).

Glucose meters

Enzyme systems. Meters use glucose oxidase or glucose dehydrogenase (Pullano 2022). Amperometric sensor generations are covered in Analytical Methods and Immunoassays in Clinical Chemistry.

Source of meter error Effect Source
High hematocrit Underestimation from reduced plasma diffusion Pullano 2022
Low hematocrit Overestimation; positive bias at 20%–30% hematocrit on two hospital meters Pullano 2022; Pudineh Moarref 2026
Glucose dehydrogenase-pyrroloquinoline quinone (GDH-PQQ) strips Cross-reaction with galactose, maltose and xylose; direct oxidation by N-acetylcysteine and ascorbic acid (bias up to 446%, 99% and 61% for galactose, ascorbic acid and N-acetylcysteine on one meter) Pudineh Moarref 2026
FAD-dependent glucose dehydrogenase with a low-potential mediator Minimal interference from galactose, ascorbic acid and N-acetylcysteine Pudineh Moarref 2026
Glucose oxidase strips Interference from uric acid, galactose, xylose, L-dopa, acetaminophen and ascorbic acid Pullano 2022
Maltose-containing intravenous solutions Listed by FDA as an exogenous interference hazard for meters FDA 2020

FDA guidance for prescription point-of-care meters (September 2020). For health care professional use, 95% of meter results fall within ±12% of the comparator above 75 mg/dL and within ±12 mg/dL below 75 mg/dL. In addition, 98% fall within ±15% above 75 mg/dL and within ±15 mg/dL below 75 mg/dL. Hospital meters measure accurately from 10 to 500 mg/dL. Neonatal samples are evaluated separately because neonatal blood often has a hematocrit of 51%–65% and glucose of 20–80 mg/dL (FDA 2020). This guidance replaced the version of October 11, 2016 (FDA 2020).

Critically ill patients. In a systematic review, arterial blood gas analyzers were more accurate than glucose meters with capillary blood. Errors were more frequent below 81 mg/dL and with edema, vasopressors or insulin infusion (Inoue 2013).

Point-of-care blood gases and electrolytes

  • Undetected hemolysis. Detection of hemolysis at the point of care is limited because whole blood is not separated (Pighi 2025). In 472 emergency department arterial blood gas samples tested with a separate hemolysis device, 14.4% were hemolyzed. Potassium was 4.60 mmol/L in hemolyzed and 3.99 mmol/L in nonhemolyzed samples (Nigro 2022).
  • Whole-blood hemolysis index. A blood gas analyzer that measures a whole-blood hemolysis index detected potassium increases above a 7.4% allowable error with an area under the curve of 1.00 at an optimal cutoff of 102 mg/dL (Pighi 2025).

Point-of-care urine hCG

  • Hook effect. Qualitative sandwich urine hCG devices can be falsely negative at very high hCG concentrations through the high-dose hook effect, covered in Analytical Methods and Immunoassays in Clinical Chemistry.
  • hCG β-core fragment. Urinary hCG β-core fragment exceeds intact hCG throughout pregnancy and peaks at 10–16 weeks. High concentrations cause false-negative results on some qualitative devices (Nerenz 2016).

Plasma Proteins, Protein Electrophoresis, Free Light Chains and CSF Oligoclonal Bands

Definition. Serum protein electrophoresis (SPEP) separates serum proteins by charge, size and shape into albumin and five globulin fractions, and densitometry gives the absolute and relative amount of each fraction (O'Connell 2005). SPEP detects and quantifies a monoclonal immunoglobulin (M-protein). Immunofixation electrophoresis (IFE) establishes its isotype, and the serum free light chain (FLC) assay measures free kappa and lambda light chains (Murray 2021). Paired cerebrospinal fluid (CSF) and serum analysis detects intrathecal immunoglobulin synthesis by oligoclonal bands (OCB) or by the kappa FLC index (Hegen 2023).

Related page: Analytical Methods and Immunoassays in Clinical Chemistry (electrophoresis principles, nephelometry, antigen excess and immunoassay interference) Related page: Hemolytic Anemias: Red Cell Membrane and Enzyme Defects and Paroxysmal Nocturnal Hemoglobinuria (haptoglobin and hemopexin as hemolysis markers) Related page: Hemoglobin Variant Analysis and Laboratory Diagnosis of Thalassemia (hemoglobin electrophoresis and HPLC) Related page: Automated Blood Counts, Reticulocyte Count and Peripheral Smear Review (cryoglobulin artifacts and rouleaux on blood counts) Related page: CSF Specimen Handling and Normal and Contaminant Findings (CSF cell counts and cytology) Related page: Liver, Kidney and Gastrointestinal Function Tests (proteinuria evaluation and albuminuria categories)

Albumin, prealbumin and the acute-phase response

  • Albumin methods. Routine albumin methods are dye-binding assays with bromocresol green (BCG) or bromocresol purple (BCP), and both can lack selectivity (van Schrojenstein Lantman 2023).
  • BCG overestimation. In 163 plasma samples from patients with chronic kidney disease (CKD) stages G1–G5, measured on six BCG and BCP platforms and four immunological platforms, agreement with a reference-corrected nephelometric target was 92.7% for BCP, 86.2% for immunological methods and 66.7% for BCG. BCG overestimated albumin, and fewer patients met the albumin cutoff of <38 g/L for protein-energy wasting with BCG results (van Schrojenstein Lantman 2023).
  • Albumin and prealbumin as nutrition markers. The American Society for Parenteral and Enteral Nutrition (ASPEN) position is that serum albumin and prealbumin (transthyretin) characterize inflammation. They fall in critical and chronic illness through hepatic reprioritization of protein synthesis and increased capillary permeability. They correlate with the risk of adverse outcomes and are not used as markers of nutrition status (Evans 2021).
  • Acute-phase pattern. Acute inflammation, malignancy, trauma, necrosis, infarction, burns and chemical injury increase fibrinogen, alpha-1 antitrypsin, haptoglobin, ceruloplasmin, C-reactive protein (CRP), complement C3 and alpha-1 acid glycoprotein. Albumin and transferrin often decrease (O'Connell 2005).
  • Procalcitonin. Procalcitonin is a peptide precursor of calcitonin whose serum concentration rises with systemic inflammation from bacterial infection and sepsis. Its specificity is limited, procalcitonin methods are not harmonized, and evidence supports its use to guide antibiotic cessation in the critically ill and in some lower respiratory tract infections (Chambliss 2023).

Acute-phase reactants on SPEP.

Direction in inflammation Proteins SPEP region Source
Increased Alpha-1 antitrypsin Alpha-1 O'Connell 2005
Increased Haptoglobin, ceruloplasmin Alpha-2 O'Connell 2005
Increased Complement C3 Beta O'Connell 2005
Increased CRP Between beta and gamma O'Connell 2005
Decreased Albumin, transferrin Albumin; beta-1 O'Connell 2005

Serum protein electrophoresis zones and patterns

Albumin is the largest peak and lies closest to the anode. The globulins follow toward the cathode as alpha-1, alpha-2, beta-1, beta-2 and gamma (O'Connell 2005). Immunoglobulins are found throughout the electrophoretic spectrum, although most migrate in the gamma region (O'Connell 2005).

Zone Main proteins Increased in Decreased in Source
Albumin Albumin Dehydration Malnutrition, liver disease, nephrotic syndrome, protein-losing enteropathy, burns, pregnancy O'Connell 2005
Alpha-1 Alpha-1 antitrypsin, thyroid-binding globulin, transcortin Acute inflammation, malignancy, pregnancy Alpha-1 antitrypsin deficiency, liver disease O'Connell 2005
Alpha-2 Alpha-2 macroglobulin, haptoglobin, ceruloplasmin Acute-phase response, nephrotic syndrome, corticosteroid therapy Malnutrition, severe liver disease, Wilson disease, megaloblastic anemia O'Connell 2005
Beta-1 and beta-2 Transferrin (beta-1); beta-lipoprotein (beta-2); IgA, IgM and complement Iron deficiency anemia, obstructive jaundice, nephrosis, third-trimester pregnancy Protein malnutrition O'Connell 2005
Gamma Immunoglobulins, mainly IgG Polyclonal: chronic infection, connective tissue disease, cirrhosis; monoclonal: plasma cell and lymphoproliferative neoplasms Agammaglobulinemia, hypogammaglobulinemia O'Connell 2005
  • Monoclonal and polyclonal patterns. An M-protein forms a sharp, well-defined band with a single heavy chain and a single light chain type. A polyclonal increase forms a broad, diffuse band with both kappa and lambda light chains (O'Connell 2005).
  • SPEP in myeloma. In one series cited by O'Connell, SPEP showed a spike or localized band in 82% of patients with multiple myeloma, and the remainder had hypogammaglobulinemia or a normal-appearing pattern. Hypogammaglobulinemia without a serum spike occurs in about 10% of patients with myeloma, most of whom excrete large amounts of Bence Jones protein (O'Connell 2005).

Quantitation of the M-protein

  • Gating methods. Laboratories gate the M-protein by perpendicular drop or by tangent skimming (Turner 2020). Tangent skimming excludes polyclonal immunoglobulin and improves precision about 10-fold. It is limited to gamma-migrating M-proteins (Keren 2016).
  • Small and beta-migrating M-proteins. Electrophoretic and immunochemical methods quantify M-proteins below 10 g/L (1 g/dL) poorly when polyclonal immunoglobulins comigrate. M-proteins in the beta and alpha regions are overestimated because normal serum proteins migrate with them. Capillary electrophoresis with immunosubtraction can exclude much of the normal beta-region protein (Keren 2016).
  • Interlaboratory studies. In 16 laboratories, a higher gamma background increased imprecision and overestimation, especially with perpendicular drop. Cathodal M-proteins were quantified more accurately than central-gamma M-proteins (Turner 2020). All M-proteins ≥1 g/L were detected by SPEP, the mean intralaboratory CV was 5.0%, and serial monitoring of small M-proteins was appropriate when it was performed in the same laboratory (Jacobs 2020).
  • Measurable disease. An M-protein is considered measurable at ≥1 g/dL in serum or ≥200 mg/day in urine. Urine protein electrophoresis is recommended at least once every 3–6 months during follow-up of myeloma (Rajkumar 2024).

Pseudo-paraproteins and interferences in protein electrophoresis

Interferent SPEP finding Recognition Source
Iodinated contrast agent Peak in the beta fraction on capillary zone electrophoresis after angiography Contrast agents absorb ultraviolet light at the wavelength of peptide bonds; IFE or immunosubtraction, or a repeat specimen later, confirms the interference and excludes an M-protein Vermeersch 2006; Capaldo 2021
Bisalbuminemia Bifid albumin band Hereditary (point variant) or acquired, most often with diabetes mellitus; usually benign and found during screening for monoclonal gammopathy Avgoustou 2024
Therapeutic IgG monoclonal antibodies Daratumumab migrates in the cathodal gamma region and elotuzumab in the central gamma region IgG-kappa band on IFE that mimics a residual M-protein Turner 2020; McCudden 2016
CRP in acute inflammation Material between beta and gamma CRP concentration O'Connell 2005

Therapeutic monoclonal antibody interference

  • Daratumumab. Daratumumab is an IgG-kappa monoclonal antibody, and its IFE band mimics a disease-derived M-protein (Yasuda 2025).
  • DIRA. The daratumumab-specific immunofixation electrophoresis reflex assay (DIRA) uses a mouse anti-daratumumab antibody that shifts the migration of daratumumab and leaves the endogenous M-protein in place. Its limit of sensitivity was 0.2 g/L daratumumab (McCudden 2016).
  • Neutralizing reagent and timing. A neutralizing reagent (D-Clean) removed daratumumab bands in 19 of 20 treated patients. Daratumumab bands appeared only within 33 days after the last dose and were more frequent when polyclonal IgG was low (Yasuda 2025).
  • Mass spectrometry. Intact light chain MALDI-TOF distinguished daratumumab from IgG-kappa M-proteins in 84% of samples. Higher-resolution LC-ESI-QTOF distinguished daratumumab, elotuzumab and isatuximab from the M-protein in 100% (Murray 2021).

Immunofixation, urine studies and the screening panel

  • Screening panel. IMWG recommends SPEP, serum IFE and the serum FLC assay when myeloma is suspected. About 2% of patients with myeloma are truly nonsecretory, with no M-protein on any of these tests (Rajkumar 2024).
  • 24-hour urine. The serum FLC assay combined with SPEP and IFE gives high sensitivity and removes the need for 24-hour urine studies in screening for diagnoses other than light chain (AL) amyloidosis (Dispenzieri 2009).
  • FLC monitoring. Serial FLC measurement is used to monitor oligosecretory disease, including AL amyloidosis and oligosecretory myeloma. No data support replacing the 24-hour urine protein electrophoresis with the FLC assay for patients whose disease is measurable by serum or urine electrophoresis (Dispenzieri 2009).
  • Laboratory recommendations. Some laboratory recommendations omit serum IFE from the initial screen because it adds limited diagnostic value, which differs from the IMWG panel. They also give reporting guidance for findings other than the M-protein. External quality assurance shows wide interlaboratory variation in M-protein and FLC quantification (Lim 2024).

Serum free light chain assays and the kappa/lambda ratio

  • Original reference intervals. With the polyclonal nephelometric assay, the 95% reference intervals were 3.3–19.4 mg/L for kappa FLC and 5.7–26.3 mg/L for lambda FLC, and the diagnostic interval for the kappa/lambda ratio was 0.26–1.65. Kappa and lambda FLC rose with age, and the ratio did not (Katzmann 2002).
  • Kidney function. Polyclonal kappa and lambda FLC rose with CKD stage and correlated with cystatin C (Hutchison 2008). A kidney reference interval of 0.37–3.10 has been used for the FLC ratio in kidney disease (Long 2022).
  • Assay platforms. Freelite (polyclonal antisera) and N-Latex FLC (monoclonal antibodies) correlated well. Freelite gave higher kappa FLC and kappa/lambda ratios and lower lambda FLC, and the two assays are not interchangeable (Daves 2021).
  • Antigen excess. In a 2022 evaluation, antigen excess caused clinically relevant underestimation of kappa FLC in 7% of samples on one platform and of lambda FLC in 11% and 32.1% on two platforms. Reference values were application-specific (Van Hoovels 2022).

Serum free light chain ratio interpretation.

Item Rule Source
Ratio Kappa FLC (mg/L) ÷ lambda FLC (mg/L) Katzmann 2002
Standard diagnostic interval (established rule) 0.26–1.65 Katzmann 2002
Kidney interval used with the standard assay 0.37–3.10 Long 2022
SLiM biomarker Involved/uninvolved ratio ≥100 with involved FLC ≥100 mg/L Rajkumar 2014
iStopMM kidney intervals (proposal): eGFR 45–59 0.46–2.62 Long 2022
iStopMM kidney intervals (proposal): eGFR 30–44 0.48–3.38 Long 2022
iStopMM kidney intervals (proposal): eGFR <30 0.54–3.30 Long 2022
iStopMM age intervals (proposal), preserved kidney function: <70 years 0.44–2.16 Einarsson Long 2025
iStopMM age intervals (proposal), preserved kidney function: ≥70 years 0.46–2.59 Einarsson Long 2025

Newer FLC intervals and the proposed light chain MGUS definition

These intervals are newer proposals. IMWG criteria use the standard interval of 0.26–1.65 (Rajkumar 2014; Rajkumar 2024).

  • Kidney-specific intervals (iStopMM 2022). In 6461 Icelandic screening participants with eGFR <60 mL/min/1.73 m² and no monoclonality, 9% had a ratio outside the standard interval and 0.7% outside the kidney interval. The study proposed eGFR-based intervals (Long 2022).
  • Proposed light chain MGUS definition (2025). In 41,882 participants with preserved kidney function, the standard intervals classified 3.7% of ratios as abnormal. Age-stratified intervals lowered the prevalence of light chain MGUS from 1.54% to 0.27%, a decrease of 82%. None of the 1006 people reclassified progressed to a lymphoproliferative disorder during a median follow-up of 4.6 years (Einarsson Long 2025).
  • Validation. In a Danish cohort of 6993 people with MGUS, the revised intervals reclassified 32% of abnormal ratios as normal. The reclassified group had no increased risk of progression (hazard ratio 1.07) (Maeng 2025).

IMWG laboratory criteria for monoclonal gammopathies

The IMWG 2014 update added validated biomarkers to the CRAB features for the definition of myeloma (Rajkumar 2014). The thresholds below follow the IMWG criteria table in Rajkumar 2024.

Disorder Laboratory criteria Source
Non-IgM MGUS Serum M-protein <3 g/dL; clonal marrow plasma cells <10%; no attributable CRAB features Rajkumar 2014; Rajkumar 2024
IgM MGUS Serum IgM M-protein <3 g/dL; marrow lymphoplasmacytic infiltration <10%; no attributable anemia, constitutional symptoms, hyperviscosity, lymphadenopathy or hepatosplenomegaly Rajkumar 2014; Rajkumar 2024
Light chain MGUS Ratio <0.26 or >1.65 with increase of the involved light chain; no heavy chain on IFE; clonal marrow plasma cells <10%; urine M-protein <500 mg/24 h; no attributable end-organ damage Rajkumar 2014; Rajkumar 2024
Smoldering myeloma Serum IgG or IgA M-protein ≥3 g/dL, or urine M-protein ≥500 mg/24 h, and/or clonal marrow plasma cells 10%–60%; no myeloma-defining event or amyloidosis Rajkumar 2014; Rajkumar 2024
Multiple myeloma Clonal marrow plasma cells ≥10% or a biopsy-proven plasmacytoma, plus one or more myeloma-defining events Rajkumar 2014; Rajkumar 2024
Myeloma-defining CRAB events Calcium >0.25 mmol/L (>1 mg/dL) above the upper limit or >2.75 mmol/L (>11 mg/dL); creatinine clearance <40 mL/min or creatinine >177 µmol/L (>2 mg/dL); Hb >2 g/dL below the lower limit or <10 g/dL; one or more osteolytic lesions Rajkumar 2014; Rajkumar 2024
Myeloma-defining biomarkers (SLiM) Clonal marrow plasma cells ≥60%; involved/uninvolved FLC ratio ≥100 with involved FLC ≥100 mg/L; more than 1 focal lesion ≥5 mm on MRI Rajkumar 2014; Rajkumar 2024
Plasma cell leukemia Current rule (IMWG 2021): myeloma with ≥5% plasma cells on the peripheral blood smear differential. Previous rule (Kyle 1974): >20% circulating plasma cells and an absolute count >2 × 10⁹/L Fernández de Larrea 2021; Rajkumar 2024
  • Biomarker risk. Each SLiM biomarker is associated with an approximately 80% risk of progression to end-organ damage in two or more independent studies (Rajkumar 2024).
  • Urine requirement with the FLC ratio. Rajkumar 2024 adds a urinary M-protein of ≥200 mg/24 h to the FLC ratio ≥100 biomarker, citing Visram 2022. This addition is not part of the IMWG 2014 text (Rajkumar 2014; Rajkumar 2024).
  • High-risk smoldering myeloma (Mayo 2018). Any 2 or 3 of serum M-protein >2 g/dL, involved/uninvolved FLC ratio >20 and marrow plasma cells >20% define high-risk smoldering myeloma (Rajkumar 2024).
  • Response criteria. IMWG 2016 response categories are based on serum and urine M-protein assessment and marrow assessment, with new categories of minimal residual disease negativity (Kumar 2016).
  • Kidney lesions. The Renal Pathology Society and the International Kidney and Monoclonal Gammopathy Research Group defined consensus terminology and mandatory criteria for monoclonal gammopathy-associated kidney lesions (Nasr 2025).

Mass spectrometry for M-protein detection

  • Methods. The intact light chain MALDI-TOF method with immunoenrichment (Mass-Fix) identifies the M-protein isotype in the same way as IFE. The LC-ESI-QTOF method (miRAMM) has a limit of quantitation of 0.05 g/L and a limit of detection of 0.01 g/L. The clonotypic peptide method detects M-protein down to 0.001 g/L (Murray 2021).
  • Performance. MALDI-TOF detected the M-protein in 100% of samples positive by SPEP and IFE and in 97% of samples positive by IFE and negative by SPEP (Murray 2021).
  • IMWG 2021 recommendations. Intact light chain MALDI-TOF can be used in place of IFE in clinical practice and trials. Mass spectrometry is endorsed for distinguishing therapeutic antibodies from endogenous M-proteins. Complete response rates from mass spectrometry and from IFE are not compared across trial eras because mass spectrometry may lower complete response rates (Murray 2021).

Cryoglobulins

  • Types. Cryoglobulins are immunoglobulins that precipitate below 37 °C. Type I is mostly associated with monoclonal gammopathy or other hematologic disorders. Types II and III are mixed cryoglobulins associated with infectious and systemic diseases (Motyckova 2011).
  • Collection and processing. The blood specimen is kept at 37 °C until clotting and separation, because premature precipitation lowers the yield and causes false-negative results. After warm centrifugation, the clear serum is observed at 4 °C for a cryoprecipitate. The cryoprecipitate is washed in cold buffer, redissolved at 37 °C and typed by immunodiffusion and immunofixation (Motyckova 2011).
  • Standardization. Cryoglobulin testing has no reference range or standards, and results depend on strict temperature control (Motyckova 2011).

CSF oligoclonal bands, IgG index and the kappa FLC index

Methods for intrathecal immunoglobulin synthesis

  • Isoelectric focusing. OCB detection by isoelectric focusing (IEF) with immunodetection on paired CSF and serum is the standard method for intrathecal IgG synthesis (Hegen 2023; Freedman 2005). Its diagnostic sensitivity and specificity for MS are both about 90% (Hegen 2023).
  • IgG index. The IgG index is (CSF IgG ÷ serum IgG) ÷ (CSF albumin ÷ serum albumin) (Link 1977). Quantitative IgG formulas have a diagnostic sensitivity of about 70% in MS (Hegen 2023). The IgG index is no longer recommended for diagnosis because its sensitivity is lower than that of OCB (Deisenhammer 2025). Canadian laboratories still include adjunctive tests such as the IgG index in OCB panels (Higgins 2025).
  • Albumin quotient. The CSF/serum albumin quotient (Qalb) is the established marker of blood-CSF barrier function. Barrier function was abnormal in <10% of patients with clinically isolated syndrome or MS (Hegen 2023).
  • Kappa FLC index. Kappa FLC are produced in excess over intact immunoglobulin and accumulate in CSF with CNS inflammation. In a meta-analysis of 32 studies, the kappa FLC index had a weighted sensitivity of 88% and specificity of 89%, and OCB had 85% and 92% (Hegen 2023; Deisenhammer 2025). Published cutoffs ranged from 2.4 to 20, and the meta-analysis derived a mean cutoff of 6.1 in an exploratory analysis (Hegen 2023). The 2024 McDonald consensus recommends ≥6.1 (Deisenhammer 2025).

Oligoclonal band patterns on paired CSF and serum IEF.

Type CSF Serum Interpretation Source
1 No bands No bands No intrathecal synthesis Hegen 2023; Deisenhammer 2025
2 Bands No bands Intrathecal IgG synthesis Hegen 2023; Deisenhammer 2025
3 Bands, with additional CSF-only bands Bands identical to some CSF bands Intrathecal synthesis with a systemic reaction Hegen 2023; Deisenhammer 2025
4 Bands Identical bands (mirror pattern) Systemic immune reaction with passive transfer into CSF Deisenhammer 2025
5 Monoclonal bands Identical monoclonal bands (ladder pattern) Paraprotein Deisenhammer 2025

CSF indices.

Index Formula Interpretation Source
Albumin quotient CSF albumin ÷ serum albumin Blood-CSF barrier function Hegen 2023
IgG index (CSF IgG ÷ serum IgG) ÷ (CSF albumin ÷ serum albumin) Intrathecal IgG synthesis; no longer recommended for diagnosis Link 1977; Deisenhammer 2025
Kappa FLC index (CSF kappa FLC ÷ serum kappa FLC) ÷ (CSF albumin ÷ serum albumin) ≥6.1 recommended as positive Hegen 2023; Deisenhammer 2025

CSF testing in the 2024 McDonald criteria

  • Current rule (McDonald 2024). The 2024 McDonald criteria allow CSF kappa FLC to provide supportive evidence for MS in specific situations (Montalban 2025). Kappa FLC are used interchangeably with OCB to demonstrate intrathecal immunoglobulin synthesis (Deisenhammer 2025; Wattjes 2026). A positive CSF is defined by two or more CSF bands absent from serum (types 2 and 3) or by a kappa FLC index ≥6.1 (Deisenhammer 2025). In some scenarios dissemination in time is no longer mandatory for diagnosis (Wattjes 2026).
  • Previous rule (McDonald 2017). In a patient with a typical clinically isolated syndrome and dissemination in space, CSF-specific OCB allowed a diagnosis of MS (Thompson 2018). Kappa FLC were not part of the 2017 criteria and were recommended for inclusion in the next revision (Hegen 2023).
  • Discordant results. Concordance between the kappa FLC index and OCB is about 90%. When one test is negative and MS is strongly suspected, the other test is performed (Deisenhammer 2025).
  • Assay standardization. Kappa FLC assays lack fully standardized measurement and established reference values (Wattjes 2026). Validated nephelometric or turbidimetric assays with proficiency testing are recommended (Deisenhammer 2025).
  • Laboratory reporting (hCAMI 2026). The Canadian hCAMI subcommittee reached consensus on 24 of 25 statements covering quality assurance, specimen pairing and timing, reporting of CSF-specific bands, mirror patterns, band intensity mismatch, panel components and decision limits (Higgins 2026).

Other plasma proteins tested in the chemistry laboratory

  • Alpha-1 antitrypsin. Alpha-1 antitrypsin deficiency is autosomal codominant and is caused by SERPINA1 variants. Allele letters come from migration after isoelectric focusing. PiMM individuals have serum concentrations of 100–220 mg/dL, and PiZZ individuals have 20–45 mg/dL (10%–20% of normal). Pi*ZZ accounts for 95% of severe deficiency, and null (Q0) alleles produce no protein. Diagnosis combines the serum concentration with phenotyping or genotyping (Feitosa 2024). A decreased alpha-1 band on SPEP occurs in the deficiency (O'Connell 2005).
  • Ceruloplasmin in Wilson disease. Ceruloplasmin is the serum ferroxidase responsible for 90% of copper transport from the liver. Loss of ATP7B function produces apoceruloplasmin with a shorter half-life. Values in Wilson disease are typically <14 mg/dL (normal >20 mg/dL), and values of 14–20 mg/dL occur in asymptomatic patients. Ceruloplasmin can be low or elevated in acute liver failure from Wilson disease (Alkhouri 2023).
  • Beta-2 transferrin for CSF leak. In 149 beta-2 transferrin gel electrophoresis tests for unilateral clear rhinorrhea, sensitivity was 89.5% and specificity 78.3%. Purulent sinusitis, mucus contamination and collection errors caused false results (Eide 2025).
  • IgG4 prozone. In IgG4-related disease, 10 of 38 samples (26%) gave falsely low IgG4 from a prozone effect. Dilution raised the mean of these samples from 26 mg/dL to 2008 mg/dL (reference 2.4–121 mg/dL) (Khosroshahi 2014). One routine assay version prozoned to <0.64 g/L in 41% of samples with high IgG4 (Egner 2016).

Diagnostic Enzymes and Serum Tumor Markers

Definition. Diagnostic enzymes are measured as catalytic activity concentrations, and the IFCC has defined primary reference procedures for their measurement at 37 °C (Schumann 2002a). Serum tumor markers are proteins or glycoproteins measured by immunoassay for diagnosis, prognosis, recurrence detection and therapy monitoring in selected cancers (Sturgeon 2008b). The National Academy of Clinical Biochemistry (NACB) laboratory medicine practice guidelines set the quality requirements and the clinical indications for tumor markers (Sturgeon 2008a; Sturgeon 2008b; Sturgeon 2010).

Related page: Analytical Methods and Immunoassays in Clinical Chemistry (heterophile antibodies, the hook effect and immunoassay formats) Related page: Method Validation, Statistical Quality Control and Proficiency Testing in Clinical Chemistry (CLIA proficiency testing limits for enzymes and tumor markers) Related page: Liver, Kidney and Gastrointestinal Function Tests (liver test patterns, the R ratio and fecal screening tests) Related page: Hemolytic Anemias: Red Cell Membrane and Enzyme Defects and Paroxysmal Nocturnal Hemoglobinuria (LDH as a hemolysis marker) Related page: Plasma Proteins, Protein Electrophoresis, Free Light Chains and CSF Oligoclonal Bands (monoclonal gammopathy testing and IMWG criteria) Related page: Colorectal Cancer Staging, CAP Reporting, Biomarkers and Neoadjuvant Response (colorectal carcinoma staging and biomarkers)

Enzyme activity measurement and IFCC reference procedures at 37 °C

  • Reference system. The IFCC series defines the concept of reference procedures (Part 1) and primary reference procedures at 37 °C for creatine kinase (Part 2), lactate dehydrogenase (Part 3), alanine aminotransferase (Part 4), aspartate aminotransferase (Part 5) and gamma-glutamyltransferase (Part 6). Part 7 certifies reference materials for GGT, LDH, ALT and CK, and Part 8 covers alpha-amylase (Schumann 2002a; Schumann 2002b; Schumann 2002c; Schumann 2011).
  • Alkaline phosphatase. Part 9 defines the reference procedure for alkaline phosphatase (ALP) at 37 °C (Schumann 2011).
  • Derivation. Each 37 °C procedure was derived from the earlier 30 °C IFCC reference method, and the differences are tabulated in its appendix (Schumann 2002a; Schumann 2002b; Schumann 2011).
  • Common reference intervals. In an IFCC multicenter study of 765 selected adults measured with methods standardized to the IFCC reference systems, AST had a single interval and ALT and GGT required partitioning by sex. A worldwide common GGT interval was judged unlikely because populations differed (Ceriotti 2010).

IFCC-traceable reference intervals for adults.

Enzyme Females (U/L) Males (U/L) Source
AST 11–34 11–34 Ceriotti 2010
ALT 8–41 9–59 Ceriotti 2010
GGT 6–40 12–68 Ceriotti 2010

Aminotransferases

  • Tissue distribution. AST is present in the liver, cardiac muscle, skeletal muscle, kidney and brain. ALT is present primarily in the liver and is the more specific marker of hepatocellular injury. An AST increase without an ALT increase suggests cardiac or muscle disease (Kwo 2017).
  • ACG 2017 upper limits. A healthy normal ALT ranges from 29 to 33 U/L in males and 19 to 25 U/L in females. ALT correlates with body mass index, a normal ALT does not exclude significant liver disease, and ALT upper limits vary between laboratories (Kwo 2017).
  • Severity bands. ACG defines borderline elevation as <2× the upper limit of normal (ULN), mild as 2–5× ULN, moderate as 5–15× ULN, severe as >15× ULN and massive as >10,000 U/L (Kwo 2017).
  • AST/ALT ratio in alcohol-related liver disease. In 1979, the AST/ALT ratio was 2.85 in alcohol-related hepatitis and cirrhosis, 1.74 in postnecrotic cirrhosis, 1.3 in chronic hepatitis, 0.81 in obstructive jaundice and 0.74 in viral hepatitis. A ratio >2 occurred in 70% of patients with alcohol-related hepatitis and cirrhosis and in 4% with viral hepatitis (Cohen 1979). ACG cites a ratio of at least 2:1 with AST or ALT rarely above 300 U/L, and a ratio >3:1 further increases the likelihood of alcohol-related liver disease. The ratio reflects low ALT activity from pyridoxine deficiency (Kwo 2017).
  • Cirrhosis of other causes. AST can exceed ALT in cirrhosis of any cause, although the ratio is typically not above 2:1 (Kwo 2017).

AST/ALT ratio.

Item Rule Source
Ratio AST (U/L) ÷ ALT (U/L) Cohen 1979
>2 Suggests alcohol-related hepatitis or cirrhosis Cohen 1979; Kwo 2017
>3 Further increases the likelihood of alcohol-related liver disease Kwo 2017
<1 Typical of chronic viral hepatitis and metabolic dysfunction-associated steatotic liver disease (MASLD, formerly nonalcoholic fatty liver disease) (ALT > AST) Kwo 2017; Rinella 2023

Alkaline phosphatase, GGT and cholinesterase

  • Sources of ALP. ALP is a zinc metalloenzyme that hydrolyzes phosphate esters at alkaline pH. In the liver it is located on the canalicular membrane of hepatocytes. It is also present in bone, placenta, intestine and kidney, and bone is the most common extrahepatic source (Kwo 2017).
  • Physiologic increases. In people with blood group O or B, serum ALP can increase after a fatty meal from intestinal ALP. Placental synthesis raises ALP in pregnancy. Bone turnover raises ALP in children and older adults, especially females over 50 years (Kwo 2017).
  • Confirming hepatic origin. An elevated GGT, a canalicular enzyme, indicates that an ALP elevation is of hepatic origin. ALP fractionation separates bone, intestinal and hepatic ALP (Kwo 2017).
  • GGT and alcohol. GGT is a complementary test for identifying alcohol misuse (Kwo 2017).
  • Benign transient hyperphosphatasemia. This condition is a marked, incidental ALP increase in infants and children without bone or liver disease. It is transient and requires no further investigation once recognized (Sönmez 2018).
  • Butyrylcholinesterase. Butyrylcholinesterase is abundant in plasma and degrades succinylcholine, cocaine and acetylsalicylic acid. Activity assays are used in the diagnosis of chronic liver disease and of poisoning with organophosphates or carbamates, and the K variant slows detoxification (Pohanka 2013). Inherited deficiency is confirmed by dibucaine inhibition testing (Arslan 2022), described with the dibucaine number below.

Macroenzymes, including macro-creatine kinase

  • Macroenzymes. Macroenzymes are high-molecular-weight complexes formed when an enzyme binds immunoglobulin or other plasma components or self-polymerizes. Type 1 is a complex with IgG, IgA or IgM. Type 2 includes non-immunoglobulin complexes and oligomers of an isoenzyme (Kopoczynski 2026).
  • Clinical picture. Macroenzymes cause isolated and persistent increases in total enzyme activity, and their recognition avoids invasive or costly investigation (Galasso 1993; Kopoczynski 2026). Macro-AST has a molecular weight of about 250 kDa (Kopoczynski 2026).
  • Macro-CK. Among 8322 patients with CK isoenzyme analysis, macro-CK type 1 had a prevalence of 0.43% and type 2 of 1.20%. Type 1 accounted for about 10% and type 2 for about 25% of total CK activity. Patients with type 1 most often had myositis, and those with type 2 most often had a malignancy (Lee 1994).
  • Detection. Polyethylene glycol (PEG) precipitation is the common screening method, reported as the percentage of PEG-precipitable activity and compared with the laboratory's validated threshold. Decision thresholds vary with platform, protocol and population and are not transferable between laboratories. A negative PEG result or storage at 4 °C does not rule out a macroenzyme (Kopoczynski 2026). Gel filtration chromatography confirms the complex, and PEG precipitates a proportion of normal CK that rises with serum globulin concentration (Fahie-Wilson 2007).

Amylase and lipase in acute pancreatitis

  • Current rule (ACG 2024). Acute pancreatitis is diagnosed by 2 of 3 criteria: pain consistent with the disease, serum amylase and/or lipase >3 times the ULN, and characteristic imaging findings. Serum amylase alone cannot be used reliably for the diagnosis, and serum lipase is preferred. Lipase is more specific than amylase and remains elevated longer (Tenner 2024).
  • Previous guideline (ACG 2013). ACG 2024 notes that earlier classifications and guidelines emphasized the advantage of serum lipase. The enzyme criterion of >3 times the ULN is unchanged (Tenner 2024).
  • Amylase kinetics. Amylase rises within a few hours of symptom onset and returns to normal within 3–5 days. It can be normal on admission in up to one-fifth of patients and can be normal in alcohol-induced and hypertriglyceridemia-associated pancreatitis (Tenner 2024).
  • Nonpancreatic hyperamylasemia. Amylase is increased without pancreatitis in macroamylasemia, in which amylase forms large complexes with immunoglobulins, and with decreased GFR, salivary gland disease and inflammatory abdominal diseases such as appendicitis and cholecystitis (Tenner 2024).
  • Lipase limitations. Lipase is elevated in nonpancreatic diseases, and diabetic patients may need a threshold of more than 3–5 times the ULN. Serial amylase or lipase measurement has no relationship to severity or prognosis (Tenner 2024).

Isoenzymes, cholinesterase variants and macroamylasemia

  • LD isoenzymes. LD1 and LD2 come from heart, red cells and kidney, LD3 from lung and other tissues, LD4 from white cells, lymph nodes, muscle and liver, and LD5 from liver and skeletal muscle. Normal reference fractions are 17%–32% for LD1 and 25%–40% for LD2, so LD2 normally exceeds LD1 (Labcorp 001842).
  • Flipped LD pattern. An LD1:LD2 ratio of 0.82–0.99 is suspicious for myocardial injury, and a ratio >1.0 is diagnostic of myocardial injury if other clinical criteria are met. Megaloblastic anemia, hemolytic anemia and occasionally renal infarction also increase LD1, often with LD1:LD2 inversion. LD5 increases with striated muscle injury and liver disease (Labcorp 001842).
  • CK isoenzymes. Normal serum CK is 97%–100% CK-MM and 0%–3% CK-MB. CK-MB is found in much higher concentration in cardiac muscle than in skeletal muscle (Labcorp 002154).
  • Macro-CK types. Macro-CK type 1 is CK-BB bound to IgG, and macro-CK type 2 is a polymeric complex of mitochondrial CK (Wu 1982). Type 2 has an activation energy >80 kJ/mol, compared with 40–65 kJ/mol for most serum enzymes (Stein 1982). Type 2 migrates cathodally or close to CK-MM and occurs mainly in severely ill adults with malignancy or liver disease. Macro-CK type 1 can cause a false-positive CK-MB result in some immunoassays (Labcorp 002154).
  • ALP heat stability. At 56 °C, bone ALP is inactivated fastest, with an average half-inactivation time of 112 seconds. Liver and intestinal ALP have a half-inactivation time of 456 seconds (Whitby 1975). Placental ALP withstands 70 °C for 30 minutes, whereas other human ALPs lose most of their activity at 56 °C (Neale 1965).
  • Regan isoenzyme. The Regan isoenzyme is a placental-type ALP expressed by tumors, particularly gonadal and urologic cancers (Fishman 1980).
  • 5′-nucleotidase. Serum 5′-nucleotidase is raised frequently in hepatobiliary disease and infrequently in bone disease. It indicates the source of a raised ALP more reliably than isoenzyme electrophoresis in agar gel (Belfield 1969).
  • Dibucaine number. The dibucaine number is the percentage of butyrylcholinesterase activity inhibited by dibucaine. It is about 70 for the usual enzyme. Homozygotes for the atypical (A) variant have a dibucaine number of 30 or less, occur in about 1 in 2500 people and have prolonged neuromuscular blockade after succinylcholine or mivacurium (Panhuizen 2010).
  • Macroamylasemia. In macroamylasemia, an amylase-globulin complex is too large for renal excretion and raises serum amylase. A ratio of renal amylase clearance to creatinine clearance <1% is consistent with the diagnosis (Al-Johani 2023).

Amylase-creatinine clearance ratio.

Item Rule Source
Ratio (%) (urine amylase × serum creatinine) ÷ (serum amylase × urine creatinine) × 100 Al-Johani 2023
3%–5% Normal Al-Johani 2023
<1% Consistent with macroamylasemia Al-Johani 2023

Quality requirements for tumor markers

  • Clinical question. Tumor marker testing requires a defined clinical question, the appropriate tube type and timing, internationally standardized methods and adherence to manufacturer instructions (Sturgeon 2008a).
  • Method dependence. Results from different methods are not fully interchangeable, and between-method CVs above 20% occur in proficiency testing for some markers (Sturgeon 2008a).
  • Interference. Laboratories use procedures that reduce the risk of reporting results affected by heterophilic antibodies or hook effects (Sturgeon 2008a).
  • Reporting. Cumulative or graphical reports, validated reference intervals and interpretive comments are recommended. A baseline concentration during remission supports earlier detection of progression (Sturgeon 2008a).

Serum tumor marker indications and limitations.

Marker Main indications Limitations Source
AFP, hCG, LDH Testicular germ cell tumors: diagnosis, staging, prognosis, recurrence and monitoring; AFP distinguishes nonseminomatous from seminomatous tumors AFP is not elevated in pure seminoma Sturgeon 2008b; Arranz Arija 2024
PSA Recurrence and therapy monitoring; free PSA when total PSA is <10 ng/mL Not recommended by NACB for screening Sturgeon 2008b
CEA Colorectal cancer: preoperative staging, postoperative surveillance, monitoring of metastatic disease Not recommended for gastric cancer; raised modestly by smoking and aging Sturgeon 2008b; Locker 2006; Sturgeon 2010; No 2013
CA125 Ovarian cancer: early detection in high-risk women, pelvic masses in postmenopausal women, recurrence and monitoring Early detection only with transvaginal ultrasound Sturgeon 2008b
HE4 with CA125 (ROMA) Risk of epithelial ovarian cancer in a pelvic mass, by menopausal status Separate algorithms by menopausal status Moore 2009
CA15-3, BR27.29 Monitoring of advanced breast cancer Indication limited to advanced disease Sturgeon 2008b
CA19-9 Monitoring of pancreatic cancer during therapy, every 1–3 months Largely absent in Le(a−b−) individuals Locker 2006; Liu 2025
AFP Hepatocellular carcinoma surveillance with ultrasound every 6 months; an elevated AFP (cutoff 20 ng/mL, sensitivity about 60%) prompts multiphase CT or MRI (current rule, AASLD 2023). Previous rule (NACB 2010): AFP >200 ng/mL with a typical lesion >2 cm in cirrhosis Elevated in hepatitis and cirrhosis Singal 2023; Sturgeon 2010; Hanif 2022
Thyroglobulin Differentiated thyroid cancer follow-up Anti-thyroglobulin antibodies Park 2025
Beta-2 microglobulin Myeloma staging (R-ISS) Combined with albumin, cytogenetics and LDH Palumbo 2015
Chromogranin A Neuroendocrine tumor monitoring Raised by proton pump inhibitors Korse 2011
Calcitonin Medullary thyroid carcinoma: preoperative extent and postoperative follow-up with CEA Heterophile antibodies; hook effect with large tumor burden Wells 2015

Prostate-specific antigen

  • Current rule (USPSTF 2018). For men aged 55 to 69 years, PSA-based screening is an individual decision after discussion of benefits and harms (grade C). The USPSTF recommends against PSA-based screening in men 70 years and older (grade D). Screening of 1000 men aged 55 to 69 may prevent about 1.3 prostate cancer deaths over about 13 years (USPSTF 2018). The USPSTF lists the topic as being updated, and the 2018 recommendation remains current (USPSTF 2018).
  • Previous rule (USPSTF 2012). The USPSTF recommended against PSA-based screening for all men regardless of age (grade D) (Moyer 2012).
  • Percent free PSA. In 773 men aged 50–75 years with PSA 4.0–10.0 ng/mL and a benign rectal examination, a cutoff of ≤25% free PSA detected 95% of cancers and avoided 20% of unnecessary biopsies. A lower percentage of free PSA indicated a higher cancer risk (Catalona 1998).
  • Prostate Health Index (phi). Phi combines total PSA, free PSA and [-2]proPSA. It had the highest area under the curve for clinically significant cancer in men with PSA 4–10 ng/mL (Loeb 2015).
  • PSA density. PSA density is serum PSA divided by prostate volume. In 992 men having transrectal biopsy, the AUC for clinically significant cancer was 0.78 for PSA density and 0.64 for PSA. Men with a PSA density <0.09 ng/mL² had a 4% chance of clinically significant cancer (Yusim 2020).
  • 5-alpha reductase inhibitors. Finasteride lowers PSA by about 50% during the first 12 months. In the Prostate Cancer Prevention Trial the adjustment factor needed to preserve median PSA rose from 2 at 24 months to 2.5 at 7 years (Etzioni 2005).

Percent free PSA.

Item Rule Source
Percent free PSA Free PSA (ng/mL) ÷ total PSA (ng/mL) × 100 Catalona 1998
Cutoff for biopsy ≤25% with total PSA 4.0–10.0 ng/mL and a benign rectal examination Catalona 1998
Adjustment on finasteride Measured PSA × 2 at 24 months; × 2.5 at 7 years Etzioni 2005
PSA density Serum PSA (ng/mL) ÷ prostate volume (mL); <0.09 indicates a 4% chance of clinically significant cancer Yusim 2020

Germ cell tumor markers and AJCC 8th S categories

  • Marker patterns. AFP and/or beta-hCG are elevated in about 85% of nonseminomatous germ cell tumors. Beta-hCG is elevated in <20% of seminomas, and an elevated AFP in a seminoma indicates a nonseminomatous component (Arranz Arija 2024).
  • Postorchiectomy decline. Markers decline according to their half-lives, 5–7 days for AFP and 1–3 days for beta-hCG. A decline to normal confirms removal of all tumor, and a slower decline is early evidence of residual disease (Arranz Arija 2024).

AJCC 8th edition serum tumor marker (S) categories after orchiectomy.

Category LDH hCG (mIU/mL) AFP (ng/mL) Source
S0 Within normal limits Within normal limits Within normal limits Arranz Arija 2024
S1 <1.5 × ULN and <5000 and <1000 Arranz Arija 2024
S2 1.5–10 × ULN or 5000–50,000 or 1000–10,000 Arranz Arija 2024
S3 >10 × ULN or >50,000 or >10,000 Arranz Arija 2024

Sx indicates that marker studies are not available or not performed (Arranz Arija 2024).

Tumor marker half-life and expected decline.

Item Rule Source
Expected value Initial value × 0.5^(days elapsed ÷ half-life) Arranz Arija 2024
AFP half-life 5–7 days Arranz Arija 2024
Beta-hCG half-life 1–3 days Arranz Arija 2024

Human chorionic gonadotropin outside pregnancy

  • Structure and assay specificity. About 80%–85% of the hCG beta subunit is homologous to the LH beta subunit. The 24-amino-acid C-terminal peptide is unique to hCG, and many serum assays use antibodies to it (Oyatogun 2021).
  • Hyperglycosylated hCG. Hyperglycosylated hCG is the principal form in the first 2 weeks of pregnancy and is less than 1% of total hCG in the second and third trimesters (Oyatogun 2021).
  • Phantom hCG. Phantom hCG is a false-positive immunoassay result caused by cross-reactive antibodies, most often human anti-mouse antibodies, with no true hCG. Heterophile antibodies are large glycoproteins, and patients with phantom hCG have a negative urine hCG, so a positive serum hCG with a negative urine hCG supports the diagnosis. Cross-reactivity is confirmed when serum hCG is ≥50 mIU/mL and urine hCG is negative (Oyatogun 2021). Dilution recovery criteria and other tests for antibody interference are covered in Analytical Methods and Immunoassays in Clinical Chemistry.
  • Pituitary hCG. Pituitary hCG increases with age and can produce low positive results in perimenopausal and postmenopausal women (Gronowski 2008; Oyatogun 2021). In women aged 41–55 years with serum hCG 5–14 mIU/mL, an FSH >45 IU/L was never observed with hCG of placental origin. The FSH cutoff had 100% sensitivity and 75% specificity for excluding placental hCG (Gronowski 2008).
  • Causes of hCG outside pregnancy. Nonmalignant causes include phantom hCG, pituitary hCG, familial hCG syndrome and exogenous hCG. Premalignant and malignant causes include active and quiescent gestational trophoblastic disease and nontrophoblastic malignancy (Oyatogun 2021).

Alpha-fetoprotein, CA19-9, thyroglobulin and other markers

  • AFP. AFP is produced by the yolk sac, fetal liver and gastrointestinal tract and falls to trace amounts in adults. It has low sensitivity and specificity for hepatocellular carcinoma and is raised in acute and chronic liver disease and cirrhosis (Hanif 2022).
  • AFP-L3. Lens culinaris agglutinin binding separates AFP glycoforms. AFP-L1 correlates with hepatic inflammation, AFP-L3 is more specific for hepatocellular carcinoma, and AFP-L2 is derived from the yolk sac (Hanif 2022).
  • Hereditary persistence of AFP. This benign autosomal dominant condition usually gives AFP below 200 ng/mL, with values up to 1500 ng/mL in some cases. Malignant tumors usually give AFP >500 ng/mL (Hanif 2022).
  • CA19-9 and Lewis antigens. CA19-9 is expressed mainly in Le(a+b−) and Le(a−b+) individuals and is largely absent in Le(a−b−) individuals, which causes false-negative results (Liu 2025).
  • Thyroglobulin. Anti-thyroglobulin antibodies occur in up to 25%–30% of patients with differentiated thyroid cancer. They bind thyroglobulin and cause falsely low or undetectable results in immunometric assays. LC-MS/MS measures thyroglobulin as a complementary method (Park 2025).
  • Beta-2 microglobulin. ISS stage I requires beta-2 microglobulin <3.5 mg/L with albumin ≥3.5 g/dL, and ISS stage III requires beta-2 microglobulin >5.5 mg/L. R-ISS combines ISS with high-risk cytogenetics and LDH. Five-year overall survival was 82%, 62% and 40% for R-ISS I, II and III (Palumbo 2015).
  • CEA in smokers. CEA rises modestly with aging and smoking (No 2013). In 750 adult males, median CEA was 2.4 ng/mL in cigarette smokers and 1.6 ng/mL in quitters (Kim 2025). False elevation of CEA also results from heterophile antibodies, gastrointestinal inflammatory disease and benign lung disease (Wells 2015).
  • Calcitonin in medullary thyroid carcinoma. Imaging for distant metastases is recommended before surgery in all patients with serum calcitonin >500 pg/mL. Calcitonin and CEA are measured together, and a progressive postoperative increase in calcitonin above 150 pg/mL prompts imaging. With calcitonin doubling times <6 months, 5- and 10-year survival rates were 25% and 8%. Heterophile antibodies cause falsely elevated calcitonin, and very high levels cause falsely low results through the hook effect (Wells 2015).
  • Chromogranin A. Proton pump inhibitors cause falsely elevated chromogranin A. In patients with no evidence of neuroendocrine tumor, median chromogranin A fell from 390 µg/L to 56 µg/L 2 weeks after the inhibitor was stopped (Korse 2011).

Liver, Kidney and Gastrointestinal Function Tests

Definition. Kidney function testing estimates the glomerular filtration rate (GFR) from serum filtration markers and categorizes chronic kidney disease (CKD) by cause, GFR category and albuminuria category (KDIGO 2024). Liver chemistries comprise ALT, AST, alkaline phosphatase (ALP) and bilirubin, and albumin and the prothrombin time reflect hepatocellular function (Kwo 2017). Gastrointestinal function tests include celiac serology, fecal biomarkers of inflammation and pancreatic function, stool electrolytes and stool-based colorectal cancer screening tests (Rubio-Tapia 2023; Singh 2023; USPSTF 2021).

Related page: Diagnostic Enzymes and Serum Tumor Markers (aminotransferases, ALP, GGT, macroenzymes, amylase and lipase) Related page: Plasma Proteins, Protein Electrophoresis, Free Light Chains and CSF Oligoclonal Bands (urine protein electrophoresis, Bence Jones protein and free light chains in kidney disease) Related page: Preanalytic Variables, Specimen Integrity and Point-of-Care Testing in Clinical Chemistry (specimen stability, hemolysis and icterus interference) Related page: Hemolytic Disease of the Fetus and Newborn, Fetomaternal Hemorrhage, Rh Immune Globulin and Fetal and Neonatal Transfusion (hyperbilirubinemia from hemolytic disease of the fetus and newborn) Related page: Hemolytic Anemias: Red Cell Membrane and Enzyme Defects and Paroxysmal Nocturnal Hemoglobinuria (indirect bilirubin, LDH and haptoglobin in hemolysis) Related page: Clotting Factor Assays, Factor Inhibitors and Interference by Hemophilia Therapies (factor patterns in liver disease and vitamin K deficiency) Related page: DIC, Thrombotic Microangiopathy and Viscoelastic Testing (rebalanced hemostasis and the INR in cirrhosis) Related page: Microcytic Anemias and Iron Studies (iron deficiency in gastrointestinal blood loss) Related page: Macrocytic Anemias and Vitamin B12 and Folate Testing (vitamin B12 and folate testing in malabsorption) Related page: Colorectal Adenomas, Serrated Polyps and Other Colorectal Polyps (screen-detected adenomas and serrated polyps) Related page: Colorectal Cancer Staging, CAP Reporting, Biomarkers and Neoadjuvant Response (colorectal carcinoma staging and biomarkers)

Creatinine measurement

  • Method choice. KDIGO 2024 recommends an enzymatic creatinine method where possible. Creatinine is measured with a specific, precise assay (CV <2.3%) with calibration traceable to international reference materials and bias <3.7% (KDIGO 2024).
  • Jaffe interferences. Reported interferents of Jaffe methods include acetaminophen, aspirin, ascorbic acid, bilirubin, cephalosporins, glucose, hemoglobin F, ketones and ketoacids, lipids, protein and pyruvate from delayed processing. Reported interferents of enzymatic methods include bilirubin, lidocaine metabolites, metamizole, N-acetylcysteine, proline stabilizers in intravenous immunoglobulin and phenindione. The size and direction of bias depend on the reagent and reaction conditions (KDIGO 2024).
  • Processing. Serum or plasma is separated from red cells within 12 hours of venipuncture, particularly with the Jaffe method (KDIGO 2024).
  • Diet. A cooked meat meal raised serum creatinine by about 20 µmol/L (0.23 mg/dL) in one study, and dietary intake is taken into account when creatinine is interpreted (KDIGO 2024).
  • Children. Enzymatic assays are favored in children because non-creatinine chromogens contribute more to Jaffe results and icteric and hemolyzed neonatal samples are common (KDIGO 2024).
  • Traceability (previous rule, KDIGO 2012). KDIGO 2012 recommended creatinine assays traceable to international reference materials with minimal bias against isotope-dilution mass spectrometry (IDMS) reference methodology (KDIGO 2012).

Estimated GFR equations

CKD-EPI 2021 equations without race

  • Current rule (CKD-EPI 2021). The CKD-EPI 2021 creatinine equation is the 2009 equation refit without race, and the 2021 creatinine-cystatin C equation is the 2012 equation refit without race (Inker 2021). The NKF-ASN Task Force recommended immediate implementation of the 2021 creatinine equation in all US laboratories and increased, routine use of cystatin C, especially to confirm eGFR in adults with or at risk for CKD (Delgado 2022).
  • Previous rule (CKD-EPI 2009). The 2009 creatinine equation included a coefficient of 1.159 for Black race (Inker 2021). It replaced the MDRD equation because it was more accurate, with a median bias of 2.5 versus 5.5 mL/min/1.73 m² (Levey 2009).
  • Size of the change. In the validation data, the 2009 equation overestimated measured GFR by a median of 3.7 mL/min/1.73 m² in Black participants and 0.5 in non-Black participants. The 2021 creatinine equation underestimated measured GFR by 3.6 in Black participants and overestimated it by 3.9 in non-Black participants. The 2021 creatinine-cystatin C equation was more accurate, with smaller differences between race groups (Inker 2021).
  • Laboratory reporting. The AACC/NKF guidance recommends routine cystatin C when creatinine is confounded by processes other than filtration, and it recommends calculating and reporting eGFR with both male and female coefficients for gender-diverse individuals (Pierre 2023).

CKD-EPI 2021 creatinine and creatinine-cystatin C equations, with CKD-EPI 2009 for comparison.

Equation Formula (Scr in mg/dL; Scys in mg/L; age in years) Source
CKD-EPI 2021 creatinine 142 × min(Scr/κ, 1)^α × max(Scr/κ, 1)^−1.200 × 0.9938^age × 1.012 if female; κ = 0.7 (female), 0.9 (male); α = −0.241 (female), −0.302 (male) Inker 2021
CKD-EPI 2021 creatinine-cystatin C 135 × min(Scr/κ, 1)^α × max(Scr/κ, 1)^−0.544 × min(Scys/0.8, 1)^−0.323 × max(Scys/0.8, 1)^−0.778 × 0.9961^age × 0.963 if female; α = −0.219 (female), −0.144 (male) Inker 2021
CKD-EPI 2009 creatinine (previous) 141 × min(Scr/κ, 1)^α × max(Scr/κ, 1)^−1.209 × 0.9929^age × 1.018 if female × 1.159 if Black; α = −0.329 (female), −0.411 (male) Inker 2021

KDIGO 2024 evaluation of GFR

  • Current rule (KDIGO 2024). Serum creatinine with an estimating equation is the initial assessment. KDIGO recommends eGFRcr-cys when eGFRcr is less accurate and GFR affects clinical decisions, and measured GFR when more accurate ascertainment will change treatment. A validated equation is used to derive eGFR, the same equation is used within a region, and race is avoided in the computation (KDIGO 2024; Levin 2024).
  • Previous rule (KDIGO 2012). KDIGO 2012 recommended the 2009 CKD-EPI creatinine equation for eGFRcreat in adults. It suggested cystatin C in adults with eGFRcreat 45–59 mL/min/1.73 m² without markers of kidney damage when confirmation of CKD was required, with CKD confirmed if eGFRcys or eGFRcreat-cys was also <60 (KDIGO 2012).
  • Laboratory standards (KDIGO 2024). eGFR is reported with the filtration marker concentration, rounded to a whole number and normalized to 1.73 m². Values <60 mL/min/1.73 m² are flagged as low. Cystatin C is measured with CV <2.0% and bias <3.2%, and creatinine is measured on the same sample to allow eGFRcr-cys (KDIGO 2024).

Conditions in which eGFRcr is less accurate (KDIGO 2024).

Domain Examples GFR approach Source
Body habitus and muscle mass Eating disorders, extreme exercise or bodybuilding, above-knee amputation, spinal cord injury eGFRcys or eGFRcr-cys KDIGO 2024
Class III obesity Body mass index commonly >40 or >35 kg/m², varying by region eGFRcr-cys most accurate KDIGO 2024
Diet Low-protein, ketogenic, vegetarian and high-protein diets; creatine supplements Minimal data KDIGO 2024
Chronic illness Malnutrition, cancer, heart failure, cirrhosis eGFRcr-cys; measured GFR for treatment decisions KDIGO 2024
Smoking Non-GFR determinant of cystatin C eGFRcr if creatinine determinants are unchanged KDIGO 2024
Anabolic or hormonal steroids Non-GFR determinant of creatinine; effect on cystatin C unknown eGFRcr-cys KDIGO 2024
  • Cystatin C confounders. Cystatin C is affected by steroid use, thyroid disease and cancer, and creatinine by muscle mass (KDIGO 2024).
  • Indications for measured GFR. Measured GFR by plasma or urinary clearance of an exogenous marker is indicated when eGFRcr-cys is inaccurate from catabolic states, high cell turnover, advanced cirrhosis or heart failure, high-dose steroids or frailty. It is also indicated for kidney donor candidacy, combined transplantation decisions and dosing of drugs with a narrow therapeutic index (KDIGO 2024). At best, 90% of eGFR values fall within 30% of measured GFR (KDIGO 2024).
  • Cockcroft-Gault. The Cockcroft-Gault formula predicts creatinine clearance from serum creatinine, age and body weight, with a value 15% lower in females (Cockcroft 1976).

EKFC and pediatric GFR equations

  • EKFC. The European Kidney Function Consortium equations use creatinine or cystatin C rescaled to the median value in healthy people. The cystatin C rescaling factor is 0.83 below age 50 and does not differ by race or sex, and the mean of EKFC eGFRcr and eGFRcys was more accurate than either alone (Pottel 2023). In 12,854 US participants, the race-free EKFC creatinine equation had a median bias of 0.74 mL/min/1.73 m², compared with 1.22 for CKD-EPI 2021 (Delanaye 2024).
  • CKiD U25. The CKiD under-25 equations use K × height/Scr and K × 1/cystatin C. With sex-specific constants, K is 41.8 for males and 37.6 for females for creatinine, and 81.9 and 74.9 for cystatin C. In the age-dependent forms, K for creatinine rises from 35.7 at 1 year to 50.8 at 18 years and older in males, and from 33.1 to 41.4 in females (Pierce 2021).
  • Bedside Schwartz (previous pediatric equation). The 2009 bedside equation is 0.413 × height (cm) ÷ Scr (mg/dL), which approximated the full CKiD equation in children aged 1–16 years (Schwartz 2009). KDIGO 2024 recommends validated equations developed or validated in comparable pediatric populations and allows eGFRcr <90 mL/min/1.73 m² to be flagged as low after age 2 years (KDIGO 2024).

Pediatric GFR estimation.

Equation Formula Source
Bedside Schwartz 2009 (previous) eGFR = 0.413 × height (cm) ÷ Scr (mg/dL) Schwartz 2009
CKiD U25 creatinine, sex-specific eGFR = K × height (m) ÷ Scr (mg/dL); K = 41.8 (male), 37.6 (female) Pierce 2021
CKiD U25 cystatin C, sex-specific eGFR = K × 1 ÷ cystatin C (mg/L); K = 81.9 (male), 74.9 (female) Pierce 2021

CKD categories and albuminuria testing

CKD is defined as abnormalities of kidney structure or function present for at least 3 months with implications for health. It is classified by cause, GFR category (G1–G5) and albuminuria category (A1–A3). The categories are unchanged from KDIGO 2012 (KDIGO 2024; KDIGO 2012).

KDIGO GFR and albuminuria categories.

Category Range Description Source
G1 ≥90 mL/min/1.73 m² Normal or high KDIGO 2024
G2 60–89 Mildly decreased KDIGO 2024
G3a 45–59 Mildly to moderately decreased KDIGO 2024
G3b 30–44 Moderately to severely decreased KDIGO 2024
G4 15–29 Severely decreased KDIGO 2024
G5 <15 Kidney failure KDIGO 2024
A1 ACR <30 mg/g (<3 mg/mmol); AER <30 mg/24 h Normal to mildly increased KDIGO 2024
A2 ACR 30–300 mg/g (3–30 mg/mmol); AER 30–300 mg/24 h Moderately increased KDIGO 2024
A3 ACR >300 mg/g (>30 mg/mmol); AER >300 mg/24 h Severely increased KDIGO 2024
  • Risk display. KDIGO displays prognosis by GFR and albuminuria category in four risk levels: low, moderately increased, high and very high (KDIGO 2024). In the absence of kidney damage, G1 and G2 do not fulfill the criteria for CKD (KDIGO 2024).
  • Initial albuminuria testing. A first-morning midstream sample is preferred. The order of preference is urine ACR, then reagent strip testing for albumin with automated reading. For protein, it is urine PCR, then reagent strips for total protein with automated reading, then with manual reading (KDIGO 2024).
  • Confirmation. Positive reagent strips are confirmed by quantitative ACR or PCR, and an ACR ≥30 mg/g on a random sample is confirmed with a first-morning sample. In children, both PCR and ACR are preferred (KDIGO 2024).
  • Factors affecting ACR and PCR (KDIGO 2024). Hematuria, menstruation, exercise and symptomatic urinary infection increase urine albumin or protein. Nonalbumin proteins can be missed by albumin reagent strips. Females have lower creatinine excretion and therefore higher ACR and PCR, and low body weight raises the ratio (KDIGO 2024). Bence Jones protein and urine protein electrophoresis are covered in Plasma Proteins, Protein Electrophoresis, Free Light Chains and CSF Oligoclonal Bands.

Acute kidney injury and tubular function indices

  • KDIGO AKI definition. AKI is an increase in serum creatinine by ≥0.3 mg/dL (≥26.5 µmol/L) within 48 hours, an increase to ≥1.5 times baseline within the prior 7 days, or urine volume <0.5 mL/kg/h for 6 hours (KDIGO AKI 2012).
  • Staging. Stage 1 is 1.5–1.9 times baseline or an increase of ≥0.3 mg/dL. Stage 2 is 2.0–2.9 times baseline. Stage 3 is 3.0 times baseline, creatinine ≥4.0 mg/dL, initiation of kidney replacement therapy, or eGFR <35 mL/min/1.73 m² in patients younger than 18 years (KDIGO AKI 2012).
  • FENa. In 87 patients with acute kidney failure, a FENa of 1% separated acute tubular necrosis, nonoliguric acute tubular necrosis and urinary tract obstruction (>1%) from prerenal azotemia and acute glomerulonephritis (<1%). FENa classified 86 of 87 patients correctly (Espinel 1980).
  • FEUrea. Diuretics raise FENa. In prerenal azotemia treated with diuretics, only 48% had FENa <1%, and 89% had a fractional excretion of urea ≤35%. Mean FEUrea was 27.9% in untreated prerenal azotemia, 24.5% in prerenal azotemia with diuretics and 58.6% in acute tubular necrosis (Carvounis 2002).
  • BUN/creatinine ratio. A ratio >20 is the traditional threshold for prerenal azotemia. In 3641 patients with AKI, 53.2% had a ratio >20, and these patients had higher hospital mortality than those with a lower ratio. BUN is modulated by parenteral nutrition, protein catabolism, steroid administration and gastrointestinal bleeding independent of kidney function (Uchino 2012). In 1103 emergency department patients, the ratio did not distinguish prerenal from intrinsic AKI (AUC 0.5) (Manoeuvrier 2017).
  • Cell-cycle arrest biomarkers. Urine TIMP-2 and IGFBP7 together had an AUC of 0.80 for KDIGO stage 2–3 AKI within 12 hours in critically ill adults, which exceeded previously described markers (Kashani 2013).

Fractional excretion indices.

Index Formula Interpretation Source
FENa (%) (urine Na × plasma creatinine) ÷ (plasma Na × urine creatinine) × 100 <1%: prerenal azotemia or acute glomerulonephritis; >1%: acute tubular necrosis or obstruction Espinel 1980
FEUrea (%) (urine urea nitrogen × plasma creatinine) ÷ (blood urea nitrogen × urine creatinine) × 100 ≤35%: prerenal azotemia, including with diuretics Carvounis 2002

Renal tubular acidosis patterns

All types of renal tubular acidosis cause a hyperchloremic metabolic acidosis with a normal anion gap (Palmer 2021).

Feature Distal (type 1) Proximal (type 2) Hyperkalemic (type 4) Source
Defect Decreased distal acid excretion Decreased proximal bicarbonate reabsorption Reduced acid and potassium excretion in the collecting duct Palmer 2021
Urine pH >5.3 <5.5 <5.5 Palmer 2021
Serum bicarbonate (mmol/L) 10–20 16–20 16–22 Palmer 2021
Serum potassium (mmol/L) Low (<3.5) Low (<3.5) High (5.5–6.5) Palmer 2021
Diagnostic tests Positive urine anion gap after ammonium loading Fractional bicarbonate excretion >15% or urine pH >7.5 after bicarbonate loading; glycosuria, hypophosphatemia and hypouricemia indicate Fanconi syndrome Urine potassium <40 mmol/L or fractional potassium excretion <20%; abnormal aldosterone Palmer 2021
Associated findings Nephrolithiasis and nephrocalcinosis Growth retardation in children Diabetes with mild-to-moderate CKD Palmer 2021

Uric acid in rasburicase-treated patients

  • Ex vivo uricolysis. Rasburicase continues to degrade uric acid in the tube and causes spuriously low results. Storage at 4 °C does not arrest uricolysis entirely, and "negative" uric acid values occurred in 88.5% of treatment episodes even with refrigerated samples (Depreter 2016).
  • Fluoride-EDTA-citrate tubes. A sodium fluoride-EDTA-citrate tube largely arrested uricolysis without cooling. Recovery was 97.1% at 4 hours, compared with 89.3% in a lithium heparin tube in ice water (Kalaria 2022).

Urinalysis and urinary stone analysis

  • Current rule (EFLM 2023). The EFLM European Urinalysis Guideline 2023 updates the ECLM European Urinalysis Guidelines of 2000. It recommends measurement of both urine albumin and alpha-1 microglobulin for sensitive detection of kidney disease in high-risk patients, gives performance specifications for urine protein measurement and quality control of multiproperty strips, and uses urine density as a quality indicator for chemistry and particle results (Kouri 2024).
  • Particle analysis. The 2023 guideline updates automated particle counting and visual microscopy and gives advice on verifying new instruments against reference microscopy (Kouri 2024).
  • Manual sediment preparation. About 10 mL of fresh urine is centrifuged at 400 g for at least 5 minutes, 9.5 mL of supernatant is removed, and the pellet is resuspended in the remaining urine. At least 10 fields, optimally 20, are examined at low (100×) and high (400×) magnification. Phase contrast microscopy improves the visibility of hyaline casts and dysmorphic red cells, and polarized light identifies lipids and crystals (Gaggar 2024).
  • Glomerular hematuria. The presence of ≥40% dysmorphic red cells, ≥5% acanthocytes or ≥1 red cell cast per 50 low-power fields, alone or together, is a reasonable cutoff for glomerular hematuria. Dysmorphic red cells and acanthocytes are relatively specific for glomerular damage and have limited sensitivity (Gaggar 2024).
  • Casts in tubular injury and nephrotic proteinuria. Muddy brown granular casts had 100% specificity and 100% positive predictive value for acute tubular necrosis on biopsy. Fatty casts and oval fat bodies indicate lipiduria in nephrotic-range proteinuria, and cholesterol globules form a Maltese cross under polarized light. Automated analysis fails to identify pathological casts, crystals and dysmorphic red cells (Gaggar 2024). Cytologic features of urinary cells and casts are covered in Normal and Benign Findings in Urine Cytology.
  • Reagent strip interferences. The protein pad gives false-positive results when the strip is left too long in urine and with quaternary ammonium cleaning compounds, and it is insensitive to proteins other than albumin, including light chains. The blood pad gives false-positive results with oxidizing contaminants such as hypochlorite or bacterial peroxidases, povidone-iodine, menstrual blood and semen. Alkaline pH, urinary infection, high specific gravity and high urinary ascorbate (vitamin C intake of 2–15 g/day) lower the sensitivity of the glucose oxidase pad, and the test is repeated at least one day after the last vitamin C intake. The ketone pad does not detect beta-hydroxybutyrate and gives false-positive results with levodopa metabolites and sulfhydryl drugs such as captopril (Delanghe 2014).
  • Stone analysis. Infrared spectroscopy and X-ray diffraction are the standard methods, and chemical analysis is insufficient. In a European quality assessment, only 56% of laboratories met the quality requirement, and equipment, reference spectra and staff qualification determined accuracy (Siener 2016).

Bilirubin metabolism and measurement

  • Metabolism. Bilirubin from senescent red cells circulates mainly unconjugated and bound to albumin, and it is not excreted in urine. Conjugation by UDP-glucuronosyltransferase makes it water soluble. Colonic bacteria convert excreted bilirubin to urobilinogen, and absent urobilinogen produces clay-colored stools (Kwo 2017).
  • Fractions. In the van den Bergh reaction, unconjugated bilirubin is reported as indirect bilirubin and accounts for about 70% of total serum bilirubin. Total bilirubin is usually <1.1 mg/dL. Fractionation is most helpful when ALT, AST and ALP are normal or near normal (Kwo 2017).
  • Delta bilirubin. Delta bilirubin forms from conjugated bilirubin and albumin and has the 3-week half-life of albumin. It accounts for prolonged jaundice during recovery from hepatitis or obstruction (Kwo 2017).
  • Direct bilirubin assays. In College of American Pathologists surveys, direct-reacting bilirubin results varied widely among peer groups and differed from a referred method, whereas total bilirubin agreed well. Calibration, absent serum blanks, inadequate HCl concentration and bichromatic correction caused the bias (Lott 1993).

Hereditary hyperbilirubinemias

Disorder Defect Bilirubin pattern Distinguishing laboratory finding Source
Gilbert syndrome Decreased UGT1A1 activity (≥50% reduction) Unconjugated; total almost never >6 mg/dL and usually <3 mg/dL Rises 2- to 3-fold with fasting or illness; normal aminotransferases and ALP Memon 2016; Kwo 2017
Crigler-Najjar type 1 Absent or nearly absent UGT1A1 activity Unconjugated; >20–50 mg/dL after birth Gene analysis; only trace conjugates in bile Memon 2016
Crigler-Najjar type 2 UGT1A1 activity <10% of normal Unconjugated; usually <20 mg/dL >30% fall in bilirubin with phenobarbital; monoconjugates in bile Memon 2016
Dubin-Johnson syndrome Defective MRP2 biliary excretion Conjugated Normal total urinary coproporphyrin with about 80% coproporphyrin I Memon 2016
Rotor syndrome Absent OATP1B1 and OATP1B3 reuptake Mixed conjugated and unconjugated; usually 2–5 mg/dL Total urinary coproporphyrin increased 2- to 5-fold with about 65% coproporphyrin I Memon 2016
  • Coproporphyrin in healthy people. About 75% of urinary coproporphyrin is isomer III in healthy controls (Memon 2016).
  • Gilbert syndrome frequency. Gilbert syndrome occurs in 3%–13% of the population and is the most common hereditary hyperbilirubinemia syndrome (Memon 2016). Genotyping of the A(TA)7TAA variant is useful in prolonged neonatal jaundice (Memon 2016).

Neonatal hyperbilirubinemia

  • Current rule (AAP 2022). The 2022 AAP guideline narrowly raised the phototherapy thresholds and provides hour-specific total serum bilirubin thresholds by gestational age and neurotoxicity risk factors (Kemper 2022; Slaughter 2022; Dani 2025; Zhang 2026). New evidence showed that neurotoxicity does not occur until bilirubin concentrations are well above the 2004 exchange transfusion thresholds, and the evidence supported narrowly raising the phototherapy thresholds and limiting intravenous immune globulin (Slaughter 2022).
  • Previous rule (AAP 2004). The 2004 guideline recommended promotion of breastfeeding, a predischarge risk assessment for severe hyperbilirubinemia, follow-up based on that assessment, and phototherapy or exchange transfusion when indicated (AAP 2004).
  • Hyperbilirubinemia from hemolytic disease of the fetus and newborn is covered in Hemolytic Disease of the Fetus and Newborn, Fetomaternal Hemorrhage, Rh Immune Globulin and Fetal and Neonatal Transfusion.

Liver test patterns, synthetic function and fibrosis scores

  • Patterns. Hepatocellular injury is a disproportionate elevation of AST and ALT relative to ALP, and cholestatic injury is a disproportionate elevation of ALP relative to AST and ALT. A mixed pattern elevates both (Kwo 2017).
  • R ratio. R = (ALT ÷ ALT ULN) ÷ (ALP ÷ ALP ULN). R ≥5 indicates hepatocellular injury, R ≤2 cholestatic injury and R between 2 and 5 a mixed pattern (Kwo 2017; Yu 2017).
  • Conjugated hyperbilirubinemia. An elevated conjugated bilirubin implies hepatocellular disease or biliary obstruction in most settings (Kwo 2017).
  • Albumin. Albumin is synthesized only by the liver, has a half-life of 3 weeks and is normally ≥3.5 g/dL. A low albumin usually indicates liver disease of more than 3 weeks' duration, although any significant illness lowers it (Kwo 2017).
  • Prothrombin time. The prothrombin time can be prolonged in severe liver disease of less than 24 hours' duration. Hepatocellular dysfunction prolongs it only when clotting factors fall below 10% of normal, and cholestasis prolongs it through vitamin K malabsorption (Kwo 2017). Factor patterns in liver disease are described in Clotting Factor Assays, Factor Inhibitors and Interference by Hemophilia Therapies, and rebalanced hemostasis in cirrhosis in DIC, Thrombotic Microangiopathy and Viscoelastic Testing.
  • FIB-4. FIB-4 = (age × AST) ÷ (platelet count × √ALT). In HIV/HCV coinfection, FIB-4 <1.45 had a negative predictive value of 90% for advanced fibrosis, and FIB-4 >3.25 had a specificity of 97% (Sterling 2006).
  • APRI. The AST-to-platelet ratio index (APRI) predicted significant fibrosis and cirrhosis in chronic hepatitis C with AUCs of 0.88 and 0.94 in the validation set (Wai 2003).

Liver injury pattern and fibrosis indices.

Index Formula Interpretation Source
R ratio (ALT ÷ ALT ULN) ÷ (ALP ÷ ALP ULN) ≥5 hepatocellular; >2 to <5 mixed; ≤2 cholestatic Kwo 2017; Yu 2017
FIB-4 (age [years] × AST [U/L]) ÷ (platelets [10⁹/L] × √ALT [U/L]) <1.45 excludes advanced fibrosis (NPV 90%); >3.25 specificity 97% Sterling 2006

Ammonia specimen stability

In vitro deamination generates ammonia in collected blood, so samples have traditionally been collected on ice and analyzed within about 1 hour. In plasma at 4 °C, ammonia rose 0.5 µmol/L per hour when ALT and GGT were normal and 3.6 µmol/L per hour when they were raised. Sodium borate with L-serine, or storage at −80 °C, reduced the rise (Gifford 2018). In samples from 19 patients with hyperammonemia, ammonia rose in vitro by a peak of 14.9% over 2 hours, mainly from cells. Ice did not improve stability and increased the hemolysis index. The reference change value for ammonia was 40.8%, and the authors concluded that samples received within 2 hours of venipuncture are acceptable without ice (Mercer-Smith 2025).

Celiac disease serology

  • First-line testing. Serologic testing is tTG-IgA on a gluten-containing diet, with total IgA if IgA deficiency has not been excluded. An elevated tTG-IgA is followed by upper endoscopy with duodenal biopsy (Rubio-Tapia 2023).
  • IgA deficiency. In IgA deficiency, IgG-based serology, commonly deamidated gliadin peptide (DGP) IgG and/or tTG-IgG, is measured (Rubio-Tapia 2023).
  • Negative predictive value. A negative tTG-IgA without IgA deficiency has a high negative predictive value when pretest probability is low or moderate. With high pretest probability, biopsy is considered despite negative serology (Rubio-Tapia 2023).
  • Nonbiopsy diagnosis. In children, a tTG-IgA >10 times the ULN with a positive endomysial antibody in a second blood sample is reliable for diagnosis. The same criteria may be considered in symptomatic adults who cannot undergo endoscopy (Rubio-Tapia 2023).
  • Biopsy sampling. One or two biopsies are taken from the bulb and four from the distal duodenum (Rubio-Tapia 2023).

Fecal biomarkers, pancreatic function and stool chemistry

  • Fecal calprotectin in ulcerative colitis. In symptomatic remission, fecal calprotectin <150 µg/g, normal fecal lactoferrin and/or normal CRP rule out active inflammation. In moderate to severe symptoms, a calprotectin >150 µg/g, an elevated lactoferrin or an elevated CRP is used to guide treatment without routine endoscopy (Singh 2023).
  • Fecal elastase-1. Against secretin stimulation testing, fecal elastase-1 had a pooled sensitivity of 0.77 and specificity of 0.88 for exocrine pancreatic insufficiency. A normal level above 200 µg/g rules out insufficiency in patients with low pretest probability, and a low level has a high false-positive rate in that group (Vanga 2018).
  • Quantitative fecal fat. Fecal fat is measured in grams over a 72-hour stool collection while the patient consumes a standardized amount of dietary fat, typically 100 g/day. It is the reference method for fat malabsorption. Under physiologic conditions, no more than 7% of fat ingested on a 100 g/day diet is excreted in the feces. The test quantifies steatorrhea. It does not distinguish pancreatic, enteric and biliary causes, and its use is often restricted to cases in which other tests are inconclusive. Fat malabsorption is typical of severe exocrine pancreatic insufficiency and also occurs in untreated celiac disease, terminal ileal disease and short bowel syndrome. The steatocrit on a random stool has been suggested as a semiquantitative alternative, and the ¹³C-mixed triglyceride breath test has been established as an alternative to quantitative fecal fat measurement (Lenti 2025).
  • Fecal osmotic gap. With an assumed fecal osmolality of 290 mOsm/kg, the gap was always <50 mOsm/kg in phenolphthalein-induced secretory diarrhea and always >50 mOsm/kg in osmotic diarrhea from polyethylene glycol, magnesium hydroxide, lactulose and sorbitol. Sodium sulfate produced osmotic diarrhea with a gap <50 mOsm/kg and was distinguished by fecal chloride (Eherer 1992).
  • Stool pH. In carbohydrate malabsorption from lactulose or sorbitol, fecal pH was always <5.6 and usually <5.3. Other causes rarely produced a pH of 5.6 and never <5.3 (Eherer 1992).

Fecal osmotic gap.

Item Rule Source
Fecal osmotic gap (mOsm/kg) 290 − 2 × (stool Na + stool K) Eherer 1992
<50 mOsm/kg Secretory diarrhea (or sodium sulfate) Eherer 1992
>50 mOsm/kg Osmotic diarrhea Eherer 1992
Stool pH <5.6 Carbohydrate malabsorption Eherer 1992

Stool-based colorectal cancer screening

  • Current rule (USPSTF 2021). The USPSTF recommends screening in adults aged 50 to 75 years (grade A) and 45 to 49 years (grade B), and selective screening at 76 to 85 years (USPSTF 2021).
  • Previous rule (USPSTF 2016). Screening began at age 50 years and continued to 75 years in average-risk adults (USPSTF 2016).
  • Test principles. High-sensitivity guaiac fecal occult blood testing (gFOBT) detects blood chemically, and the fecal immunochemical test (FIT) uses antibodies. In 2021, the only FDA-approved stool DNA test was a multitarget test with a FIT component (sDNA-FIT). Abnormal stool tests require follow-up colonoscopy (USPSTF 2021).

USPSTF 2021 stool-based screening intervals.

Test Interval Comment Source
High-sensitivity gFOBT Every year Chemical detection of blood; uncertain sensitivity estimates USPSTF 2021
FIT Every year Antibody detection of blood; 20 µg hemoglobin/g feces threshold used in modeling USPSTF 2021
sDNA-FIT Every 1 to 3 years Annual sDNA-FIT yields more colonoscopies than annual FIT USPSTF 2021

Gastrointestinal hormones and 5-HIAA

  • Gastrin provocative testing. In two-thirds of patients with Zollinger-Ellison syndrome, fasting serum gastrin falls within the range seen in other hypergastrinemic conditions. A secretin-stimulated increase of ≥120 pg/mL had a sensitivity of 94% and specificity of 100%, and secretin testing was more sensitive than calcium testing (94% versus 62%) (Berna 2006).
  • 5-HIAA. Plasma and 24-hour urine 5-HIAA had similar diagnostic accuracy for neuroendocrine tumors, with AUCs of 0.917 and 0.920. Serum values showed a positive bias against plasma and rose once eGFR fell below 60 mL/min/1.73 m² (Adaway 2016).

References

  1. Abdel GMT, El-Masry MI. Verification of quantitative analytical methods in medical laboratories. J Med Biochem. 2021;40(3):225–236. doi:10.5937/jomb0-24764. PMID 34177366
  2. Adaway JE, Dobson R, Walsh J, et al. Serum and plasma 5-hydroxyindoleacetic acid as an alternative to 24-h urine 5-hydroxyindoleacetic acid measurement. Ann Clin Biochem. 2016;53(Pt 5):554–560. doi:10.1177/0004563215613109. PMID 26438520
  3. Al-Johani WM. Macroamylasemia as a rare cause of hyperamylasemia: a case report. Korean J Fam Med. 2023;44(6):347–349. doi:10.4082/kjfm.23.0195. PMID 37989276
  4. Alkhouri N, Gonzalez-Peralta RP, Medici V. Wilson disease: a summary of the updated AASLD Practice Guidance. Hepatol Commun. 2023;7(6). doi:10.1097/HC9.0000000000000150. PMID 37184530
  5. American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics. 2004;114(1):297–316. doi:10.1542/peds.114.1.297. PMID 15231951 (AAP 2004)
  6. Anderson N. The Individualized Quality Control Plan – coming soon to clinical microbiology laboratories everywhere! Clin Microbiol Newsl. 2015;37(22):177–185. doi:10.1016/j.clinmicnews.2015.11.001. PMID 26997689
  7. Armbruster DA, Pry T. Limit of blank, limit of detection and limit of quantitation. Clin Biochem Rev. 2008;29(Suppl 1):S49–S52. PMID 18852857
  8. Arranz Arija JA, Del Muro XG, Caro RL, et al. SEOM-GG clinical guidelines for the management of germ-cell testicular cancer (2023). Clin Transl Oncol. 2024;26(11):2783–2799. doi:10.1007/s12094-024-03532-2. PMID 38958901
  9. Arslan M, Novak M, Rosenthal D, et al. Cholinesterase deficiency syndrome: a pitfall in the use of butyrylcholinesterase as a biomarker for Wilson's disease. Biomolecules. 2022;12(10):1398. doi:10.3390/biom12101398. PMID 36291607
  10. Avgoustou E, Kounatidis D, Vallianou NG, et al. Incidental detection of hereditary bisalbuminemia in a patient with positive DAT Coombs: a case-based review. Metabol Open. 2024;23:100307. doi:10.1016/j.metop.2024.100307. PMID 39185032
  11. Bayat H, Westgard SA, Westgard JO. The value of Sigma-metrics in laboratory medicine. Clin Chem Lab Med. 2024;62(12):2401–2404. doi:10.1515/cclm-2024-0609. PMID 38861264
  12. Bazzano G, Galazzi A, Giusti GD, Panigada M, Laquintana D. The order of draw during blood collection: a systematic literature review. Int J Environ Res Public Health. 2021;18(4):1568. doi:10.3390/ijerph18041568. PMID 33562241
  13. Belfield A, Goldberg DM. Activation of serum 5′ nucleotidase by magnesium ions and its diagnostic applications. J Clin Pathol. 1969;22(2):144–151. doi:10.1136/jcp.22.2.144. PMID 5776544
  14. Benamour M, Brouwers P, Nevraumont A, et al. Double trouble: unmasking two hook effects on Siemens Atellica – total PSA and total hCG assays. Pract Lab Med. 2024;39:e00366. doi:10.1016/j.plabm.2024.e00366. PMID 38352133
  15. Benati M, Pighi L, Paviati E, Visconti S, Lippi G, Salvagno GL. Preanalytical impact of incomplete K2EDTA blood tube filling in molecular biology testing. Diagnostics (Basel). 2024;14(17):1934. doi:10.3390/diagnostics14171934. PMID 39272719
  16. Benozzi SF, Unger G, Campion A, Milano PG, Pennacchiotti GL. Coffee intake one hour prior to phlebotomy produces no clinically significant changes in routine biochemical test results. Biochem Med (Zagreb). 2023;33(2):020705. doi:10.11613/BM.2023.020705. PMID 37324115
  17. Berna MJ, Hoffmann KM, Long SH, et al. Serum gastrin in Zollinger-Ellison syndrome: II. Prospective study of gastrin provocative testing in 293 patients from the National Institutes of Health and comparison with 537 cases from the literature. Medicine (Baltimore). 2006;85(6):331–364. doi:10.1097/MD.0b013e31802b518c. PMID 17108779
  18. Bilić-Zulle L. Comparison of methods: Passing and Bablok regression. Biochem Med (Zagreb). 2011;21(1):49–52. doi:10.11613/bm.2011.010. PMID 22141206
  19. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1(8476):307–310. PMID 2868172
  20. Bodor GS. The laboratory's role in opioid pain medication monitoring. EJIFCC. 2012;23(2):55–62. PMID 27683413
  21. Broughton PMG. Carry-over in automatic analysers. J Automat Chem. 1984;6(2):94–95. doi:10.1155/S1463924684000201. PMID 18924602
  22. Capaldo C, El Aouni MC, Laurelli D, et al. Detection of monoclonal protein by capillary zone electrophoresis can be challenged by iodinated contrast agent interference: a case report. Biochem Med (Zagreb). 2021;31(2):021001. doi:10.11613/BM.2021.021001. PMID 33927559
  23. Carraro P, Plebani M. Errors in a stat laboratory: types and frequencies 10 years later. Clin Chem. 2007;53(7):1338–1342. doi:10.1373/clinchem.2007.088344. PMID 17525103
  24. Carvounis CP, Nisar S, Guro-Razuman S. Significance of the fractional excretion of urea in the differential diagnosis of acute renal failure. Kidney Int. 2002;62(6):2223–2229. doi:10.1046/j.1523-1755.2002.00683.x. PMID 12427149
  25. Catalona WJ, Partin AW, Slawin KM, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA. 1998;279(19):1542–1547. doi:10.1001/jama.279.19.1542. PMID 9605898
  26. Centers for Medicare & Medicaid Services; Centers for Disease Control and Prevention. Developing an IQCP: a step-by-step guide (IQCP workbook). https://www.cms.gov/regulations-and-guidance/legislation/clia/downloads/iqcp-workbook.pdf (CMS IQCP workbook)
  27. Centers for Medicare & Medicaid Services. Clinical Laboratory Improvement Amendments (CLIA) proficiency testing related to analytes and acceptable performance; correction. Fed Regist. 2022;87:68912. FR Doc 2022-24990 (87 FR 68912)
  28. Centers for Medicare & Medicaid Services. Clinical Laboratory Improvement Amendments of 1988 (CLIA) proficiency testing regulations related to analytes and acceptable performance. Final rule. Fed Regist. 2022;87(131):41194–41242. FR Doc 2022-14513 (87 FR 41194)
  29. Centers for Medicare & Medicaid Services. Individualized Quality Control Plans. Page last modified August 24, 2026. https://www.cms.gov/medicare/health-safety-standards/clinical-laboratory-improvement-amendments-clia/clia-regulations-compliance/individualized-quality-control-plans (CMS 2026)
  30. Ceriotti F, Henny J, Queraltó J, et al. Common reference intervals for aspartate aminotransferase (AST), alanine aminotransferase (ALT) and γ-glutamyl transferase (GGT) in serum: results from an IFCC multicenter study. Clin Chem Lab Med. 2010;48(11):1593–1601. doi:10.1515/CCLM.2010.315. PMID 21034260
  31. Chambliss AB, Patel K, Colón-Franco JM, et al. AACC guidance document on the clinical use of procalcitonin. J Appl Lab Med. 2023;8(3):598–634. doi:10.1093/jalm/jfad007. PMID 37140163
  32. Chiu ML, Ytterberg AJ, Ogorzalek Loo RR, et al. Characterization of morphine-glucose-6-phosphate dehydrogenase conjugates by mass spectrometry. Bioconjug Chem. 2011;22(8):1595–1604. doi:10.1021/bc2001352. PMID 21678975
  33. Chong YK, Ho CC, Leung SY, et al. Clinical mass spectrometry in the bioinformatics era: a hitchhiker's guide. Comput Struct Biotechnol J. 2018;16:316–334. doi:10.1016/j.csbj.2018.08.003. PMID 30237866
  34. Cinquanta L, Fontana DE, Bizzaro N. Chemiluminescent immunoassay technology: what does it change in autoantibody detection? Auto Immun Highlights. 2017;8(1):9. doi:10.1007/s13317-017-0097-2. PMID 28647912
  35. Clark AE, Kaleta EJ, Arora A, Wolk DM. Matrix-assisted laser desorption ionization-time of flight mass spectrometry: a fundamental shift in the routine practice of clinical microbiology. Clin Microbiol Rev. 2013;26(3):547–603. doi:10.1128/CMR.00072-12. PMID 23824373
  36. Clinical and Laboratory Standards Institute. CLSI GP40: Preparation and testing of reagent water in the medical laboratory. 5th ed. December 10, 2024. Product page: https://clsi.org/shop/standards/gp40/ (CLSI 2024)
  37. Clinical and Laboratory Standards Institute. Order of blood draw tubes and additives. CLSI Insights blog, March 19, 2019. https://clsi.org/about/blog/order-of-blood-draw-tubes-and-additives/ (refers to CLSI GP41, Collection of Diagnostic Venous Blood Specimens) (CLSI 2019)
  38. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41. doi:10.1159/000180580. PMID 1244564
  39. Cohen JA, Kaplan MM. The SGOT/SGPT ratio: an indicator of alcoholic liver disease. Dig Dis Sci. 1979;24(11):835–838. doi:10.1007/BF01324898. PMID 520102
  40. Cristelli L, Occhipinti F, Tumiatti D, et al. Implementation of new Westgard rules suggested by the Westgard Advisor software for five immunological parameters. Biochem Med (Zagreb). 2025;35(1):010701. doi:10.11613/BM.2025.010701. PMID 39703760
  41. Cuhadar S, Koseoglu M, Atay A, Dirican A. The effect of storage time and freeze-thaw cycles on the stability of serum samples. Biochem Med (Zagreb). 2013;23(1):70–77. doi:10.11613/bm.2013.009. PMID 23457767
  42. Dani C, Fusco M, Andreini M, et al. Implementation of the 2022 AAP guidelines for neonatal hyperbilirubinemia could reduce the need for phototherapy in Italy. Ital J Pediatr. 2025;51(1):162. doi:10.1186/s13052-025-02002-x. PMID 40437558
  43. Daves M, Piccin A, Roccaforte V, et al. Comparison of Freelite and N-Latex serum free light chain assays: a critical review. Biochem Med (Zagreb). 2021;31(3):030701. doi:10.11613/BM.2021.030701. PMID 34393594
  44. De Guire V, Galoro CAO, Ibarz M, et al. Recommendations from the IFCC Working Group on Laboratory Errors and Patient Safety for the global adoption of an essential quality indicators panel in laboratory medicine. Clin Chem Lab Med. 2026;64(4):806–812. doi:10.1515/cclm-2025-1462. PMID 41259049
  45. Deisenhammer F, Hegen H, Arrambide G, et al. Positive cerebrospinal fluid in the 2024 McDonald criteria for multiple sclerosis. EBioMedicine. 2025;120:105905. doi:10.1016/j.ebiom.2025.105905. PMID 40967951
  46. Delanaye P, Rule AD, Schaeffner E, et al. Performance of the European Kidney Function Consortium (EKFC) creatinine-based equation in United States cohorts. Kidney Int. 2024;105(3):629–637. doi:10.1016/j.kint.2023.11.024. PMID 38101514
  47. Delanghe J, Speeckaert M. Preanalytical requirements of urinalysis. Biochem Med (Zagreb). 2014;24(1):89–104. doi:10.11613/BM.2014.011. PMID 24627718
  48. Delgado C, Baweja M, Crews DC, et al. A unifying approach for GFR estimation: recommendations of the NKF-ASN Task Force on reassessing the inclusion of race in diagnosing kidney disease. Am J Kidney Dis. 2022;79(2):268–288.e1. doi:10.1053/j.ajkd.2021.08.003. PMID 34563581
  49. Delgado JA, Lopez B, Morell-García D, et al. Clinical thresholds for pseudohyperkalemia and pseudonormokalemia in patients with thrombocytosis. EJIFCC. 2022;33(3):233–241. PMID 36447798
  50. Depreter B, Stove V, Delanghe J. Sampling on ice will not yield reliable uric acid monitoring in rasburicase-treated patients. Clin Biochem. 2016;49(18):1390–1395. doi:10.1016/j.clinbiochem.2016.04.011. PMID 27129796
  51. Dibbasey M, Umukoro S, Bojang A. Comparative and stability study of glucose concentrations measured in both sodium fluoride and serum separator tubes. Pract Lab Med. 2024;39:e00360. doi:10.1016/j.plabm.2024.e00360. PMID 38313813
  52. Dimeski G, Badrick T, John AS. Ion selective electrodes (ISEs) and interferences – a review. Clin Chim Acta. 2010;411(5–6):309–317. doi:10.1016/j.cca.2009.12.005. PMID 20004654
  53. Dispenzieri A, Kyle R, Merlini G, et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia. 2009;23(2):215–224. doi:10.1038/leu.2008.307. PMID 19020545
  54. Don BR, Sebastian A, Cheitlin M, Christiansen M, Schambelan M. Pseudohyperkalemia caused by fist clenching during phlebotomy. N Engl J Med. 1990;322(18):1290–1292. doi:10.1056/NEJM199005033221806. PMID 2325722
  55. Draviam EJ, Custer EM, Schoen I. Vapor pressure and freezing point osmolality measurements applied to a volatile screen. Am J Clin Pathol. 1984;82(6):706–709. doi:10.1093/ajcp/82.6.706. PMID 6507382
  56. Egner W, Swallow K, Lock RJ, et al. Falsely low immunoglobulin (Ig)G4 in routine analysis: how not to miss IgG4 disease. Clin Exp Immunol. 2016;186(1):57–63. doi:10.1111/cei.12805. PMID 27125474
  57. Eherer AJ, Fordtran JS. Fecal osmotic gap and pH in experimental diarrhea of various causes. Gastroenterology. 1992;103(2):545–551. doi:10.1016/0016-5085(92)90845-p. PMID 1634072
  58. Eide JG, Mason W, Mackie H, et al. Diagnostic accuracy of beta-2 transferrin gel electrophoresis for detecting cerebrospinal fluid rhinorrhea. Laryngoscope. 2025;135(1):94–96. doi:10.1002/lary.31845. PMID 39400322
  59. Einarsson Long T, Rognvaldsson S, Thorsteinsdottir S, et al. New definition of light chain monoclonal gammopathy of undetermined significance. JAMA Oncol. 2025;11(7):753–761. doi:10.1001/jamaoncol.2025.1285. PMID 40440024 (Einarsson Long 2025)
  60. Electronic Code of Federal Regulations. 42 CFR 493.931 and 493.933, point-in-time version of January 1, 2024. https://www.ecfr.gov/on/2024-01-01/title-42/chapter-IV/subchapter-G/part-493
  61. Electronic Code of Federal Regulations. 42 CFR Part 493 – Laboratory Requirements (sections 493.2, 493.801, 493.803, 493.807, 493.841, 493.931, 493.933, 493.1236, 493.1253, 493.1255, 493.1256). Current as of November 6, 2026. https://www.ecfr.gov/current/title-42/chapter-IV/subchapter-G/part-493
  62. Electronic Code of Federal Regulations. 42 CFR Part 493 – Laboratory Requirements (sections 493.5, 493.15 and 493.803). Current as of November 6, 2026. https://www.ecfr.gov/current/title-42/chapter-IV/subchapter-G/part-493
  63. Ercan Ş, Ramadan B, Gerenli O. Order of draw of blood samples affect potassium results without K-EDTA contamination during routine workflow. Biochem Med (Zagreb). 2021;31(2):020704. doi:10.11613/BM.2021.020704. PMID 33927554
  64. Espinel CH, Gregory AW. Differential diagnosis of acute renal failure. Clin Nephrol. 1980;13(2):73–77. PMID 7363517
  65. Etzioni RD, Howlader N, Shaw PA, et al. Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial. J Urol. 2005;174(3):877–881. doi:10.1097/01.ju.0000169255.64518.fb. PMID 16093979
  66. Evans DC, Corkins MR, Malone A, et al. The use of visceral proteins as nutrition markers: an ASPEN position paper. Nutr Clin Pract. 2021;36(1):22–28. doi:10.1002/ncp.10588. PMID 33125793
  67. Fahie-Wilson MN, Burrows S, Lawson GJ, et al. Prevalence of increased serum creatine kinase activity due to macro-creatine kinase and experience of screening programmes in district general hospitals. Ann Clin Biochem. 2007;44(Pt 4):377–383. doi:10.1258/000456307780945642. PMID 17594785
  68. Feitosa PHR, Castellano MVCO, Costa CHD, et al. Recommendations for the diagnosis and treatment of alpha-1 antitrypsin deficiency. J Bras Pneumol. 2024;50(5):e20240235. doi:10.36416/1806-3756/e20240235. PMID 39661838
  69. Fernández de Larrea C, Kyle R, Rosiñol L, et al. Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage. Blood Cancer J. 2021;11(12):192. doi:10.1038/s41408-021-00587-0. PMID 34857730
  70. Fishman WH. Immunology and biochemistry of the Regan isoenzyme. Prostate. 1980;1(4):399–410. doi:10.1002/pros.2990010403. PMID 7024957
  71. Flatt JF, Bruce LJ. The molecular basis for altered cation permeability in hereditary stomatocytic human red blood cells. Front Physiol. 2018;9:367. doi:10.3389/fphys.2018.00367. PMID 29713289
  72. Food and Drug Administration. Biotin interference with troponin lab tests – assays subject to biotin interference. Content current as of June 21, 2022. https://www.fda.gov/medical-devices/in-vitro-diagnostics/biotin-interference-troponin-lab-tests-assays-subject-biotin-interference (FDA 2022)
  73. Food and Drug Administration. Blood glucose monitoring test systems for prescription point-of-care use. Guidance for industry and Food and Drug Administration staff. September 2020. Docket FDA-2013-D-1445. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/blood-glucose-monitoring-test-systems-prescription-point-care-use (FDA 2020)
  74. Food and Drug Administration. Medical devices; laboratory developed tests; implementation of vacatur. Final rule. Fed Regist. 2025;90:45134. FR Doc 2025-18239 (90 FR 45134)
  75. Food and Drug Administration. Medical devices; laboratory developed tests. Final rule. Fed Regist. 2024;89:37286. FR Doc 2024-08935 (89 FR 37286)
  76. Foroughi M, Parikh D, Wassell J, Hatfield R. Influence of light and time on bilirubin degradation in CSF spectrophotometry for subarachnoid haemorrhage. Br J Neurosurg. 2010;24(4):401–404. doi:10.3109/02688697.2010.495172. PMID 20632882
  77. Freedman MS, Thompson EJ, Deisenhammer F, et al. Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement. Arch Neurol. 2005;62(6):865–870. doi:10.1001/archneur.62.6.865. PMID 15956157
  78. Gaggar P, Raju SB. Diagnostic utility of urine microscopy in kidney diseases. Indian J Nephrol. 2024;34(3):213–221. doi:10.25259/ijn_362_23. PMID 39114391
  79. Galasso PJ, Litin SC, O'Brien JF. The macroenzymes: a clinical review. Mayo Clin Proc. 1993;68(4):349–354. doi:10.1016/s0025-6196(12)60129-3. PMID 7681133
  80. Ghazal K, Brabant S, Prie D, Piketty ML. Hormone immunoassay interference: a 2021 update. Ann Lab Med. 2022;42(1):3–23. doi:10.3343/alm.2022.42.1.3. PMID 34374345
  81. Giavarina D. Understanding Bland Altman analysis. Biochem Med (Zagreb). 2015;25(2):141–151. doi:10.11613/BM.2015.015. PMID 26110027
  82. Gifford JL, Nguyen WNT, de Koning L, Seiden-Long I. Stabilizing specimens for routine ammonia testing in the clinical laboratory. Clin Chim Acta. 2018;478:37–43. doi:10.1016/j.cca.2017.12.022. PMID 29258744
  83. Gronowski AM, Fantz CR, Parvin CA, et al. Use of serum FSH to identify perimenopausal women with pituitary hCG. Clin Chem. 2008;54(4):652–656. doi:10.1373/clinchem.2007.100305. PMID 18258666
  84. Gruber L, Hausch A, Mueller T. Internal quality controls in the medical laboratory: a narrative review of the basic principles of an appropriate quality control plan. Diagnostics (Basel). 2024;14(19):2223. doi:10.3390/diagnostics14192223. PMID 39410627
  85. Haddad RA, Giacherio D, Barkan AL. Interpretation of common endocrine laboratory tests: technical pitfalls, their mechanisms and practical considerations. Clin Diabetes Endocrinol. 2019;5:12. doi:10.1186/s40842-019-0086-7. PMID 31367466
  86. Hajdin I, Prkić A. 3D printed ion-selective electrodes enriched with ZnO nanoparticles for potassium detection. Sensors (Basel). 2026;26(6):1960. doi:10.3390/s26061960. PMID 41902127
  87. Hanif H, Ali MJ, Susheela AT, et al. Update on the applications and limitations of alpha-fetoprotein for hepatocellular carcinoma. World J Gastroenterol. 2022;28(2):216–229. doi:10.3748/wjg.v28.i2.216. PMID 35110946
  88. Harb R, Coverdell TC, Shalabi H, et al. Diagnostic pitfalls in assessment of ferritin following CAR-T-cell therapy: understanding the hook effect. Pediatr Blood Cancer. 2024;71(9):e31171. doi:10.1002/pbc.31171. PMID 38961599
  89. Hegen H, Arrambide G, Gnanapavan S, et al. Cerebrospinal fluid kappa free light chains for the diagnosis of multiple sclerosis: a consensus statement. Mult Scler. 2023;29(2):182–195. doi:10.1177/13524585221134217. PMID 36527368
  90. Higgins V, Chen Y, Freedman MS, et al. A review of laboratory practices for CSF oligoclonal banding and associated tests. Crit Rev Clin Lab Sci. 2025;62(5):363–385. doi:10.1080/10408363.2025.2490166. PMID 40254719 (Higgins 2025)
  91. Higgins V, Parker ML, Ahmed B, et al. Best practice recommendations for laboratory analysis and reporting of cerebrospinal fluid oligoclonal banding and associated tests for multiple sclerosis (MS): a consensus report from the hCAMI subcommittee of the Canadian Society of Clinical Chemists. Clin Biochem. 2026;142:111098. doi:10.1016/j.clinbiochem.2026.111098. PMID 41692184 (Higgins 2026)
  92. Hoffmann G, Trulson I, Adler J, et al. Indirect methods for the verification of reference intervals in laboratory medicine. Crit Rev Clin Lab Sci. 2026:1–17. doi:10.1080/10408363.2026.2687513. PMID 42384440
  93. Hoofnagle AN, Wener MH. The fundamental flaws of immunoassays and potential solutions using tandem mass spectrometry. J Immunol Methods. 2009;347(1–2):3–11. doi:10.1016/j.jim.2009.06.003. PMID 19538965
  94. Hunter CL, Ladde J. Molar pregnancy with false negative β-hCG urine in the emergency department. West J Emerg Med. 2011;12(2):213–215. PMID 21691529
  95. Hutchison CA, Harding S, Hewins P, et al. Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease. Clin J Am Soc Nephrol. 2008;3(6):1684–1690. doi:10.2215/CJN.02290508. PMID 18945993
  96. Iacovetti G, Collier BB, Rafalko JM, et al. Assessment of the stability of 20 biochemical analytes in serum and whole blood samples after storage at nonstandard temperatures. Pract Lab Med. 2026;48:e00514. doi:10.1016/j.plabm.2025.e00514. PMID 41503054
  97. Ialongo C, Bernardini S. Phlebotomy, a bridge between laboratory and patient. Biochem Med (Zagreb). 2016;26(1):17–33. doi:10.11613/BM.2016.002. PMID 26981016
  98. Illana FJ, García-Osuna Á, Sospedra M, et al. Quality assurance of add-on testing in plasma samples: stability limit for 29 biochemical analytes. Biochem Med (Zagreb). 2024;34(2):020704. doi:10.11613/BM.2024.020704. PMID 38665870
  99. Inker LA, Eneanya ND, Coresh J, et al. New creatinine- and cystatin C-based equations to estimate GFR without race. N Engl J Med. 2021;385(19):1737–1749. doi:10.1056/NEJMoa2102953. PMID 34554658
  100. Inoue S, Egi M, Kotani J, Morita K. Accuracy of blood-glucose measurements using glucose meters and arterial blood gas analyzers in critically ill adult patients: systematic review. Crit Care. 2013;17(2):R48. doi:10.1186/cc12567. PMID 23506841
  101. Jacobs JFM, Turner KA, Graziani MS, et al. An international multi-center serum protein electrophoresis accuracy and M-protein isotyping study. Part II: limit of detection and follow-up of patients with small M-proteins. Clin Chem Lab Med. 2020;58(4):547–559. doi:10.1515/cclm-2019-1105. PMID 31940285
  102. Jones GRD, Haeckel R, Loh TP, et al. Indirect methods for reference interval determination – review and recommendations. Clin Chem Lab Med. 2018;57(1):20–29. doi:10.1515/cclm-2018-0073. PMID 29672266
  103. Kalaria T, Fenn J, Whitmill R, et al. Acid freezes uricolysis in addition to glycolysis: utility of fluoride-EDTA-citrate tube in the measurement of uric acid for patients administered rasburicase. Ann Clin Biochem. 2022;59(3):178–182. doi:10.1177/00045632211066275. PMID 34989247
  104. Kashani K, Al-Khafaji A, Ardiles T, et al. Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury. Crit Care. 2013;17(1):R25. doi:10.1186/cc12503. PMID 23388612
  105. Katzmann JA, Clark RJ, Abraham RS, et al. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem. 2002;48(9):1437–1444. PMID 12194920
  106. Kemper AR, Newman TB, Slaughter JL, et al. Clinical practice guideline revision: management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics. 2022;150(3):e2022058859. doi:10.1542/peds.2022-058859. PMID 35927462 (Kemper 2022)
  107. Keren DF, Schroeder L. Challenges of measuring monoclonal proteins in serum. Clin Chem Lab Med. 2016;54(6):947–961. doi:10.1515/cclm-2015-0862. PMID 26910744
  108. Khan AI. Best laboratory practices regarding POCT in different settings (hospital and outside the hospital). EJIFCC. 2021;32(2):124–130. PMID 34421480
  109. Khosroshahi A, Cheryk LA, Carruthers MN, et al. Brief report: spuriously low serum IgG4 concentrations caused by the prozone phenomenon in patients with IgG4-related disease. Arthritis Rheumatol. 2014;66(1):213–217. doi:10.1002/art.38193. PMID 24431286
  110. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012;2(1):1–138. https://kdigo.org/wp-content/uploads/2016/10/KDIGO-2012-AKI-Guideline-English.pdf (KDIGO AKI 2012)
  111. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3(1):1–150. https://kdigo.org/wp-content/uploads/2017/02/KDIGO_2012_CKD_GL.pdf (KDIGO 2012)
  112. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;105(4S):S117–S314. doi:10.1016/j.kint.2023.10.018. PMID 38490803. https://kdigo.org/wp-content/uploads/2024/03/KDIGO-2024-CKD-Guideline.pdf (KDIGO 2024)
  113. Kim DH, Hong SW, Park N. Comparative analysis of alpha-fetoprotein, carbohydrate antigen 19-9, carcinoembryonic antigen, and prostate-specific antigen among conventional cigarette smokers, heated tobacco product users and quitters. Tob Induc Dis. 2025;23. doi:10.18332/tid/200890. PMID 40078230
  114. Kim S, Jeong TD, Lee K, et al. Quantitative evaluation of the real-world harmonization status of laboratory test items using external quality assessment data. Ann Lab Med. 2024;44(6):529–536. doi:10.3343/alm.2024.0082. PMID 38919008
  115. Kimura S, Iyama S, Yamaguchi Y, Kanakura Y. Homogenous enzyme immunoassay for cyclosporine in whole blood using the EMIT 2000 cyclosporine specific assay with the COBAS MIRA-plus analyzer. J Clin Lab Anal. 2001;15(6):319–323. doi:10.1002/jcla.1044. PMID 11793432
  116. Klionsky DJ. It's apples and oranges (or chalk and cheese, depending on where you live): RPM versus RCF. Autophagy. 2026;22(10):2521. doi:10.1080/15548627.2026.2685350. PMID 42788748
  117. Kopoczynski L, Lasota A, Bartkowiak D, et al. Macroenzymes in isolated hyperenzymemia: detection methods and decision thresholds for polyethylene glycol-precipitable activity. Cureus. 2026;18:e117331. doi:10.7759/cureus.117331. PMID 42967200
  118. Korse CM, Muller M, Taal BG. Discontinuation of proton pump inhibitors during assessment of chromogranin A levels in patients with neuroendocrine tumours. Br J Cancer. 2011;105(8):1173–1175. doi:10.1038/bjc.2011.380. PMID 21989216
  119. Kouri TT, Hofmann W, Falbo R, et al. The EFLM European Urinalysis Guideline 2023. Clin Chem Lab Med. 2024;62(9):1653–1786. doi:10.1515/cclm-2024-0070. PMID 38534005
  120. Kristinsdottir EA, Statkevicius S, Sigurdsson MI, Hansson F, Broman ME. Effects of analysis delay on pH, pO2, pCO2, bicarbonate, glucose, lactate, electrolytes, and other arterial blood gas variables. Acta Anaesthesiol Scand. 2025;69(6):e70049. doi:10.1111/aas.70049. PMID 40331397
  121. Krleza JL, Dorotic A, Grzunov A, Maradin M. Capillary blood sampling: national recommendations on behalf of the Croatian Society of Medical Biochemistry and Laboratory Medicine. Biochem Med (Zagreb). 2015;25(3):335–358. doi:10.11613/BM.2015.034. PMID 26524965
  122. Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328–e346. doi:10.1016/S1470-2045(16)30206-6. PMID 27511158
  123. Kwo PY, Cohen SM, Lim JK. ACG clinical guideline: evaluation of abnormal liver chemistries. Am J Gastroenterol. 2017;112(1):18–35. doi:10.1038/ajg.2016.517. PMID 27995906
  124. Labcorp. Creatine kinase (CK), total plus isoenzymes, test 002154. https://www.labcorp.com/tests/002154/creatine-kinase-ck-total-plus-isoenzymes (accessed 2026-11-10) (Labcorp 002154)
  125. Labcorp. Lactate dehydrogenase (LD) isoenzymes, test 001842. https://www.labcorp.com/tests/001842/lactate-dehydrogenase-ld-isoenzymes (accessed 2026-11-10) (Labcorp 001842)
  126. Larsson A, Campbell A, Eriksson M. Chicken antibodies are highly suitable for particle enhanced turbidimetric assays. Front Immunol. 2022;13:1016781. doi:10.3389/fimmu.2022.1016781. PMID 36304451
  127. Laur N, Kinscherf R, Pomytkin K, et al. ICP-MS trace element analysis in serum and whole blood. PLoS One. 2020;15(5):e0233357. doi:10.1371/journal.pone.0233357. PMID 32433650
  128. Lee KN, Csako G, Bernhardt P, et al. Relevance of macro creatine kinase type 1 and type 2 isoenzymes to laboratory and clinical data. Clin Chem. 1994;40(7 Pt 1):1278–1283. PMID 8013099
  129. Lenti MV, Hammer HF, Tacheci I, et al. European Consensus on Malabsorption-UEG & SIGE, LGA, SPG, SRGH, CGS, ESPCG, EAGEN, ESPEN, and ESPGHAN. Part 1: Definitions, clinical phenotypes, and diagnostic testing for malabsorption. United European Gastroenterol J. 2025;13(4):599–613. doi:10.1002/ueg2.70012. PMID 40129317
  130. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–612. doi:10.7326/0003-4819-150-9-200905050-00006. PMID 19414839
  131. Levin A, Ahmed SB, Carrero JJ, et al. Executive summary of the KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease: known knowns and known unknowns. Kidney Int. 2024;105(4):684–701. doi:10.1016/j.kint.2023.10.016. PMID 38519239
  132. Li D, Ferguson A, Cervinski MA, Lynch KL, Kyle PB. AACC guidance document on biotin interference in laboratory tests. J Appl Lab Med. 2020;5(3):575–587. doi:10.1093/jalm/jfz010. PMID 32445355
  133. Lim SM, Wijeratne N, Choy KW, et al. A review of clinical guidelines, laboratory recommendations and external quality assurance programs for monoclonal gammopathy testing. Crit Rev Clin Lab Sci. 2024;61(2):107–126. doi:10.1080/10408363.2023.2257306. PMID 37776896
  134. Lin KY, Chen PC, Chen SC, et al. Evaluation of the effects of glucose on osmolal gap using freezing point depression and vapor pressure methods. Kaohsiung J Med Sci. 2018;34(7):409–414. doi:10.1016/j.kjms.2018.03.002. PMID 30063014
  135. Link H, Tibbling G. Principles of albumin and IgG analyses in neurological disorders. III. Evaluation of IgG synthesis within the central nervous system in multiple sclerosis. Scand J Clin Lab Invest. 1977;37(5):397–401. doi:10.1080/00365517709091498. PMID 337461
  136. Lippi G, Cadamuro J, von Meyer A, Simundic AM. Practical recommendations for managing hemolyzed samples in clinical chemistry testing. Clin Chem Lab Med. 2018;56(5):718–727. doi:10.1515/cclm-2017-1104. PMID 29373316
  137. Liu Y, Zhang J, Zheng Z, et al. The interplay between CA19-9 and the Lewis blood group system: implications for the diagnosis of gallbladder cancer. Can J Gastroenterol Hepatol. 2025;2025:8465615. doi:10.1155/cjgh/8465615. PMID 41245225
  138. Locker GY, Hamilton S, Harris J, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol. 2006;24(33):5313–5327. doi:10.1200/JCO.2006.08.2644. PMID 17060676
  139. Loeb S, Sanda MG, Broyles DL, et al. The prostate health index selectively identifies clinically significant prostate cancer. J Urol. 2015;193(4):1163–1169. doi:10.1016/j.juro.2014.10.121. PMID 25463993
  140. Long TE, Indridason OS, Palsson R, et al. Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: results of the iStopMM study. Blood Cancer J. 2022;12(9):133. doi:10.1038/s41408-022-00732-3. PMID 36100605 (Long 2022)
  141. Lott JA, Doumas BT. "Direct" and total bilirubin tests: contemporary problems. Clin Chem. 1993;39(4):641–647. PMID 8472359
  142. Maeng CV, Rögnvaldsson S, Einarsson Long T, et al. Revised free light chain reference intervals enhance risk stratification in monoclonal gammopathy of undetermined significance and reduce overdiagnosis. Blood Cancer J. 2025;15(1):80. doi:10.1038/s41408-025-01289-7. PMID 40295472
  143. Manoeuvrier G, Bach-Ngohou K, Batard E, et al. Diagnostic performance of serum blood urea nitrogen to creatinine ratio for distinguishing prerenal from intrinsic acute kidney injury in the emergency department. BMC Nephrol. 2017;18(1):173. doi:10.1186/s12882-017-0591-9. PMID 28545421
  144. Martin-Almedina S, Mansour S, Ostergaard P. Human phenotypes caused by PIEZO1 mutations; one gene, two overlapping phenotypes? J Physiol. 2018;596(6):985–992. doi:10.1113/JP275718. PMID 29331020
  145. McCudden C, Axel AE, Slaets D, et al. Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference. Clin Chem Lab Med. 2016;54(6):1095–1104. doi:10.1515/cclm-2015-1031. PMID 27028734
  146. Memon N, Weinberger BI, Hegyi T, et al. Inherited disorders of bilirubin clearance. Pediatr Res. 2016;79(3):378–386. doi:10.1038/pr.2015.247. PMID 26595536
  147. Mercer-Smith GW, Appleton M, Hanon ÉA, et al. Blood samples for ammonia analysis do not require transport to the laboratory on ice: a study of ammonia stability and cause of in vitro ammonia increase in samples from patients with hyperammonaemia. Clin Chem Lab Med. 2025;63(6):1132–1138. doi:10.1515/cclm-2024-1304. PMID 39753336
  148. Messiaen AS, De Sloovere MMW, Claus PE, et al. Performance evaluation of serum free light chain analysis: nephelometry vs turbidimetry, monoclonal vs polyclonal reagents. Am J Clin Pathol. 2017;147(6):611–622. doi:10.1093/ajcp/aqx037. PMID 28575180
  149. Michaelis L, Menten ML, Johnson KA, Goody RS. The original Michaelis constant: translation of the 1913 Michaelis-Menten paper. Biochemistry. 2011;50(39):8264–8269. doi:10.1021/bi201284u. PMID 21888353
  150. Mikkelsen G, Thorstensen K, Lian IA, et al. Sample stability of forty-two analytes in plasma or serum pools after one to four repeated −80 °C freeze-thaw cycles. Scand J Clin Lab Invest. 2025;85(8):695–701. doi:10.1080/00365513.2025.2605637. PMID 41428452
  151. Montalban X, Lebrun-Frénay C, Oh J, et al. Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria. Lancet Neurol. 2025;24(10):850–865. doi:10.1016/S1474-4422(25)00270-4. PMID 40975101 (Montalban 2025)
  152. Monteyne T, Oyaert M, Van Dalem A, et al. Impact of bicarbonate interference on routine ion-selective electrode chloride measurements. Ann Lab Med. 2022;42(5):566–574. doi:10.3343/alm.2022.42.5.566. PMID 35470274
  153. Moore RG, McMeekin DS, Brown AK, et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol. 2009;112(1):40–46. doi:10.1016/j.ygyno.2008.08.031. PMID 18851871
  154. Motyckova G, Murali M. Laboratory testing for cryoglobulins. Am J Hematol. 2011;86(6):500–502. doi:10.1002/ajh.22023. PMID 21594887
  155. Moyer VA; US Preventive Services Task Force. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157(2):120–134. doi:10.7326/0003-4819-157-2-201207170-00459. PMID 22801674 (Moyer 2012)
  156. Münte E, Zhang X, Khurana A, et al. Prevalence of extremely severe obesity and metabolic dysfunction among US children and adolescents. JAMA Netw Open. 2025;8(7):e2521170. doi:10.1001/jamanetworkopen.2025.21170. PMID 40668581 (SI conversion factors)
  157. Murray DL, Puig N, Kristinsson S, et al. Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report. Blood Cancer J. 2021;11(2):24. doi:10.1038/s41408-021-00408-4. PMID 33563895
  158. Naser AM, He FJ, Rahman M, et al. Urinary sodium excretion and blood pressure relationship across methods of evaluating the completeness of 24-h urine collections. Nutrients. 2020;12(9):2772. doi:10.3390/nu12092772. PMID 32932868
  159. Nasr SH, Royal V, Best Rocha A, et al. Renal Pathology Society/International Kidney and Monoclonal Gammopathy Research Group consensus on pathologic definitions and terminology of monoclonal gammopathy-associated kidney lesions. Kidney Int. 2025;108(2):184–193. doi:10.1016/j.kint.2025.04.007. PMID 40280412
  160. Neale FC, Clubb JS, Hotchkis D, et al. Heat stability of human placental alkaline phosphatase. J Clin Pathol. 1965;18(3):359–363. doi:10.1136/jcp.18.3.359. PMID 14304254
  161. Neeley WE. A reflectance photometer with a square photodiode array detector for use on multilayer dry-film slides. Clin Chem. 1988;34(11):2367–2370. PMID 3180435
  162. Nerenz RD, Yarbrough ML, Stenman UH, Gronowski AM. Characterizing urinary hCGβcf patterns during pregnancy. Clin Biochem. 2016;49(10–11):777–781. doi:10.1016/j.clinbiochem.2016.04.006. PMID 27087510
  163. Newbigging A, Landry N, Brun M, et al. New solutions to old problems: a practical approach to identify samples with intravenous fluid contamination in clinical laboratories. Clin Biochem. 2024;127–128:110763. doi:10.1016/j.clinbiochem.2024.110763. PMID 38615787
  164. Nichols JH, Alter D, Chen Y, et al. AACC guidance document on management of point-of-care testing. J Appl Lab Med. 2020;5(4):762–787. doi:10.1093/jalm/jfaa059. PMID 32496555
  165. Nigro M, Valli G, Marchionne ML, et al. Is there a risk of misinterpretation of potassium concentration from undetectable hemolysis using a POCT blood gas analyzer in the emergency department? Medicina (Kaunas). 2022;59(1):66. doi:10.3390/medicina59010066. PMID 36676689
  166. Nikolac Gabaj N, Miler M, Vrtarić A, et al. Precision, accuracy, cross reactivity and comparability of serum indices measurement on Abbott Architect c8000, Beckman Coulter AU5800 and Roche Cobas 6000 c501 clinical chemistry analyzers. Clin Chem Lab Med. 2018;56(5):776–788. doi:10.1515/cclm-2017-0889. PMID 29315074
  167. Nikolac N. Lipemia: causes, interference mechanisms, detection and management. Biochem Med (Zagreb). 2014;24(1):57–67. doi:10.11613/BM.2014.008. PMID 24627715
  168. No JI, Yang JY, Hyun HJ, et al. Factors associated with serum levels of carcinoembryonic antigen in healthy non-smokers. Korean J Fam Med. 2013;34(6):413–419. doi:10.4082/kjfm.2013.34.6.413. PMID 24340163
  169. Nounou OS, Mamy N, Dahlia P, et al. Comparison of the glucose stability effect between citrate-sodium fluoride-EDTA, heparin, and sodium fluoride containing tubes: a prospective experimental study in the biochemistry laboratory at the University Clinic of Kinshasa, DR Congo. EJIFCC. 2026;37(4):621–631. PMID 42730030
  170. O'Connell TX, Horita TJ, Kasravi B. Understanding and interpreting serum protein electrophoresis. Am Fam Physician. 2005;71(1):105–112. https://www.aafp.org/pubs/afp/issues/2005/0101/p105.html. PMID 15663032
  171. Oddoze C, Lombard E, Portugal H. Stability study of 81 analytes in human whole blood, in serum and in plasma. Clin Biochem. 2012;45(6):464–469. doi:10.1016/j.clinbiochem.2012.01.012. PMID 22285385
  172. Opallage PM, De Silva M, Dunn RC. Dual detection high-speed capillary electrophoresis for simultaneous serum protein analysis and immunoassays. Sci Rep. 2022;12(1):1951. doi:10.1038/s41598-022-05956-8. PMID 35121780
  173. Oshina I, Spigulis J. Beer-Lambert law for optical tissue diagnostics: current state of the art and the main limitations. J Biomed Opt. 2021;26(10):100901. doi:10.1117/1.JBO.26.10.100901. PMID 34713647
  174. Oyatogun O, Sandhu M, Barata-Kirby S, et al. A rational diagnostic approach to the "phantom hCG" and other clinical scenarios in which a patient is thought to be pregnant but is not. Ther Adv Reprod Health. 2021;15:26334941211016412. doi:10.1177/26334941211016412. PMID 34179786
  175. Ozarda Y, Sikaris K, Streichert T, Macri J; IFCC Committee on Reference Intervals and Decision Limits. Distinguishing reference intervals and clinical decision limits – a review by the IFCC Committee on Reference Intervals and Decision Limits. Crit Rev Clin Lab Sci. 2018;55(6):420–431. doi:10.1080/10408363.2018.1482256. PMID 30047297 (Ozarda 2018)
  176. Ozarda Y. Reference intervals: current status, recent developments and future considerations. Biochem Med (Zagreb). 2016;26(1):5–16. doi:10.11613/BM.2016.001. PMID 26981015 (Ozarda 2016)
  177. Paal M, Habler K, Vogeser M. Estimation of inter-laboratory reference change values from external quality assessment data. Biochem Med (Zagreb). 2021;31(3):030902. doi:10.11613/BM.2021.030902. PMID 34393596
  178. Palmer BF, Kelepouris E, Clegg DJ. Renal tubular acidosis and management strategies: a narrative review. Adv Ther. 2021;38(2):949–968. doi:10.1007/s12325-020-01587-5. PMID 33367987
  179. Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised International Staging System for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015;33(26):2863–2869. doi:10.1200/JCO.2015.61.2267. PMID 26240224
  180. Panhuizen IF, Snoeck MM, Levano S, et al. Prolonged neuromuscular blockade following succinylcholine administration to a patient with a reduced butyrylcholinesterase activity. Case Rep Med. 2010;2010:472389. doi:10.1155/2010/472389. PMID 20589221
  181. Park SH, Shin DY. LC-MS/MS for thyroglobulin: a complementary approach to immunoassay limitations for thyroid cancer. Endocrinol Metab (Seoul). 2025;40(6):866–868. doi:10.3803/EnM.2025.2822. PMID 41479268
  182. Petrovic I, et al. Influence of thyroglobulin autoantibodies on thyroglobulin levels measured by different methodologies: IMA, LC-MS/MS, and RIA. J Clin Endocrinol Metab. 2024;109(12):3254–3263. doi:10.1210/clinem/dgae286. PMID 38686504
  183. Pierce CB, Muñoz A, Ng DK, et al. Age- and sex-dependent clinical equations to estimate glomerular filtration rates in children and young adults with chronic kidney disease. Kidney Int. 2021;99(4):948–956. doi:10.1016/j.kint.2020.10.047. PMID 33301749
  184. Pierre CC, Marzinke MA, Ahmed SB, et al. AACC/NKF guidance document on improving equity in chronic kidney disease care. J Appl Lab Med. 2023;8(4):789–816. doi:10.1093/jalm/jfad022. PMID 37379065
  185. Pighi L, Salvagno GL, Marcazzan F, et al. Improved potassium reliability in whole blood through hemolysis detection on the novel GEM Premier 7000 blood gas analyzer. J Med Biochem. 2025;44(4):915–918. doi:10.5937/jomb0-58604. PMID 40837359
  186. Plebani M, Carraro P. Mistakes in a stat laboratory: types and frequency. Clin Chem. 1997;43(8 Pt 1):1348–1351. PMID 9267312
  187. Pohanka M. Butyrylcholinesterase as a biochemical marker. Bratisl Lek Listy. 2013;114(12):726–734. doi:10.4149/bll_2013_153. PMID 24329513
  188. Pottel H, Björk J, Rule AD, et al. Cystatin C-based equation to estimate GFR without the inclusion of race and sex. N Engl J Med. 2023;388(4):333–343. doi:10.1056/NEJMoa2203769. PMID 36720134
  189. Pudineh Moarref M, Black W, Chen Y. Performance of new Roche Cobas Pulse glucose meter against potential interfering substances and hematocrit variations. Diagnostics (Basel). 2026;16(9):1383. doi:10.3390/diagnostics16091383. PMID 42122086
  190. Pullano SA, Greco M, Bianco MG, et al. Glucose biosensors in clinical practice: principles, limits and perspectives of currently used devices. Theranostics. 2022;12(2):493–511. doi:10.7150/thno.64035. PMID 34976197
  191. Purssell RA, Pudek M, Brubacher J, Abu-Laban RB. Derivation and validation of a formula to calculate the contribution of ethanol to the osmolal gap. Ann Emerg Med. 2001;38(6):653–659. doi:10.1067/mem.2001.119455. PMID 11719745
  192. Qriouet Z, Qmichou Z, Bouchoutrouch N, et al. Analytical methods used for the detection and quantification of benzodiazepines. J Anal Methods Chem. 2019;2019:2035492. doi:10.1155/2019/2035492. PMID 31583157
  193. Raghavan R, Eknoyan G. Acute interstitial nephritis: a reappraisal and update. Clin Nephrol. 2014;82(3):149–162. doi:10.5414/cn108386. PMID 25079860
  194. Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538–e548. doi:10.1016/S1470-2045(14)70442-5. PMID 25439696 (Rajkumar 2014)
  195. Rajkumar SV. Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol. 2024;99(9):1802–1824. doi:10.1002/ajh.27422. PMID 38943315 (Rajkumar 2024)
  196. Reslova N, Michna V, Kasny M, Mikel P, Kralik P. xMAP technology: applications in detection of pathogens. Front Microbiol. 2017;8:55. doi:10.3389/fmicb.2017.00055. PMID 28179899
  197. Reuter T, Müller M, Stelter F, Durner J, Kramer J. Time as a significant factor in the release of potassium from lithium heparin plasma and serum. PLoS One. 2024;19(12):e0313572. doi:10.1371/journal.pone.0313572. PMID 39652602
  198. Ricós C, Fernandez-Calle P, Perich C, Westgard JO. Internal quality control – past, present and future trends. Adv Lab Med. 2022;3(3):243–262. doi:10.1515/almed-2022-0029. PMID 37362142
  199. Rinella ME. Examining the nomenclature change from NAFLD and NASH to MASLD and MASH. Gastroenterol Hepatol (N Y). 2023;19(11):697–699. PMID 38405223 (Rinella 2023)
  200. Rolić T, Pavlić I, Sarić I. Spurious life-threatening hypermagnesemia caused by a preanalytical error in an intensive care unit: a case report. Biochem Med (Zagreb). 2026;36(3):031001. doi:10.11613/BM.2026.031001. PMID 42621980
  201. Rubio-Tapia A, Hill ID, Semrad C, et al. American College of Gastroenterology guidelines update: diagnosis and management of celiac disease. Am J Gastroenterol. 2023;118(1):59–76. doi:10.14309/ajg.0000000000002075. PMID 36602836
  202. Ruffing U, Mickeler S, Kraft M, et al. Analytical performance evaluation of a new integrated clinical chemistry and immunoassay analyzer. Pract Lab Med. 2024;41:e00427. doi:10.1016/j.plabm.2024.e00427. PMID 39310744
  203. Šálek T, Musil P, Vermeersch P, et al. Preservation of urine specimens for metabolic evaluation of recurrent urinary stone formers. Clin Chem Lab Med. 2025;63(1):129–138. doi:10.1515/cclm-2024-0773. PMID 39072394
  204. Sandberg S, Coskun A, Carobene A, et al. Analytical performance specifications based on biological variation data – considerations, strengths and limitations. Clin Chem Lab Med. 2024;62(8):1483–1489. doi:10.1515/cclm-2024-0108. PMID 38501489 (Sandberg 2024)
  205. Sandberg S, Fraser CG, Horvath AR, et al. Defining analytical performance specifications: consensus statement from the 1st Strategic Conference of the European Federation of Clinical Chemistry and Laboratory Medicine. Clin Chem Lab Med. 2015;53(6):833–835. doi:10.1515/cclm-2015-0067. PMID 25719329 (Sandberg 2015)
  206. Schumann G, Bonora R, Ceriotti F, et al. IFCC primary reference procedures for the measurement of catalytic activity concentrations of enzymes at 37 °C. Part 4. Reference procedure for the measurement of catalytic concentration of alanine aminotransferase. Clin Chem Lab Med. 2002;40(7):718–724. doi:10.1515/CCLM.2002.124. PMID 12241021 (Schumann 2002a)
  207. Schumann G, Bonora R, Ceriotti F, et al. IFCC primary reference procedures for the measurement of catalytic activity concentrations of enzymes at 37 °C. Part 5. Reference procedure for the measurement of catalytic concentration of aspartate aminotransferase. Clin Chem Lab Med. 2002;40(7):725–733. doi:10.1515/CCLM.2002.125. PMID 12241022 (Schumann 2002b)
  208. Schumann G, Bonora R, Ceriotti F, et al. IFCC primary reference procedures for the measurement of catalytic activity concentrations of enzymes at 37 °C. Part 6. Reference procedure for the measurement of catalytic concentration of gamma-glutamyltransferase. Clin Chem Lab Med. 2002;40(7):734–738. doi:10.1515/CCLM.2002.126. PMID 12241023 (Schumann 2002c)
  209. Schumann G, Klauke R, Canalias F, et al. IFCC primary reference procedures for the measurement of catalytic activity concentrations of enzymes at 37 °C. Part 9: reference procedure for the measurement of catalytic concentration of alkaline phosphatase. Clin Chem Lab Med. 2011;49(9):1439–1446. doi:10.1515/CCLM.2011.621. PMID 21702699 (Schumann 2011)
  210. Schwartz GJ, Muñoz A, Schneider MF, et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol. 2009;20(3):629–637. doi:10.1681/ASN.2008030287. PMID 19158356
  211. Serdarević N, Malesić I, Kozjek F. Comparison of Vitros dry slide technology for determination of lithium ions with other methods. Bosn J Basic Med Sci. 2006;6(2):32–36. doi:10.17305/bjbms.2006.3191. PMID 16879110
  212. Shepard CL, Bliumkin L. Adsorption of therapeutic and recreational drugs during prolonged storage of plasma samples in gel separator tubes. J Anal Toxicol. 2023;46(9):999–1007. doi:10.1093/jat/bkab118. PMID 34849993
  213. Shin S, Yu S, Kim S, et al. Proposal for delta check limits of frequently requested hormones using real-world data. Biochem Med (Zagreb). 2025;35(1):010704. doi:10.11613/BM.2025.010704. PMID 39974195
  214. Siener R, Buchholz N, Daudon M, et al. Quality assessment of urinary stone analysis: results of a multicenter study of laboratories in Europe. PLoS One. 2016;11(6):e0156606. doi:10.1371/journal.pone.0156606. PMID 27248840
  215. Simundic AM, Baird G, Cadamuro J, Costelloe SJ, Lippi G. Managing hemolyzed samples in clinical laboratories. Crit Rev Clin Lab Sci. 2020;57(1):1–21. doi:10.1080/10408363.2019.1664391. PMID 31603708
  216. Simundic AM, Bölenius K, Cadamuro J, et al. Joint EFLM-COLABIOCLI recommendation for venous blood sampling. Clin Chem Lab Med. 2018;56(12):2015–2038. doi:10.1515/cclm-2018-0602. PMID 30004902 (Simundic 2018)
  217. Singal AG, Llovet JM, Yarchoan M, et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023;78(6):1922–1965. doi:10.1097/HEP.0000000000000466. PMID 37199193 (Singal 2023)
  218. Singh S, Ananthakrishnan AN, Nguyen NH, et al. AGA clinical practice guideline on the role of biomarkers for the management of ulcerative colitis. Gastroenterology. 2023;164(3):344–372. doi:10.1053/j.gastro.2022.12.007. PMID 36822736
  219. Slaughter JL, Kemper AR, Newman TB. Technical report: diagnosis and management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics. 2022;150(3):e2022058865. doi:10.1542/peds.2022-058865. PMID 35927519 (Slaughter 2022)
  220. Solé-Enrech G, Cano-Corres R, Escribano-Tembleque R, et al. Evaluation of the impact of reducing fasting hours on laboratory results in a Mediterranean population. Biochem Med (Zagreb). 2025;35(2):020703. doi:10.11613/BM.2025.020703. PMID 40469569
  221. Sönmez AB, Arifoğlu İ, Yıldırım A, et al. Benign transient hyperphosphatasemia in an infant during zinc supplementation. Turk Pediatri Ars. 2018;53(2):120–123. doi:10.5152/TurkPediatriArs.2017.3158. PMID 30116134
  222. Spencer CA, Takeuchi M, Kazarosyan M, MacKenzie F, Beckett GJ, Wilkinson E. Interlaboratory/intermethod differences in functional sensitivity of immunometric assays of thyrotropin (TSH) and impact on reliability of measurement of subnormal concentrations of TSH. Clin Chem. 1995;41(3):367–374. PMID 7882510 (Spencer 1995)
  223. Spencer CA, Takeuchi M, Kazarosyan M. Current status and performance goals for serum thyrotropin (TSH) assays. Clin Chem. 1996;42(1):140–145. PMID 8565217 (Spencer 1996)
  224. Stein W, Bohner J, Steinhart R, et al. Macro creatine kinase: determination and differentiation of two types by their activation energies. Clin Chem. 1982;28(1):19–24. PMID 7055910
  225. Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43(6):1317–1325. doi:10.1002/hep.21178. PMID 16729309
  226. Sturgeon CM, Duffy MJ, Hofmann BR, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers. Clin Chem. 2010;56(6):e1–e48. doi:10.1373/clinchem.2009.133124. PMID 20207771 (Sturgeon 2010)
  227. Sturgeon CM, Duffy MJ, Stenman UH, et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem. 2008;54(12):e11–e79. doi:10.1373/clinchem.2008.105601. PMID 19042984 (Sturgeon 2008b)
  228. Sturgeon CM, Hoffman BR, Chan DW, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in clinical practice: quality requirements. Clin Chem. 2008;54(8):e1–e10. doi:10.1373/clinchem.2007.094144. PMID 18606634 (Sturgeon 2008a)
  229. Sun G, Miao W, Liu S, et al. Intensive systolic blood pressure reduction and kidney and cardiovascular outcomes: a secondary analysis of a randomized clinical trial. JAMA Netw Open. 2025;8(7):e2519604. doi:10.1001/jamanetworkopen.2025.19604. PMID 40643915 (SI conversion factor for uric acid)
  230. Tate J, Ward G. Interferences in immunoassay. Clin Biochem Rev. 2004;25(2):105–120. PMID 18458713
  231. Tenner S, Vege SS, Sheth SG, et al. American College of Gastroenterology guidelines: management of acute pancreatitis. Am J Gastroenterol. 2024;119(3):419–437. doi:10.14309/ajg.0000000000002645. PMID 38857482 (Tenner 2024)
  232. Thomas SN, French D, Jannetto PJ, Rappold BA, Clarke WA. Liquid chromatography-tandem mass spectrometry for clinical diagnostics. Nat Rev Methods Primers. 2022;2(1):96. doi:10.1038/s43586-022-00175-x. PMID 36532107
  233. Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162–173. doi:10.1016/S1474-4422(17)30470-2. PMID 29275977 (Thompson 2018)
  234. Tjernvoll E, Åsberg A, Lian IA, et al. Stability of 17 endocrine analytes in serum or plasma after four cycles of repeated freezing and thawing. Scand J Clin Lab Invest. 2025;85(3):190–195. doi:10.1080/00365513.2025.2487989. PMID 40243258
  235. Turner KA, Frinack JL, Ettore MW, et al. An international multi-center serum protein electrophoresis accuracy and M-protein isotyping study. Part I: factors impacting limit of quantitation of serum protein electrophoresis. Clin Chem Lab Med. 2020;58(4):533–546. doi:10.1515/cclm-2019-1104. PMID 31940284
  236. Uçar KT, Çat A, Gümüş A, Nurlu N. Interferograms plotted with reference change value (RCV) may facilitate the management of hemolyzed samples. J Med Biochem. 2022;41(1):53–61. doi:10.5937/jomb0-31250. PMID 35291494
  237. Uchino S, Bellomo R, Goldsmith D. The meaning of the blood urea nitrogen/creatinine ratio in acute kidney injury. Clin Kidney J. 2012;5(2):187–191. doi:10.1093/ckj/sfs013. PMID 29497527
  238. Umińska A, Wieczorek-Breitzke E, Ćwiklińska A, et al. Spurious hyperkalemia without hemolysis: a case-based presentation of preanalytical errors and diagnostic pitfalls. Diagnostics (Basel). 2026;16(16):2676. doi:10.3390/diagnostics16162676. PMID 42651077
  239. US Preventive Services Task Force; Bibbins-Domingo K, Grossman DC, et al. Screening for colorectal cancer: US Preventive Services Task Force recommendation statement. JAMA. 2016;315(23):2564–2575. doi:10.1001/jama.2016.5989. PMID 27304597 (USPSTF 2016)
  240. US Preventive Services Task Force; Davidson KW, Barry MJ, et al. Screening for colorectal cancer: US Preventive Services Task Force recommendation statement. JAMA. 2021;325(19):1965–1977. doi:10.1001/jama.2021.6238. PMID 34003218. Recommendation page: https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening (USPSTF 2021)
  241. US Preventive Services Task Force; Grossman DC, Curry SJ, et al. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. JAMA. 2018;319(18):1901–1913. doi:10.1001/jama.2018.3710. PMID 29801017. Recommendation page: https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/prostate-cancer-screening (USPSTF 2018)
  242. Van Hoovels L, Vercammen M, Nevejan L, et al. Serum free light chain analysis: persisting limitations with new kids on the block. Clin Chem Lab Med. 2022;60(9):1440–1448. doi:10.1515/cclm-2022-0347. PMID 35781357
  243. van Schrojenstein Lantman M, van de Logt AE, Prudon-Rosmulder E, et al. Albumin determined by bromocresol green leads to erroneous results in routine evaluation of patients with chronic kidney disease. Clin Chem Lab Med. 2023;61(12):2167–2177. doi:10.1515/cclm-2023-0463. PMID 37401696
  244. Vanga RR, Tansel A, Sidiq S, et al. Diagnostic performance of measurement of fecal elastase-1 in detection of exocrine pancreatic insufficiency: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2018;16(8):1220–1228.e4. doi:10.1016/j.cgh.2018.01.027. PMID 29374614
  245. Vermeersch P, Mariën G, Bossuyt X. Pseudoparaproteinemia related to iomeprol administration after angiocardiography: detection in the beta fraction by capillary zone electrophoresis. Clin Chem. 2006;52(12):2312–2313. doi:10.1373/clinchem.2006.078584. PMID 17138856
  246. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38(2):518–526. doi:10.1053/jhep.2003.50346. PMID 12883497
  247. Walker JA, Schwartzbard A, Krauss EA, Sherman RA, Eisinger RP. The missing gap. A pitfall in the diagnosis of alcohol intoxication by osmometry. Arch Intern Med. 1986;146(9):1843–1844. doi:10.1001/archinte.146.9.1843. PMID 3753127
  248. Ward G, Simpson A, Boscato L, Hickman PE. The investigation of interferences in immunoassay. Clin Biochem. 2017;50(18):1306–1311. doi:10.1016/j.clinbiochem.2017.08.015. PMID 28847718
  249. Wattjes MP, Bayas A, Bittner S, et al. Implementing the 2024 revision of the McDonald diagnostic criteria for multiple sclerosis in Germany: practical considerations and consensus recommendations. Ther Adv Neurol Disord. 2026;19:17562864261481602. doi:10.1177/17562864261481602. PMID 42662141
  250. Wells SA Jr, Asa SL, Dralle H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015;25(6):567–610. doi:10.1089/thy.2014.0335. PMID 25810047
  251. Westgard JO, Barry PL, Hunt MR, Groth T. A multi-rule Shewhart chart for quality control in clinical chemistry. Clin Chem. 1981;27(3):493–501. PMID 7471403 (Westgard 1981)
  252. Westgard JO, Bayat H, Westgard SA. Planning SQC strategies and adapting QC frequency for patient risk. Clin Chim Acta. 2021;523:1–5. doi:10.1016/j.cca.2021.08.028. PMID 34464612 (Westgard 2021)
  253. Westgard JO, Westgard SA. Establishing evidence-based statistical quality control practices. Am J Clin Pathol. 2019;151(4):364–370. doi:10.1093/ajcp/aqy158. PMID 30517600 (Westgard 2019)
  254. Westgard S, Bayat H, Westgard JO. Analytical Sigma metrics: a review of Six Sigma implementation tools for medical laboratories. Biochem Med (Zagreb). 2018;28(2):020502. doi:10.11613/BM.2018.020502. PMID 30022879 (Westgard S 2018)
  255. Whitby LG, Moss DW. Analysis of heat inactivation curves of alkaline phosphatase isoenzymes in serum. Clin Chim Acta. 1975;59(3):361–367. doi:10.1016/0009-8981(75)90012-1. PMID 1126023
  256. Wu AH, Bowers GN Jr. Evaluation and comparison of immunoinhibition and immunoprecipitation methods for differentiating MB and BB from macro forms of creatine kinase isoenzymes in patients and healthy individuals. Clin Chem. 1982;28(10):2017–2021. PMID 7127730
  257. Wu SJ, Hayden JA. Upfront dilution of ferritin samples to reduce hook effect, improve turnaround time and reduce costs. Biochem Med (Zagreb). 2018;28(1):010903. doi:10.11613/BM.2018.010903. PMID 29187801
  258. Xiong W, Song J, Yue Z, et al. Case report: familial pseudohyperkalemia due to red blood cell membrane leak in a Chinese patient. Front Med (Lausanne). 2022;9:825174. doi:10.3389/fmed.2022.825174. PMID 35372423
  259. Yanagihara F, Okura H, Ichikawa H, et al. Development of an automated chemiluminescent immunoassay for cancer antigen 72-4 and the evaluation of its analytical performance. Pract Lab Med. 2023;34:e00308. doi:10.1016/j.plabm.2023.e00308. PMID 36713933
  260. Yasuda N, Nishikawa M, Yoshikawa N, et al. Evaluation of the performance of new daratumumab-specific immunofixation electrophoresis reflex agent and the timing of M-protein measurement. J Clin Exp Hematop. 2025;65(4):276–282. doi:10.3960/jslrt.25058. PMID 41443884
  261. Yu YC, Mao YM, Chen CW, et al. CSH guidelines for the diagnosis and treatment of drug-induced liver injury. Hepatol Int. 2017;11(3):221–241. doi:10.1007/s12072-017-9793-2. PMID 28405790
  262. Yusim I, Krenawi M, Mazor E, et al. The use of prostate specific antigen density to predict clinically significant prostate cancer. Sci Rep. 2020;10(1):20015. doi:10.1038/s41598-020-76786-9. PMID 33203873
  263. Zhang H, Wu B, Ke L, et al. Performance validation of Abbott Alinity i chemiluminescence analyzer for five thyroid function tests. Pract Lab Med. 2025;46:e00487. doi:10.1016/j.plabm.2025.e00487. PMID 40677411
  264. Zhang Y, Zhang Y, Huang Q, et al. Evolution and contemporary landscape of neonatal hyperbilirubinemia management guidelines: a narrative review. Front Pediatr. 2026;14:1745769. doi:10.3389/fped.2026.1745769. PMID 41727764